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Abstract 
Protein-protein interactions present challenging targets for therapeutic intervention 
with enormous potential for modulating biological pathways, particularly in the field 
of oncology. Two α-helix mediated protein-protein interactions of interest, hypoxia 
inducible factor-1α (HIF-1α)/p300 and eukaryotic initiation factor 4E (eIF4E) 
/eIF4G are introduced and their known inhibitors discussed in Chapter 1.  
Initially, biophysical assays for both interactions were developed and the binding 
requirements between peptides derived from helix donor components (HIF-1α and 
eIF4G) to their protein counterparts (p300 and eIF4E respectively) were 
investigated. This information was used to develop competition assays capable of 
identifying inhibitors and provided important insight for the rational design of 
inhibitors. 
Subsequently, a computational approach, described in Chapter 3, to inhibitor 
discovery was applied to both targets, using both docking and pharmacophore 
modelling. Several series of compounds were purchased or prepared and screened as 
inhibitors. The development of a synthetic route to a novel scaffold is described 
providing a weak small molecule inhibitor. 
In parallel, a proteomimetic approach to inhibitor design was employed, using 
sequence based rational design, drawing on the knowledge gained in Chapter 2. By 
mimicking a key helical region of HIF-1α, the interaction with p300 can be 
disrupted, as discussed in Chapter 4. Additionally, new methods for the preparation 
of oligobenzamide helix mimetics were investigated allowing the preparation of 
challenging targets, late stage functionalization and the preparation of 
oligobenzamide/peptide hybrids.  
Overall, this thesis provides an introduction to two therapeutically relevant 
interactions, provides biophysical assays for the identification of inhibitors and 
discloses the first biophysically characterised inhibitors of the HIF-1α/p300 
interaction.   
- vi - 
Table of Contents 
Intellectual Property and Publication Statements ................................................. ii 
Acknowledgements ................................................................................................... iv 
Abstract ...................................................................................................................... v 
List of Figures ............................................................................................................ x 
List of Schemes ........................................................................................................ xv 
List of Tables .......................................................................................................... xvi 
List of Abbreviations ............................................................................................ xvii 
Chapter 1 – Protein-Protein Interactions: HIF-1α/p300 and eIF4E/eIF4G ........ 1 
1.1 Protein-Protein Interactions ......................................................................... 2 
1.1.1 α-Helix Mediated Protein-Protein Interactions ................................ 2 
1.1.2 Helix-Mediated PPIs in Cancer ........................................................ 3 
1.2 Hypoxic Sensing .......................................................................................... 3 
1.2.1 HIF Regulation ................................................................................. 4 
1.2.3 HIF-1α/p300 Hotspots ..................................................................... 6 
1.2.4 Inhibitors of the Hypoxic Response Pathway .................................. 8 
1.3 Control of Translation ................................................................................ 11 
1.3.1 Structural Biology of eIF4E/eIF4G ................................................ 13 
1.3.2 eIF4E/eIF4G Hotspots ................................................................... 14 
1.3.3 Inhibitors of Cap-Mediated Translation ......................................... 15 
1.4 Summary .................................................................................................... 17 
1.5 Project Aims ............................................................................................... 17 
Chapter 2 – Assay Development ............................................................................ 18 
2.1 Assay Development ................................................................................... 19 
2.1.1 The basis of fluorescence anisotropy
86
 .......................................... 19 
2.2 HIF-1α/p300 Assay Development ............................................................. 20 
2.2.1 Direct Binding of HIF-1α CTAD to p300 ...................................... 20 
2.2.2 Time and Temperature Dependence of HIF-1α/p300 
Interaction ...................................................................................... 21 
2.2.3 Isothermal Titration Calorimetry analysis of HIF-1α/p300 ........... 24 
2.2.4 Competition Assay for inhibitors of HIF-1α/p300 ......................... 26 
2.2.5 HIF-1α/p300 Binding Hotspots ...................................................... 27 
2.2.6 Comparison of Helical Regions ..................................................... 27 
2.2.7 Exploration of Cooperativity.......................................................... 29 
2.2.8 Peptide Inhibitor Screening ............................................................ 33 
- vii - 
2.2.9 Conclusions on HIF-1α/p300 binding requirements ...................... 35 
2.3 eIF4E/eIF4G Assay Development ............................................................. 35 
2.3.1 Direct binding of eIF4G peptide to eIF4E ..................................... 35 
2.3.2 Time and Temperature Dependence of eIF4E/eIF4G 
Interaction ...................................................................................... 37 
2.3.3 Cap dependence of eIF4E/eIF4G interaction ................................. 40 
2.3.5 Competition assay for inhibitors of the eIF4E/eIF4G 
interaction ....................................................................................... 41 
2.4 Summary and Conclusions ......................................................................... 42 
Chapter 3 – Computational Approaches to Inhibitors ........................................ 44 
3.1 Computational Chemistry in Lead Discovery ............................................ 45 
3.2 Identification of Commercially Available Inhibitors ................................. 45 
3.3 Docking Virtual Libraries .......................................................................... 45 
3.3.1 HIF-1α/p300 Docking .................................................................... 45 
3.3.2 eIF4E/eIF4G Docking .................................................................... 47 
3.4 Shape Based Screening .............................................................................. 48 
3.5 Compound Selection .................................................................................. 50 
3.6 Compound Screening ................................................................................. 51 
3.6.1 HIF-1α/p300 Screening .................................................................. 51 
3.6.2 eIF4E/eIF4G Screening .................................................................. 53 
3.6.3 Analogue synthesis ........................................................................ 56 
3.7 Design of Bespoke Compound Libraries ................................................... 58 
3.7.1 Synthesis of selected scaffold ........................................................ 60 
3.7.2 Screening of Designed Compounds ............................................... 61 
3.8 Summary and Conclusions ......................................................................... 63 
Chapter 4 Development of Oligobenzamide α-Helix Mimetics as 
Inhibitors of the HIF-1α/p300 protein-protein interaction ........................ 65 
4.1 The Concept of Helix Mimicry .................................................................. 66 
4.2 Application to the HIF-1α/p300 Protein-Protein Interaction ..................... 70 
4.2.1 Helix 3 Mimicry ............................................................................. 70 
4.2.2 Helix 2 Mimicry ............................................................................. 79 
4.3 Late Stage Functionalization ...................................................................... 84 
4.4 Photo-crosslinking Compounds ................................................................. 88 
4.4.1 Protein Digestion Analysis ............................................................. 90 
4.5 Protein Prosthesis ....................................................................................... 93 
4.5.1 Oligobenzamide-Peptide Hybrids .................................................. 93 
- viii - 
4.5.2 Method Development ..................................................................... 94 
4.5.3 Application to HIF-1α/p300 ........................................................... 98 
4.5.4 Assessment of Inhibitory Activity ................................................. 99 
4.6 Summary and Conclusions ....................................................................... 101 
Thesis Summary and Future Work ..................................................................... 103 
Chapter 5 – Experimental Section ....................................................................... 106 
5.1 General Experimental............................................................................... 107 
5.1.1 Oligobenzamide Nomenclature .................................................... 108 
5.2 Experimental for Chapter 2 ...................................................................... 109 
5.2.1 HIF-1α CTAD Peptides ............................................................... 109 
5.2.2 Determination of the Binding of Labelled HIF-1α Peptide to 
p300 Protein ................................................................................. 109 
5.2.3 Competition Assays ..................................................................... 111 
5.2.4 Calculation of occluded surface area ........................................... 112 
5.2.5 Peptide Synthesis ......................................................................... 113 
5.2.6 Peptide-PEG Conjugates .............................................................. 115 
5.2.7 eIF4G Peptide Synthesis .............................................................. 118 
5.2.8 Determination of the Binding of Labelled eIF4G Peptide to 
eIF4E Protein ............................................................................... 119 
5.2.9 Competition Assays ..................................................................... 120 
5.3 Experimental for Chapter 3 ...................................................................... 122 
5.3.1 Docking ........................................................................................ 122 
5.3.2 Pharmacophore modelling ........................................................... 123 
5.3.3 Library Enumeration .................................................................... 124 
5.3.4 Synthesis of Compound 4 analogues ........................................... 127 
5.3.5 Synthesis of designed compounds ............................................... 134 
5.4 Experimental for Chapter 4 ...................................................................... 146 
5.4.1 Synthesis of Oligobenzamides ..................................................... 147 
5.4.2 Library Synthesis ......................................................................... 157 
5.4.3 Synthesis of KCN-1 ..................................................................... 162 
5.4.4 Synthesis of Helix 2 Mimetics ..................................................... 164 
5.4.5 Late Stage Functionalization ........................................................ 174 
5.4.6 Protein Digestion and LC-MS/MS ............................................... 186 
5.4.7 Photo-Crosslinking Experiments ................................................. 187 
5.4.8 Synthesis of glycine linked monomer .......................................... 187 
5.4.9 Preparation of Peptide-Oligobenzamide Hybrids ........................ 190 
- ix - 
Appendix I – Alternative Peptide PEG Linking Strategies ............................... 193 
Appendix II – Alternative Synthetic Routes to Designed Compounds ............ 196 
Appendix III – Crystallographic Data ................................................................ 198 
Appendix IV ........................................................................................................... 200 
Bibliography .......................................................................................................... 201 
 
  
- x - 
List of Figures 
Figure 1 - Schematic representation of an α-helix mediated protein-protein 
interaction. The helix donor is shown in red whilst the helix acceptor is 
shown in blue. .................................................................................................... 2 
Figure 2 - HIF pathways under normoxic and hypoxic conditions. HIF-1α - 
Hypoxia Inducible Factor 1α, HIF-1β - Hypoxia Inducible Factor 1β, 
PHD – prolyl hydroxylase domain, HRE – hypoxic response element. ............ 4 
Figure 3 - Domains of HIF-1α. bHLH – basic helix-loop-helix, PAS – per 
ARNT-AHR-Sim, ODDD - oxygen-dependent degradation domain, 
NTAD – N-terminal transactivation domain, CTAD – C-terminal 
transactivation domain. ...................................................................................... 5 
Figure 4 - NMR structures of (a) p300 CH1 domain (green) in the complex 
(peptide not shown) (b) Complex between HIF-1α CTAD (blue) and 
p300 CH1 domain (green) (zinc omitted for clarity) PDB ID: 1L8C (c) 
primary sequence of HIF-1α CTAD with helical regions indicated .................. 6 
Figure 5 - Helix 2 binding site with reported hotspot residues highlighted ................ 7 
Figure 6 - Helix 3 binding site with reported hotspot residues highlighted ................ 7 
Figure 7 - Structures of HIF-1 dimerization inhibitors ............................................... 8 
Figure 8 - Structures of compounds capable of ejecting zinc from p300 ................... 9 
Figure 9 - Structure of KCN-1 .................................................................................. 10 
Figure 10 - Structures of i to i+4 hydrogen bond and hydrogen bond surrogate. ..... 10 
Figure 11 - Structures of proteomimetic inhibitors of HIF-1α/p300 ........................ 11 
Figure 12 - Schematic representation of the eIF4 recruitment of 5’Cap-mRNA 
to the ribosome ................................................................................................. 12 
Figure 13 - Structure of eIF4E (green) bound to a peptide derived from eIF4G 
(red) and m7G Cap (structure coloured by element) (PDB ID: 2W97) ........... 14 
Figure 14 - Hotspot residues for the eIF4E/eIF4G interaction ................................. 14 
Figure 15 - Structures of mTOR inhibitors ............................................................... 15 
Figure 16 - Structures of compounds that bind in the eIF4E cap binding 
region. Ribavirin shown protonated as it is thought to be protonated at 
physiological pH. ............................................................................................. 15 
Figure 17 - Higher affinity eIF4G peptides (a) generic stapled peptide 
structure (b) structure of AIB (c) the structure of the amino acid 
incorporated for peptide stapling via metathesis (d) structures of eIF4G 
peptides with increased affinity. X represents AIB incorporation, * 
represents the stapled positions. ....................................................................... 16 
Figure 18 - Structure of small molecules inhibitors of eIF4E/eIF4G. PAINS 
substructure highlighted in red. ........................................................................ 16 
- xi - 
Figure 19 – Cartoon illustrating fluorescence anisotropy of peptide tracer 
ligand with and without competitive inhibitor present .................................... 19 
Figure 20 - HIF-1α CTAD peptide sequences .......................................................... 20 
Figure 21 – Binding curve for FITC HIF-1α CTAD/p300 CH1 domain (80 nM 
FITC-HIF-1α CTAD, 40 mM sodium phosphate, 100 mM NaCl, 1 mM 
DTT, 5% glycerol). Error bars represent the standard deviation of 3 
repeats. ............................................................................................................. 21 
Figure 22 - Time dependence on fluorescence anisotropy assays between 
FITC-HIF-1α and p300. (80 nM FITC-HIF-1α CTAD, 40 mM sodium 
phosphate, 100 mM NaCl, 1 mM DTT, 5% glycerol). Error bars 
represent the standard deviation of 3 repeats. .................................................. 22 
Figure 23 - Temperature dependence of HIF-1α/p300 interaction(80 nM FITC-
HIF-1α CTAD, 40 mM sodium phosphate, 100 mM NaCl, 1 mM DTT, 
5% glycerol). Error bars represent the standard deviation of 3 repeats. .......... 23 
Figure 24 - Van't Hoff Analysis for the HIF-1α/p300 interaction ............................ 24 
Figure 25 - Isothermal titration calorimetry analysis of the HIF-1 CTAD/p300 
Interaction ........................................................................................................ 25 
Figure 26 - Competition titration of HIF-1α CTAD vs FITC HIF-1α CTAD. 
(80 nM FITC-HIF-1α CTAD, 0.1 µM p300, 40 mM sodium phosphate, 
100 mM NaCl, 1 mM DTT, 5% glycerol, 0.1% triton).  Error bars 
represent the standard deviation of 3 repeats. .................................................. 26 
Figure 27 - Schematic representation of peptide prepared containing helical 
regions of HIF-1α ............................................................................................. 28 
Figure 28 - Fluorescence anisotropy binding of different peptides to p300 (80 
nM FITC-peptide, 40 mM sodium phosphate, 100 mM NaCl, 1 mM 
DTT, 5% glycerol). Error bars represent the standard deviation of 3 
repeats. ............................................................................................................. 29 
Figure 29 - Fluorescence anisotropy binding of helix 3 in the presence and 
absence of helix 2. (80 nM FITC-HIF-1α CTAD, 3 mM helix 2 peptide, 
40 mM sodium phosphate, 100 mM NaCl, 1 mM DTT, 5% glycerol). 
Error bars represent the standard deviation of 3 repeats. ................................. 30 
Figure 30 - Ensemble NMR structures of helix 2 to helix 3 linker region. 1 
backbone representation shown for clarity. ..................................................... 31 
Figure 31 - PEG linked peptide sequences ............................................................... 32 
Figure 32  - Binding curves for FITC peptide PEG conjugates (80 nM FITC-
Peptide, 40 mM sodium phosphate, 100 mM NaCl, 1 mM DTT, 5% 
glycerol). Error bars represent the standard deviation of 3 repeats. ................ 32 
Figure 33 - Sequences of peptides used to explore inhibitory ability of HIF-1α 
CTAD regions .................................................................................................. 34 
Figure 34 - Competition assay with peptide portions of HIF-1α against FITC 
HIF-1α CTAD. (80 nM FITC-HIF-1α CTAD, 0.1 µM p300, 40 mM 
sodium phosphate, 100 mM NaCl, 1 mM DTT, 5% glycerol, 0.1% 
triton).  Error bars represent the standard deviation of 3 repeats. .................... 34 
Figure 35 - eIF4G peptide sequences ........................................................................ 35 
- xii - 
Figure 36 - Binding curve for FITC-eIF4G/eIF4E (80 nM FITC-eIF4G, 40 
mM sodium phosphate, 200 mM NaCl, 1 mM DTT, 5% glycerol, 0.1% 
triton). Error bars represent the standard deviation of 3 repeats ...................... 36 
Figure 37 - Comparison of labelled eIF4G binding to eIF4E and eIF4E-SUMO 
by anisotropy (80 nM FITC-eIF4G, 40 mM sodium phosphate, 200 mM 
NaCl, 1 mM DTT, 5% glycerol, 0.1% triton). Error bars represent the 
standard deviation of 3 repeats......................................................................... 37 
Figure 38 - Incubation time dependence on fluorescence anisotropy assays 
between eIF4G and eIF4E (80 nM FITC-eIF4G, 40 mM sodium 
phosphate, 200 mM NaCl, 1 mM DTT, 5% glycerol, 0.1% triton). Error 
bars represent the standard deviation of 3 repeats ........................................... 38 
Figure 39 - Temperature dependence of eIF4G/eIF4G interaction (80 nM 
FITC-eIF4G, 40 mM sodium phosphate, 200 mM NaCl, 1 mM DTT, 5% 
glycerol, 0.1% triton). Error bars represent the standard deviation of 3 
repeats .............................................................................................................. 39 
Figure 40 - Van't Hoff Analysis for the eIF4E/eIF4G interaction ............................ 39 
Figure 41 - Structures of 5' Cap and Cap Analogue used in binding 
investigation ..................................................................................................... 40 
Figure 42 - Effect of cap or cap analogue on eIF4E/eIF4G binding interaction 
(80 nM FITC-eIF4G, 40 mM sodium phosphate, 200 mM NaCl, 1mM 
Cap or Analogue, 1 mM DTT, 5% glycerol, 0.1% triton). Error bars 
represent the standard deviation of 3 repeats ................................................... 40 
Figure 43 - Competition titration of eIF4G vs FITC-eIF4G with eIF4E 
followed by fluorescence anisotropy (80 nM FITC-eIF4G, 3 µM eIF4E, 
40 mM sodium phosphate, 200 mM NaCl, 1 mM DTT, 5% glycerol, 
0.1% triton). Error bars represent the standard deviation of 3 repeats............. 41 
Figure 44 - Structure of known eIF4E/eIF4G inhibitors ........................................... 41 
Figure 45 - Competition titration of 41R-Cat vs FITC-eIF4G with eIF4E 
followed by fluorescence anisotropy (80 nM FITC-eIF4G, 3 µM eIF4E, 
40 mM sodium phosphate, 200 mM NaCl, 1 mM DTT, 5% glycerol, 
0.1% triton). Error bars represent the standard deviation of 3 repeats............. 42 
Figure 46 - Helix 2 binding region ............................................................................ 46 
Figure 47 - Helix 3 binding region ............................................................................ 46 
Figure 48 – eIF4G binding region ............................................................................. 47 
Figure 49 - Structure of known eIF4E/eIF4G inhibitor, 4EGI-1 used in 
docking validation ............................................................................................ 47 
Figure 50 - Ten overlaid structures of known eIF4E/eIF4G inhibitor, 4EGI-1 ........ 48 
Figure 51 - ROCS query preparation. From left to right: helical region of 
peptide extracted from 1L8C, helical region with non-bonding 
sidechains removed, helical region with backbone converted to carbon 
chain. ................................................................................................................ 49 
Figure 52 - ROCS queries employed in pharmacophore searching. From left to 
right: HIF-1α helix 2, HIF-1α helix 3, eIF4G .................................................. 49 
- xiii - 
Figure 53 - Competition Assay of Compound 10 against HIF-1α/p300 (80 nM 
FITC-HIF-1α CTAD, 0.1 µM p300, 40 mM sodium phosphate, 100 mM 
NaCl, 1 mM DTT, 5% glycerol, 0.1% triton).  Error bars represent the 
standard deviation of 3 repeats......................................................................... 52 
Figure 54 – Mass spectrometric analysis of p300 (100 μM) and compound 10. 
Top panel – protein mass spectrum with no compound, Bottom panel – 
after treatment for 30 minutes with 100 uM compound 10 for 30 
minutes. Blue diamonds denote protein peaks, red squares denote 
protein-compound complex ............................................................................. 53 
Figure 55 - Competition curve for compound 4 in the eIF4E/eIF4G 
competition assay. IC50 - 612 ± 59 μM. 80 nM FITC-eIF4G, 3 µM 
eIF4G, 40 mM sodium phosphate, 200 mM NaCl, 1 mM DTT, 5% 
glycerol, 0.1% triton). Error bars represent the standard deviation of 3 
repeats. ............................................................................................................. 54 
Figure 56 - Docked pose for compound 4 in the eIF4G binding domain of 
eIF4E with ligand interaction diagram (inset). Docking performed using 
Glide ................................................................................................................. 55 
Figure 57 - Analogues of compound 4 ...................................................................... 55 
Figure 58 - Initial hits from docking of de novo library against helix 2 binding 
region ............................................................................................................... 58 
Figure 59 – Core structure of enumerated bicyclic compound library. .................... 59 
Figure 60 - Example docked structures of de novo designed compounds in the 
helix 2 binding site of p300. (a) helix 2 in the binding (b-d) docked 
compound structures ........................................................................................ 59 
Figure 61 - X-ray crystal structure of compound cis-42 ........................................... 61 
Figure 62 - Competition Assay of Compound 46 against HIF-1α/p300 (80 nM 
FITC-HIF-1α CTAD, 0.1 µM p300, 40 mM sodium phosphate, 100 mM 
NaCl, 1 mM DTT, 5% glycerol, 0.1% triton).  Error bars represent the 
standard deviation of 3 repeats......................................................................... 63 
Figure 63 - Schematic representation of the proteomimetic concept ........................ 66 
Figure 64 - Structures of foldamer helix mimetics ................................................... 67 
Figure 65 - Structures of 3-O-alkylated oligo-benzamides, N-alkylated oligo-
benzamides and the oligopyridylamides .......................................................... 68 
Figure 66 - Structures of constrained peptides .......................................................... 69 
Figure 67 – Rational design of helix 3 mimics. From left to right: Helix 
mimetic 3D structure, Helix 3 excised from the NMR structure of  p300 
in complex with the C-terminal transactivation domain of HIF-1α (PDB 
ID: 1L8C), superimposed 3D structures and chemical structures of 
designed oligobenzamide mimics .................................................................... 70 
Figure 68 - Structures of monomers.......................................................................... 71 
Figure 69 - Representative fluorescence anisotropy titration data for the 
unlabelled HIF-1α (red) and compound 1 (black). (40 mM sodium 
phosphate buffer pH 7.5, 80 nM FITC-HIF-1α, 100 nM p300) ...................... 74 
- xiv - 
Figure 70 - Proposed binding modes of compound 1 in the Helix 3 binding 
cleft .................................................................................................................. 76 
Figure 71 - Competition assay for compound 1 against the eIF4E/eIF4G 
Protein-Protein Interaction (80 nM FITC-eIF4G, 3 µM eIF4E, 40 mM 
sodium phosphate, 200 mM NaCl, 1 mM DTT, 5% glycerol, 0.1% 
triton). Error bars represent the standard deviation of 3 repeats ...................... 78 
Figure 72 - N-alkylated analogues. From left to right, superimposed structures 
of N-alkylated proteomimetic and the HIF-1 Helix 3 excised from the 
NMR structure of  p300 in complex with the C-terminal transactivation 
domain of HIF-1α (PDB ID: 1L8C), 3d model of N-alkylated oligo-
benzamide in the extended conformation, structure of N-alkylated oligo-
benzamide 81. .................................................................................................. 79 
Figure 73 – Rational design of helix 2 mimetics. Top from left to right: Helix 
mimetic 3D structure, Helix 2 excised from the NMR structure of  p300 
in complex with the C-terminal transactivation domain of HIF-1α (PDB 
ID: 1L8C), superimposed 3D structures. Bottom chemical structures of 
designed oligobenzamide mimics .................................................................... 80 
Figure 74 - Allyl precursors for late stage functionalization .................................... 85 
Figure 75 - Schematic representation of photo-crosslinking approach ..................... 88 
Figure 76 - Structure of cross linking compounds prepared ..................................... 90 
Figure 77 - LC trace and example MS/MS for p300 digestion ................................. 91 
Figure 78 - Analytical data for photo-crosslinking experiments. (a) 
Chromatogram of 150 μM compound 129 in buffer prior to UV 
irradiation. The peak corresponding to compound 129 is denoted by the 
asterisk (b) Chromatogram of 150 μM compound 129 in buffer post UV 
irradiation (365 nm, 1 hour) (c) mass spectrum of protein before UV 
irradiation (365 nm, 1 hour)  (d) mass spectrum of protein after UV 
activation (365 nm, 1 hour) .............................................................................. 92 
Figure 79 - Structure of oligobenzamide peptide hybrid 137 ................................... 98 
Figure 80 - Structure of oligobenzamide peptide hybrid 138 ................................... 99 
Figure 81 - Fluorescence anisotropy inhibitor curves for hybrid 138 and the 
helix 2-3 peptide ............................................................................................ 100 
Figure 82 - Overlaid NMR structure and docked pose showing mismatch at the 
N-terminus of helix 3 ..................................................................................... 101 
Figure 83 - Library enumeration protocol ............................................................... 125 
Figure 84 - Starting cyclic sulfamidate for bicyclic core enumeration ................... 125 
Figure 85 - Alkylating groups for bicyclic core enumeration ................................. 125 
Figure 86 - Protected amino esters for bicyclic core enumeration.......................... 126 
Figure 87 - Capping groups for bicyclic core enumeration .................................... 127 
- xv - 
List of Schemes 
Scheme 1 - Preparation of aminothiazoles ................................................................ 56 
Scheme 2 – Synthetic route to bicyclic target compound ......................................... 60 
Scheme 3 – Preparation and alkylation of methyl 3-hydroxy-4-nitrobenzoate, 
58 ...................................................................................................................... 71 
Scheme 4 - Monomer differentiation via either reduction or ester hydrolysis. ........ 72 
Scheme 5 - Assembly of oligobenzamide helix mimetics via iterative coupling 
and reduction cycles ending with a final hydrolysis ........................................ 73 
Scheme 6 – Synthesis of sulfonamide, KCN-1 ......................................................... 77 
Scheme 7 - Synthesis of protected helix 2 monomers .............................................. 81 
Scheme 8 - Synthesis of dimers via acyl transfer ..................................................... 83 
Scheme 9 - Example de-allylation reaction of trimer 103 ........................................ 86 
Scheme 10 - Example late stage functionalization ................................................... 86 
Scheme 11 - Synthesis of trifluoromethyldiazarine building block .......................... 89 
Scheme 12 - Late stage one-pot synthesis of photocrosslinking helix mimetic ....... 89 
Scheme 13 - Previously developed iterative solid phase synthesis of 
oligobenzamides
150
 .......................................................................................... 94 
Scheme 14 - Attempted coupling of Fmoc-Glycine to the N-terminus of an 
oligobenzamide trimer ..................................................................................... 95 
Scheme 15 - Synthesis of Fmoc-Gly iBu monomer, 136 ......................................... 96 
Scheme 16 - Solid phase synthesis of oligobenzamide peptide hybrids ................... 97 
Scheme 17 - Route for virtual enumeration ............................................................ 124 
- xvi - 
List of Tables 
Table 1 – Distances from helix 2-3 and PEG linker lengths. .................................... 31 
Table 2 - Binding constants for PEG linked constructs determined by 
fluorescence anisotropy protein titrations ........................................................ 33 
Table 3 – Compounds selected for screening from commercially available 
libraries ............................................................................................................ 50 
Table 4 – Compound 4 analogue library prepared .................................................... 56 
Table 5 - Bicyclic compounds prepared from computationally designed library ..... 62 
Table 6 - Structures and IC50 values for Oligobenzamide library ............................. 75 
Table 7 – Results from coupling experiments towards helix 2 mimetics ................. 82 
- xvii - 
List of Abbreviations 
 
4E-BP 4E-Binding Protein 
AIB Amino iso-butyric Acid 
ARNT Aryl hydrocarbon receptor nuclear transporter 
bHLH Basic loop-helix-loop 
Boc t-Butyl Carbamate 
CBP cAMP response element-binding protein (CREB) 
binding protein 
CH Cysteine/histidine-rich 
CITED CREB-binding protein/p300-interacting transactivator 
with ED-rich tail 
CTAD C-terminal transactivation domain 
DIPEA Diisopropylethylamine 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic acid 
DTT Dithiothreitol 
eIF4E Eukaryotic initiation factor 4E 
eIF4G Eukaryotic initiation factor 4G 
FIH Factor inhibiting HIF 
FITC Fluorescein isothiocyanate 
Fmoc 9-Fluorenylmethyl 
HAT Histone acetyl transferase 
HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate 
HBS Hydrogen bond surrogate 
HCTU N,N,N′,N′-Tetramethyl-O-(6-chloro-1H-benzotriazol-1-
yl)uronium hexafluorophosphate 
hDM2 Human double minute 2 
- xviii - 
HIF Hypoxia inducible factor 
HPLC High pressure liquid chromatography 
HRE Hypoxic response element 
HRMS High resolution mass spectrometry 
HSQC Heteronuclear single quantum correlation 
IC50 Half maximal inhibitory concentration 
IRES Internal ribosome entry site 
ITC Isothermal titration calorimetry 
Kd Dissociation constant 
Ki Inhibition constant 
LC-MS Liquid chromatography-mass spectrometry 
LC-MS/MS Liquid chromatography- mass spectrometry/mass 
spectrometry 
m7G 7-Methylguanylate 
MOM Methoxymethyl 
mRNA Messenger ribonucleic acid 
mTOR Mammalian target of rapamycin 
NMR Nuclear magnetic resonance 
ODDD Oxygen dependant degradation domain 
PAINS Pan Assay Interference Compounds 
PAS Per-ARNT-AHR-Sim 
PEG Polyethylene glycol 
PHD Prolylhydroxylase domain 
PPI Protein-Protein Interaction 
pTSA Para-toluene sulfonic acid 
pVHL Von-Hippel Lindau protein 
PyBOP Benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate 
ROCS Rapid overlay of chemical shape 
SAR Structure activity relationship 
- xix - 
SCX Strong Cation Exchange 
SPPS Solid phase peptide synthesis 
SUMO Small ubiquitin-like modifier 
TFA Trifluoroacetic acid 
TLC Thin layer chromatography 
VEGF Vascular endothelial growth factor 
 
  
- xx - 
Amino Acid Abbreviations 
Full name Abbreviation Single letter code 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamine Gln Q 
Glutamic Acid Glu E 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
- 1 - 
Chapter 1 – Protein-Protein Interactions: HIF-1α/p300 and 
eIF4E/eIF4G 
The candidate confirms that the work submitted is his own, except where work 
which has formed part of jointly authored publications has been included. The 
contribution of the candidate and the other authors to this work has been explicitly 
indicated below. The candidate confirms that appropriate credit has been given 
within the thesis where reference has been made to the work of others. 
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1.1 Protein-Protein Interactions 
Historically, drug discovery has focussed on the modulation of enzymes to elicit a 
pharmacological response. This approach has many advantages such as a potentially 
well-defined binding pocket or an endogenous substrate to use as a starting point for 
small molecule design.
1
 However protein-protein interactions (PPIs) are implicated 
in virtually all biological pathways
2
 and are emerging as new targets for therapeutic 
intervention. The inhibition of protein-protein interactions represents an unaddressed 
challenge with significant potential in chemical biology and drug discovery. 
The challenges involved in inhibiting PPIs are based around the differences from the 
approach used to inhibit enzymatic targets. A protein-protein interface is often seen 
as two large flat featureless surfaces interacting but this is seldom the case;
3
 there 
may be key “hotspots”,4 defined or transitory binding residues or regions, which 
provide the majority of the affinity.
5
 
1.1.1 α-Helix Mediated Protein-Protein Interactions 
Of particular interest are α-helix-mediated PPIs where a key helical region of a 
protein, the helix donor, binds into a cleft on a partner protein, the helix acceptor 
(Figure 1).
6
 The helix acceptor complements the well-defined structure of an α-helix 
and can therefore be inhibited by other small peptides with similar conformations 
and compatible side chains or small molecules that bind strongly into the helix 
acceptor cleft. 
 
Figure 1 - Schematic representation of an α-helix mediated protein-protein 
interaction. The helix donor is shown in red whilst the helix acceptor is shown 
in blue. 
It has been estimated the human interactome contains over 650,000 pairwise PPIs
7
 
offering many opportunities for signalling pathway modulation. Analysis of the 
protein structure database shows that 62% of all multi-protein complexes feature an 
α-helix at the interface between the proteins. Furthermore, computational alanine 
scanning estimates around 60% of these helix-mediated PPIs feature a proposed 
hotspot contained within the helical region.
8
  
- 3 - 
Due to the well conserved structure of helical protein domains, significant efforts 
have been focussed on the mimicry of helices to develop inhibitors.
9
 These efforts 
have led to a wealth of technologies for inhibition of helix mediated PPIs (see 
Chapter 5) which have afforded potent inhibitors. This success, and the success of 
more traditional drug discovery approaches toward this subset of PPIs, has led to 
interactions involving an α-helix being considered more tractable.9  
1.1.2 Helix-Mediated PPIs in Cancer 
A wide range of helix mediated PPIs has been implicated in cancer progression.
10
 
The prototypical helix-mediated PPI is the interaction between p53 and hDM2 
which has been widely studied allowing several potent  inhibitor compounds to be 
discovered.
11
 Many of the PPIs studied for cancer therapy are involved in the 
regulation of apoptosis,
12
  however there exists a multitude of other PPIs relevant to 
cancer. Discussed below are two therapeutically-relevant α-helix-mediated PPIs 
which are the focus of this thesis. 
1.2 Hypoxic Sensing 
Homeostasis is key for health and the body has evolved a large number of sensing 
systems and feedback loops to allow tissue to respond to changes and return to the 
“normal” state. Arguably the most important factor for survival is oxygen level. 
Sensing hypoxia is crucial for healthy tissue growth as when growing tissue 
exhausts the supply of oxygenated blood, there must be a pathway through which 
the growth of additional vasculature is stimulated.   
Hypoxia Inducible Factor-1α (HIF-1α) plays a major role in oxygen sensing within 
tissues. HIF-1α is constitutively expressed in cells but rapidly degraded  or 
deactivated via oxygen-dependent mechanisms under normoxic conditions. This 
degradation of HIF-1α is so efficient and rapid that there is effectively no HIF-1α in 
cells under normoxic conditions.
13
  
When HIF-1α accumulates, it translocates to the nucleus and forms a heterodimer 
with HIF-1β. It also forms a PPI with the promiscuous transcriptional co-factor p300 
(Figure 2).
14, 15
 p300 has a homolog known as CREB binding protein (CBP) which is 
considered largely functionally and structurally redundant.
15
 The HIF-1 dimer/p300 
complex binds to hypoxic response elements (HRE) on DNA and causes a plethora 
of downstream events via transcription mediation.
16
 Perhaps most crucially, it 
induces expression of vascular endothelial growth factor (VEGF) which stimulates 
angiogenesis, thus resupplying the hypoxic region with oxygen-rich blood and 
relieving the hypoxic state. Another effect downstream of HRE binding is regulation 
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of oxygen usage, switching the cell from aerobic to anaerobic respiration by 
expression of glycolytic enzymes.
17
 
 
Figure 2 - HIF pathways under normoxic and hypoxic conditions. HIF-1α - Hypoxia 
Inducible Factor 1α, HIF-1β - Hypoxia Inducible Factor 1β, PHD – prolyl 
hydroxylase domain, HRE – hypoxic response element. 
However, the hypoxic response pathway can be exploited by cancers. Rapidly 
dividing cells, forming solid tumours, will rapidly deplete the local oxygen supply 
and become hypoxic. The hypoxic response cascade will then resupply the tissue 
with oxygen via angiogenesis. The fact that the hypoxic response facilitates the 
growth and survival of solid tumours makes it a potential target for therapeutic 
intervention.
18, 19
 
1.2.1 HIF Regulation 
The major pathway through which HIF-1α is degraded is via prolyl hydroxylase 
domain (PHD) enzymes.
13, 20
 PHD enzymes function via the reaction between 2-
oxoglutarate and oxygen, mediated via non-haem iron, to hydroxylate two proline 
residues (Pro402 and Pro564) in the oxygen dependent domains of HIF-1α (Figure 3). 
This PHD mediated hydroxylation of HIF-1α stimulates an interaction with the von-
Hippel Lindau protein, an E3 ligase which ubiquitinates HIF-1α, targeting it for 
proteasomal degradation (Figure 2).
13
 
Another pathway through which HIF-1α is regulated is also via oxygen-dependent 
hydroxylation by a protein known as Factor Inhibiting HIF (FIH).
21
 Hydroxylation 
by FIH of an asparagine residue (Asn803) on the C-Terminal Transactivation Domain 
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(CTAD) of HIF-1α prevents its association with p300.22 Through this mechanism, 
FIH acts as a second oxygen sensor. Under hypoxic conditions, neither the PHDs 
nor FIH are active and as such the level of HIF-1α increases. Through these oxygen 
sensing enzymes, cells regulate their metabolism as discussed above and respond to 
hypoxia. 
1.2.2 Structural Biology of HIF-1α/p300 
As previously discussed, HIF-1 is a heterodimer of HIF-1α and HIF-1β (sometimes 
known as aryl hydrocarbon receptor nuclear translocator, ARNT). There are also 2 
isoforms of HIF-1α, known as HIF-2α and HIF-3α. Whilst both can form dimers 
with HIF-1β, HIF-3α lacks the ability to bind the co-activator protein and thus is 
inactive.
19
 When HIF-2α and HIF-3α form complexes with HIF-1β they are known 
as HIF-2 and HIF-3 respectively and have been reported to be expressed in different 
amounts in different tissues.
23
 
 
Figure 3 - Domains of HIF-1α. bHLH – basic helix-loop-helix, PAS – per ARNT-
AHR-Sim, ODDD - oxygen-dependent degradation domain, NTAD – N-terminal 
transactivation domain, CTAD – C-terminal transactivation domain. 
The dimerization occurs through a basic helix-loop-helix (bHLH) domain and 2 per-
ARNT-AHR-Sim (PAS) domains on both the HIF-1α subunit and the HIF-1β 
subunit.
24
 PAS domains are implicated in protein-protein interactions in other 
systems.
25
 It is also thought that coiled coil co-activators play a role in the 
dimerization.
26
 HIF-1α has several other key domains, as shown in Figure 3, the 
oxygen-dependent degradation domain (ODDD) which contains the proline residues 
which are hydroxylated under normoxia and both the N-terminal and C-terminal 
transactivation domains.
27
 The C-terminal transactivation domain (CTAD) is the 
region that interacts with p300. 
p300 is a  large multidomain protein that acts as a transcriptional co-activator for 
many transcription factors. It also has epigenetic modulation functions via its 
bromodomain and HAT domains.
15
 p300 has three cysteine/histidine-rich (CH) 
domains, CH1, CH2 and CH3, which all bind zinc. Transcription factors bind at the 
CH domains and this binding is usually specific to one of the CH domains. HIF-1α 
binds to the CH1 (sometimes known as transcriptional adapter zinc-binding (TAZ)1 
domain) domain of p300.
28
  
Structures of the HIF-1α CTAD complexed with p300 was determined by two 
groups simultaneously by solution NMR studies.
29, 30
 To date, no X-ray crystal 
structure of the HIF-1α/p300 complex has been reported. The p300 CH1 domain 
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forms a rigid structure consisting of 4 helices constrained and stabilised by binding 3 
zinc atoms whilst the HIF-1α CTAD is thought to be unstructured in the absence of 
p300. Upon binding to the CH-1 domain, HIF-1α forms three helical regions which 
appear to mediate the binding between the two proteins (Figure 4). The CH-1 
domain of p300 is also the binding site for the CREB-binding protein/p300-
interacting transactivator with ED-rich tail (CITED) family of proteins which can 
compete with HIF-1α.31, 32 
 
Figure 4 - NMR structures of (a) p300 CH1 domain (green) in the complex (peptide 
not shown) (b) Complex between HIF-1α CTAD (blue) and p300 CH1 domain 
(green) (zinc omitted for clarity) PDB ID: 1L8C (c) primary sequence of HIF-
1α CTAD with helical regions indicated 
1.2.3 HIF-1α/p300 Hotspots 
Functional analysis of the binding between HIF-1 and p300 has identified several 
hot spot residues which are focussed on two of the helical regions, helix 2 and helix 
3.
33
 Throughout this thesis, the helices in the HIF-1α CTAD are numbered 
sequentially from N- to C-terminus as shown in Figure 4.  
Helix 2 of the HIF-1α CTAD features two reported hot-spot residues. The first is the 
asparagine previously discussed as the target for FIH. Hydroxylation of Asn803 
prevents a key intermolecular hydrogen bond and introduces a steric clash.
29
 Also 
considered a hotspot residue, is Cys800 on helix 2.
34
 A C800A mutation has been 
reported to reduce binding to p300.
35
 It has been suggested that post-translational 
nitrosylation of Cys800 can regulate the interaction between HIF-1α and p300 but 
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there is conflicting evidence as to whether it increases
36
 or decreases
35
 binding. Both 
of these residues are on the same face of helix 2, binding into the surface of p300 
(Figure 5).  
 
Figure 5 - Helix 2 binding site with reported hotspot residues highlighted 
Truncations of the CTAD to remove helix 3 have been reported to prevent binding 
between HIF-1α and p300.33 Further analysis by mutagenesis and alanine scanning 
has identified several important hydrophobic residue on helix 3.
34
 Again, these 
hotspot residues align along one face of the helix in the i, i+4 and i+7 positions as 
shown in Figure 6. 
 
Figure 6 - Helix 3 binding site with reported hotspot residues highlighted 
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Whilst a large amount of work has been done to explore the requirements for 
binding of HIF-1α to p300 it is still not clear which of the hotspots provides the 
primary driving force for the interaction. Further work is required to allow targeted 
design of inhibitors. 
1.2.4 Inhibitors of the Hypoxic Response Pathway 
There are several potential points of intervention along the hypoxic response 
pathways, described in Figure 2, at which it has been modulated by various 
compounds.
19
 For example, both inhibitors
37
 and activators
38
 of the PHD enzymes 
have been reported. The Crews lab has published inhibitors of the HIF-1α/pVHL 
interaction.
39, 40
 Significantly these modulators focus on the normoxic response 
pathways, however under hypoxic conditions, such as in solid tumours, these 
pathways are not active due to their intrinsic dependence on oxygen. 
Inhibitors active under hypoxic conditions must therefore focus on the interactions 
between proteins or between proteins and hypoxic response elements. Several 
families of compounds have been identified which inhibit the interaction between 
HIF-1α and HIF-1β. Acriflavine (Figure 7) was identified as an inhibitor of 
dimerization in a screen of compounds that had previously entered phase II clinical 
trials.
41
 The Tavassoli group has used genetically encoded libraries to identify cyclic 
peptide inhibitors of HIF dimerization such as cyclo-CLLFVY (Figure 7).
42
 
Interestingly, a selective small molecule inhibitor of HIF-2 heterodimer formation 
has been identified that does not affect HIF-1 formation.
43
  
 
Figure 7 - Structures of HIF-1 dimerization inhibitors 
Another approach to mediating the hypoxic response is to prevent transcription of 
hypoxic response elements. Dervan and co-workers have achieved this using 
rationally designed polyamides which selectively bind the HRE for VEGF.
44
 
Echinomycin has also been shown to prevent HIF-1α DNA interactions.45 Inhibitors 
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of HIF-1β binding to coiled-coil co-activators have also been shown to decrease HIF 
mediated transcription under hypoxic conditions.
46
 
Perhaps the main target for inhibition of the hypoxic response is the HIF-1α/p300 
interaction although it has been called “ a considerable challenge”29 based on the 
area over which the interaction occurs. High-throughput screening has identified 
several compounds capable of eliciting a cellular response consistent with HIF-
1α/p300 inhibition. A natural product, Chetomin (Figure 8), was identified as an 
inhibitor and shown to be effective at down-regulating HIF-controlled transcription 
as well as reducing tumour size in mouse models.
47
 The epidithiodiketopiperazine 
(ETP) functionality contained in Chetomin has been shown to disrupt the folding of 
the CH-1 domain of p300, via zinc ejection, preventing interaction with HIF-1α.48 
Indeed, much simpler ETP containing compounds have been shown to be sufficient 
for activity.
48, 49
 Additional families of compounds capable of disrupting the folding 
of the p300 CH1 domain by zinc ejection have been identified, including ninhydrin 
(Figure 8).
50
 Compounds with zinc ejection-based mechanisms are likely to 
encounter issues with selectivity and toxicity, due to interactions with other zinc-
binding proteins and the fact that p300 has multiple binding partners.
49
 
 
Figure 8 - Structures of compounds capable of ejecting zinc from p300 
A small molecule called KCN-1 (Figure 9), reported to inhibit the HIF-1α/p300 
interaction, was identified through high-throughput cell based screening of a 
combinatorial library.
51
 KCN-1 has been shown to prevent HIF-regulated expression 
and reduce tumour size in animal models but the exact mode of action still remains 
unclear
52, 53
 (See Chapter 5 for further discussion). 
- 10 - 
 
Figure 9 - Structure of KCN-1 
The Arora group has employed hydrogen-bond surrogate (HBS) peptides to inhibit 
the HIF-1α/p300 interaction. HBS peptides constrain the conformation of a helix by 
replacing the N-terminal i to i+4 hydrogen-bond with a covalent link (Figure 10) 
thus inducing helicity. The Arora group have reported HBS peptides for both helix 
2
54
 and helix 3
55
 regions of the HIF-1α CTAD. 
 
 
Figure 10 - Structures of i to i+4 hydrogen bond and hydrogen bond surrogate. 
The work presented in Chapter 5 of this thesis describes the development of the first 
small molecule inhibitors 1 of HIF-1α/p300 to be characterised biophysically.53 
Subsequently, the Arora group has also published small molecule inhibitors, such as 
2, of the HIF-1α/p300 PPI based on a similar proteomimetic approach.56, 57 Although 
Arora’s compounds show high affinity binding to p300 and reduce HIF-regulated 
transcription, they have not been explicitly shown to disrupt the interaction between 
HIF-1 and p300.  
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Figure 11 - Structures of proteomimetic inhibitors of HIF-1α/p300 
There is still a need for potent, selective inhibitors of the interaction between the 
HIF-1α CTAD and the CH1 domain of p300. The inhibitors discussed above provide 
some evidence that the interaction is tractable and a valid target, however none of 
them are understood well enough or have the correct properties to enter the clinic. 
1.3 Control of Translation 
As discussed above, cancers can exploit cellular pathways to control protein 
transcription but other systems for protein level control exists, such as those 
controlling HIF-1α levels. Once genes are transcribed from DNA to mRNA, they 
must be translated into proteins. In eukaryotes, mRNA must be recruited to the 
ribosome for translation to occur. One way in which this occurs is the cap-dependent 
recruitment mediated by the eukaryotic initiation factor (eIF)-4 complex outlined in 
Figure 12.  
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Figure 12 - Schematic representation of the eIF4 recruitment of 5’Cap-mRNA to the 
ribosome 
The 5′-end of certain mRNAs is capped with 7-methylguanylate (m7G), the 
structure of which is shown in Figure 12. mRNA bearing this modification can bind 
to eIF4E, a subunit of the eIF4 complex which in turn forms a protein-protein 
interaction with the N-terminal domain of eIF4G.
58, 59
 eIF4G is a large scaffolding 
protein with also binds the eIF4a subunit, which is thought to unwind mRNA. The 
formation of this eIF4/mRNA complex facilitates the recruitment of 5′-cap mRNA 
to the 40S subunit of the ribosome, initiating translation. An alternative form of cap-
independent translation can occur if the mRNA features a structure known as an 
internal ribosome entry site (IRES) which facilitates direct recruitment to the 40S 
subunit.
60, 61
 
eIF4E recruitment to the eIF4 complex can be inhibited by binding to a protein 
called 4E binding partner (4E-BP) (Figure 12). 4E-BP binds to the same site on 
eIF4E as eIF4G via a conserved YX4Lɸ amino acid sequence (where X = any 
residue and ɸ = a hydrophobic residue.62 The YX4Lɸ is the same recognition 
element employed by eIF4G.
63
 4E-BP Phosphorylation state is crucial for the 
regulation of 4E-BP binding to eIF4E allowing cellular regulation of translation. 
When phosphorylated, 4E-BP binds with significantly lower affinity than when non-
phosphorylated thus the phosphorylation event releases eIF4E to interact with 
eIF4G.
64
 It has also been shown that 4E-BP binds to eIF4E at a distal non-
competitive site which induces dissociation of eIF4G.
65
 
Due to sequestration by 4E-BP and low levels of endogenous expression, eIF4E is 
the limiting partner for the formation of the eIF4 complex and as such regulates 
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which mRNAs are translated into proteins. This regulation occurs through the 
competition of mRNA for eIF4E; well-defined 5′ end RNA sequences are rapidly 
translated whilst ill-defined 5′ end RNA sequences are translated slower. This leads 
to regulation of the proteins expressed by cells.
66
 Some key genes implicated in 
cancer cell survival are regulated at this level and in cancer cells the level of eIF4E 
is increased and thus the proteins involved in cell growth and inhibition of cell 
apoptosis are expressed at higher levels.
67
 The mRNA strands for these oncogenes 
have ill-defined 5′ ends so are usually out-competed by other mRNA strands. If the 
eIF4E protein is overexpressed, this regulation is no longer efficient and cancer cells 
can survive and proliferate. However, if the interaction between the eIF4E and 
eIF4G proteins is inhibited, the eIF4 complex cannot form and the proteins essential 
for cancer cell survival cannot be produced. Thus the interaction between eIF4E and 
eIF4G is also a potential target for the treatment of cancer.
67
 
1.3.1 Structural Biology of eIF4E/eIF4G 
The eIF4E protein has been crystallised in the presence of a peptide derived from 
eIF4G and the m7G cap structure.
68
 The X-ray crystal structure reveals that eIF4E 
consists of a large β-sheet and 3 long helices (Figure 13).69 The eIF4G derived 
peptide, acting as a helix donor, binds on one face of the  eIF4E protein whilst the 
m7G cap binds in a hydrophobic pocket at a distal site (Figure 13). It is unclear 
whether there is any cooperativity between cap and peptide binding (see Chapter 
2).
70, 71
 For both eIF4G and 4E-BP, the YX4Lɸ eIF4E recognition domain is thought 
to be unstructured in the absence of eIF4E.
62
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Figure 13 - Structure of eIF4E (green) bound to a peptide derived from eIF4G (red) 
and m7G Cap (structure coloured by element) (PDB ID: 2W97)  
1.3.2 eIF4E/eIF4G Hotspots 
Alanine scanning has been used to identified hot spot residues for the eIF4E/eIFG4 
interaction which match the conserved sequences (Figure 14).
63
 The tyrosine residue 
at position 416 is essential, mutation of this residue completely abrogates binding.
72
 
The leucine residues at positions 421 and 422 are also important but the non-
conserved Leu422 can be exchanged for another hydrophobic residue. 
 
Figure 14 - Hotspot residues for the eIF4E/eIF4G interaction 
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1.3.3 Inhibitors of Cap-Mediated Translation 
Several potential targets exist for the inhibition of cap-dependent translation and 
these have been exploited in several ways. For example, one of the kinases 
responsible for 4E-BP phosphorylation is mammalian target of rapamycin (mTOR). 
Inhibitors of mTOR prevent the phosphorylation of 4E-BP thus decreasing the 
amount of eIF4E available for eIF4 complex formation, preventing translation.
73
 
Many examples of mTOR inhibitors
74
 such as  AZD8055
75
 and rapamycin
73
  (Figure 
15) itself have been shown to prevent 4E-BP phosphorylation and decrease cap-
dependent translation.  
 
Figure 15 - Structures of mTOR inhibitors 
Another potential target for the inhibition of cap dependent translation is the binding 
of m7G to eIF4E. Ribavirin is currently used as an anti-viral, but has been shown to 
bind to eIF4E and compete for 5′-cap mRNA (Figure 16).76 It has also been shown 
to significantly reduce tumour size in murine models. Ribavirin mimics guanine 
ribonucleosides which is responsible for both its antiviral and anti-cancer activity. 
Figure 16 shows how Ribavirin is capable of mimicking m7G. 
 
Figure 16 - Structures of compounds that bind in the eIF4E cap binding region. 
Ribavirin shown protonated as it is thought to be protonated at physiological 
pH. 
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Considerable effort has been expended in the development of peptide based 
inhibitors of the eIF4E/eIF4G interaction. Since the requirements for peptide 
binding is well understood, as discussed above, various modifications to the peptide 
sequence have been made in positions where they will be tolerated. Short peptide 
sequences containing the YX4Lɸ  sequence conjugated to cell penetrating peptides 
have been shown to induce apoptosis.
77
 Increasing the helicity of eIF4G derived 
peptides by incorporating helix inducing amino iso-butyric acid (AIB) residues
72
 or 
peptide stapling
78
 has also been shown to increase affinity for eIF4E (Figure 17). A 
phage display approach was also used to identify peptides with an increased affinity 
for eIF4E (Figure 17).
79
 
 
Figure 17 - Higher affinity eIF4G peptides (a) generic stapled peptide structure (b) 
structure of AIB (c) the structure of the amino acid incorporated for peptide 
stapling via metathesis (d) structures of eIF4G peptides with increased affinity. 
X represents AIB incorporation, * represents the stapled positions. 
Finally, several groups have identified small molecules capable of inhibiting the 
interaction between eIF4E and eIF4G. High throughput screening (HTS) was used to 
identify eIF4E/eIF4G inhibitor 1 (4EGI-1) (Figure 18) which is capable of inducing 
the dissociation of eIF4G from eIF4E.
80
 Initially, it was thought that 4EGI-1 was an 
orthosteric inhibitor but it was subsequently shown to act through an allosteric 
mechanism by X-ray crystallography.
71
 Attempts have been made to optimise 4EGI-
1 for affinity by increasing its rigidity.
81
 
 
Figure 18 - Structure of small molecules inhibitors of eIF4E/eIF4G. PAINS 
substructure highlighted in red. 
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A second small molecule, 4E1R-Cat, also identified by HTS, was shown to inhibit 
the binding of both eIF4G and 4E-BP to eIF4E.
82
 However, the central core (shown 
in red in Figure 18) of 4E1R-Cat has been identified as a pan assay interference
83
 
(PAINS) compound and 4EIR-Cat or close analogues have been identified in a 
number of screens against different targets.
84
 Geldanamycin has also been reported 
to weakly inhibit the interaction between eIF4E and eIF4G.
85
  
As with the HIF-1α/p300 interaction, the inhibitors discussed above provide 
confidence that the eIF4E/eIF4G is a relevant and tractable target for the modulation 
of α-helix mediated protein-protein interactions but also that further study is 
required to develop potent inhibitors. 
1.4 Summary 
This chapter briefly introduced PPIs and their role in cancer then describes two 
potential targets for therapeutic intervention in the field of oncology: HIF-1α/p300 
which is activated as a response to a lack of oxygen and controls transcription and 
eIF4E/eIF4G which is activated by an overexpression of the eIF4E protein and 
controls translation. Initial success in the field has shown that these targets are 
potentially tractable and may lead to new therapeutics. The rest of this thesis will 
focus on enhancing the understanding of the interactions and the development of 
inhibitors of both the eIF4E/eIF4G and HIF-1α/p300 interactions. 
1.5 Project Aims 
This chapter has described two therapeutically relevant protein-protein interactions 
for which there is a clear need for new/improved inhibitors. The aim of this project 
was primarily to identify new compounds capable of inhibiting either/both of these 
targets.  
Initially this required the development of assays capable of identifying inhibitors. As 
this chapter outlines, the interaction between HIF-1α and p300 occurs over a large 
surface area and is a challenging target for modulation, the work presented within 
this thesis will endeavour to further elucidate the requirements for binding and thus 
allow targeted inhibitor design. 
Finally a variety of computational and synthetic approaches to inhibitor 
discovery/development were to be employed in the search for potent inhibitors of 
both the HIF-1α/p300 interaction and the eIF4E/eIF4G interaction. 
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Chapter 2 – Assay Development  
The candidate confirms that the work submitted is his own, except where work 
which has formed part of jointly authored publications has been included. The 
contribution of the candidate and the other authors to this work has been explicitly 
indicated below. The candidate confirms that appropriate credit has been given 
within the thesis where reference has been made to the work of others. 
 
Portions of the work presented in this chapter were included in a research paper that 
was accepted for publication in February 2014 (G.M. Burslem, H.F. Kyle, A.L. 
Breeze, T.A. Edwards,
  
A. Nelson,
 
S.L. Warriner
  
and A.J. Wilson, ChemBioChem, 
2014, 15, 1083). The contributions of the authors were as follows: GMB (the 
candidate) performed all synthetic chemistry, peptide synthesis and modelling, HFK 
performed all protein expression, GMB and HFK performed all assays jointly. GMB 
prepared a draft of the manuscript which was then edited into its present form 
(attached) by all authors. 
Portions of the work described in this chapter were submitted as part of a research 
paper describing the requirements for HIF-1α/p300 binding (Exploration of the HIF-
1α/p300 binding interface using peptide and adhiron phage display technologies to 
locate binding hot-spots for inhibitor development, H. F. Kyle, K. F. Wickson, J. 
Stott, G. M. Burslem, A. L. Breeze, D. C. Tomlinson, S. L. Warriner, A. Nelson, A. 
J. Wilson and T. A. Edwards, submitted). H.F.K. expressed proteins, carried out 
phage display experiments, performed NMR and crystallographic analysis. K.F.W. 
assisted with phage display experiments, J.S. perform bioinformatics analysis, 
G.M.B. (the candidate) prepared reagents. Binding studies were performed jointly 
by H.F.K. and G.M.B. A.L.B., D.C.T., S.L.W., A.N., A.J.W., and T.A.E. supervised 
the research. H.F.K. prepared a draft which was edited into its present form 
(attached) by all authors. Portions of the work performed by the candidate are 
included in this chapter. 
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2.1 Assay Development 
To facilitate the discovery of inhibitors of the interactions of interest, namely the 
HIF-1α/p300 interaction and the eIF4E/eIF4G interaction, it was necessary to 
develop competition assays capable of monitoring the inhibition of binding between 
peptide (derived from HIF-1α or eIF4G) and the corresponding protein binding 
partner (p300 or eIF4E respectively). Fluorescence anisotropy assays were selected 
as the primary screen as it is a relatively high throughput biophysical assay
86
 and has 
previously been used for the successful identification of PPI inhibitors by the Wilson 
group
87-90
 and others
80, 91, 92
 
2.1.1 The basis of fluorescence anisotropy
86
 
Fluorescence anisotropy is a technique based on polarized light and the time it takes 
for a molecule in solution to tumble. If a fluorophore is excited with polarized light 
at its excitation frequency, it will emit polarised light at the emission frequency. 
However, when a molecule is in solution it is tumbling so that although the light 
emitted is still polarised with respect to the incident angle, the light emitted from a 
sample is no longer as polarised. The degree to which the light at the emission 
frequency is polarised depends on the rate of tumbling of the molecule which in turn 
is dependent on the size (radius of gyration) of the molecule. For example, a large 
molecule, such as a protein, will rotate slowly in solution compared to a small 
molecule, so the degree of polarised light emitted from a sample of fluorescent 
protein will be higher than that of a fluorescent small molecule or peptide. This can 
be used to monitor complexation in solution. If a labelled small molecule in solution 
is tumbling rapidly then the light emitted will not be polarised but should it form a 
complex with a larger molecule then its effective size will increase, its rate of 
tumbling will decrease and thus the degree of polarized light will increase as 
illustrated in Figure 19. 
 
Figure 19 – Cartoon illustrating fluorescence anisotropy of peptide tracer ligand 
with and without competitive inhibitor present 
Anisotropy is calculated by measuring the intensity of light emitted with the same 
polarisation as the exciting source, s, and the intensity of light emitted with 
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perpendicular polarisation to the exciting source, p. From these measured values the 
total intensity, i, can be calculated from equation (1). The anisotropy, r, can then be 
calculated using equation (2). 
𝑖 = (2𝑝) + 𝑠     (1) 
 
𝑟 =
(𝑠−𝑝)
𝑖
      (2) 
To identify inhibitors of protein-protein interactions, anisotropy can be utilised by 
having a small fluorescently labelled peptide which contains key binding residues 
and the protein to which it binds in solution. Potential inhibitors can then be titrated 
into the solution and the fluorescence anisotropy measured. If the inhibitor competes 
away the labelled peptide from the protein then the fluorescence anisotropy should 
decrease because the small peptide is tumbling in solution faster than it could when 
complexed with the large protein. Ideally, the size difference between the peptide 
and protein would be large so that the change in tumbling rate would be large and 
the change in anisotropy would be greater. 
2.2 HIF-1α/p300 Assay Development 
2.2.1 Direct Binding of HIF-1α CTAD to p300 
As discussed in the previous chapter, the C-terminal transactivation domain (CTAD) 
of HIF-1α interacts with the CH1 domain of p300.30 To investigate this interaction 
and develop an assay capable of identifying inhibitors, the p300 CH1 domain 
(prepared by recombinant expression by H. Kyle) was titrated against a fluorescein 
labelled peptide (prepared by Proteogenix, France) derived from the sequence of the 
HIF-1α CTAD, shown in Figure 20, and the anisotropy measured (as described in 
the experimental section). An increase in the anisotropy, as shown in Figure 21, 
shows that as the protein concentration was increased, it bound to the fluorescent 
peptide and the rate of fluorophore tumbling decreased. Fitting this data to a 1:1 
binding model allowed the calculation of a binding constant (Kd) of 37.4 ± 4.4 nM 
which is in good agreement with the literature. 
29, 35, 55
  
 
 
Figure 20 - HIF-1α CTAD peptide sequences 
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Figure 21 – Binding curve for FITC HIF-1α CTAD/p300 CH1 domain (80 nM 
FITC-HIF-1α CTAD, 40 mM sodium phosphate, 100 mM NaCl, 1 mM DTT, 
5% glycerol). Error bars represent the standard deviation of 3 repeats. 
2.2.2 Time and Temperature Dependence of HIF-1α/p300 Interaction 
Initially the assay plates were prepared and allowed to equilibrate for approximately 
40 minutes. To ensure this was sufficient for an equilibrium to be reached, a plate 
was prepared and read at different time points; 40 minutes, 5 hours and 18 hours. 
The plot below, Figure 22, shows that no significant change was observed between 
40 minutes and 5 hours. A slightly different Kd was observed after 18 hours but due 
to the unknown stability of the protein and the fact that incubation for 18 hours is 
impractical, an incubation time of 40 minutes was selected. 
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Figure 22 - Time dependence on fluorescence anisotropy assays between FITC-
HIF-1α and p300. (80 nM FITC-HIF-1α CTAD, 40 mM sodium phosphate, 
100 mM NaCl, 1 mM DTT, 5% glycerol). Error bars represent the standard 
deviation of 3 repeats. 
A temperature screen was also conducted to assess the thermodynamic parameters 
governing complex formation, a plate was prepared and measured at different 
temperatures set by the plate-readers internal temperature control. The plate was 
incubated within the plate reader as the temperature was increased and held at the set 
temperature for a minimum of 20 minutes. A general increase in the rate of tumbling 
in solution as the temperature increases manifests itself as a decrease in the 
minimum and maximum anisotropy as seen in Figure 23.  
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Figure 23 - Temperature dependence of HIF-1α/p300 interaction(80 nM FITC-HIF-
1α CTAD, 40 mM sodium phosphate, 100 mM NaCl, 1 mM DTT, 5% 
glycerol). Error bars represent the standard deviation of 3 repeats. 
 
A general downwards trend was observed in the binding constant as the temperature 
increases. Performing a Van’t Hoff analysis (a plot of 1/T against ln Kd) on this data 
shows a positive gradient suggesting an exothermic interaction with an enthalpic 
driving force. The negative entropic contribution could be attributed to the adoption 
of ordered helical regions observed in NMR structures over the random coil thought 
to exist in the absence of p300.
30
 The enthalpic/entropic contributions are 
corroborated by the ITC experiment discussed below. 
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Figure 24 - Van't Hoff Analysis for the HIF-1α/p300 interaction 
2.2.3 Isothermal Titration Calorimetry analysis of HIF-1α/p300 
To further confirm this interaction, an isothermal titration calorimetry (ITC) 
experiment was conducted. ITC gives useful information about binding affinity but 
also provides information about the stoichiometry of an interaction and 
enthalpic/entropic contributions to the binding free energy. During an ITC 
experiment one binding partner is injected in aliquots into a temperature controlled 
cell containing the other binding partner. As the partners interact, a reference cell is 
either heated or cooled to maintain the same temperature between the two cells. The 
energy required to alter the reference cell temperature can be used to derive a 
binding isotherm. By employing this technique a Kd of 45 ± 4 nM was  measured for 
the HIF-1α/p300 interaction as shown in Figure 25. Interestingly during these ITC 
experiments the delay times between injections had to be extended to allow a the 
signal to return to the baseline, suggesting a relatively slow on-rate. 
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Figure 25 - Isothermal titration calorimetry analysis of the HIF-1 CTAD/p300 
Interaction 
The Kd measured by ITC and fluorescence anisotropy are in good agreement with 
each other and with literature values.
29, 35, 55
 The stoichiometry, n of the interaction 
observed by ITC was 0.69, slightly less than the expected 1:1, but this can be 
rationalised by the possible presence of some partially unfolded/misfolded protein. 
The total protein concentration in the cell can be measured but the degree to which it 
was properly folded/functional cannot be easily assessed. 
 
ΔH  = - 57.3 kJ Mol-1 
ΔS  = 52.0 J Mol-1Deg-1 
N = 0.67 
Kd = 45 nM 
u 
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2.2.4 Competition Assay for inhibitors of HIF-1α/p300 
To identify inhibitors, a competition assay was required. To this end a concentration 
of p300 that gave sub-maximum binding was selected and the unlabelled analogue 
of the HIF-1α CTAD titrated into a mixture of the p300 CH1 domain and the FITC-
HIF-1α CTAD. The unlabelled peptide competes with the labelled analogue for 
binding to the p300, resulting in a decrease in anisotropy (Figure 26).  
 
Figure 26 - Competition titration of HIF-1α CTAD vs FITC HIF-1α CTAD. (80 nM 
FITC-HIF-1α CTAD, 0.1 µM p300, 40 mM sodium phosphate, 100 mM NaCl, 
1 mM DTT, 5% glycerol, 0.1% triton).  Error bars represent the standard 
deviation of 3 repeats. 
The decrease in anisotropy validated the assay for the identification of inhibitors of 
this interaction. The IC50 value derived from this assay is 228 ± 25 nM which when 
converted to an inhibition constant (Ki) using the method of Lebeda et al. gives 42.2 
± 7.67 nM which is in good agreement with the direct binding measured for the 
same peptide sequence as above.
93
 The slight discrepancy may be due to interactions 
made by the fluorophore in the labelled peptide. 
To enable the identification of even weak inhibitors of this interaction, the screening 
of inhibitors at relatively high concentrations (~1 mM) was envisaged. To enable 
this, it was necessary to perform the assay not only in aqueous buffer solutions but 
also in DMSO/buffer mixtures. To ensure this would not prevent the assay from 
functioning a 20% volume solution of DMSO in buffer was serially diluted into a 
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plate containing the protein and tracer as a mock inhibitor and the anisotropy 
measured. No change in anisotropy or intensity was observed at this level of DMSO 
confirming that a moderate level of co-solvent could be used during screening.  
2.2.5 HIF-1α/p300 Binding Hotspots 
As discussed in chapter 1, the surface area over which the HIF-1α CTAD and p300 
interact is large. By measuring the solvent exposed area of both components of the 
complex separately and then the solvent exposed area of the complex, the occluded 
surface area of approximately 4200 Å
2
 can be calculated (see experimental 
section).
94
 This is considered too large an area to be blocked by a traditional small 
molecule inhibitor but certain regions are often more important than others. These so 
called “hotspots” can be targeted with small molecules and by blocking the high 
affinity regions, inhibitors much smaller than the surface area of the PPI can be 
effective inhibitors.
95, 96
 
As previously mentioned, alanine scanning has been performed on the HIF-1α 
CTAD to identify key hot spot residues
33
 as well as random mutagenesis studies
34
 
however these assays were always carried out in cells. To further understand the 
molecular basis of the interaction and to inform rational inhibitor design a 
biophysical study was performed. 
A previous study, focussing on post-translational modifications, reported that N-
terminal truncations of the HIF-1α CTAD were tolerated but truncation at the C-
terminus prevented FITC-labelled peptides from binding p300.
35
 It was also 
demonstrated that S-nitrosylation of Cys800 prevented binding to p300 which is in 
conflict with another report.
36
 
2.2.6 Comparison of Helical Regions 
As described in previously, the HIF-1α/p300 interaction has been studied using 
fluorescence anisotropy and isothermal titration calorimetry with a peptide derived 
from the C-terminal transactivation domain (CTAD) and shown to have a binding 
constant of approximately 40 nM. Given the previous successes of studying helical 
regions as hotspots
9, 87, 97, 98
 and the fact that the hotspot residues are found on 
helical regions of HIF-1α, it was decided to assess the relative contributions from 
the different helical regions of HIF-1α. To this end, peptides encompassing the 
helical regions were synthesized with fluorescent labels to allow direct binding 
measurements.  
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Figure 27 - Schematic representation of peptide prepared containing helical regions 
of HIF-1α 
The hot spot residues Cys800 and Asn803 are in the i and i+4 positions of helix 2 
and the hot spot residues Leu814, Leu819 and Val821 are in the i, i+4 and i+7  
positions of helix 3 (see Chapter 1). 
Peptides comprising the helix 2 sequence, the helix 3 sequence and the sequence of 
from helix 2-3 were prepared using standard Fmoc solid phase peptide synthesis 
(SPPS) as described in the experimental section and labelled with N-terminal 
fluorescein via an aminohexanoic acid linker. It was envisaged that since the N-
terminal region of the HIF-1α CTAD has not previously been indicated as 
containing hotspots and appears as helical in only one of the two NMR structures, 
(PDB ID: 1L3E
29
 features only 2 helices) that it would not play a significant role in 
binding. Truncation at the N-terminus has previously been shown to only slightly 
reduce activity.
33
 Indeed previous work by the Arora group suggested that the helix 
2 region alone was sufficient for binding.
54
 
The binding of these three peptide sequences was assessed by direct fluorescence 
anisotropy and compared with the binding of the full length CTAD as shown in 
Figure 28. Perhaps most surprising is the approximately 80-fold decrease in binding 
between the full length CTAD and the helix 2-3 (Kd = 6.7 ± 0.5 μM) construct 
suggesting that the helix 1 region is important. Moreover it appeared that the helix 2 
region is essentially insufficient to bind p300 in the absence of the rest of the 
sequence, despite containing two reported hotspot residues. The helix 3 peptide 
binds to p300  with a significantly lower affinity, suggesting that the previous 
observations regarding helix 3 hotspots were correct.  
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Figure 28 - Fluorescence anisotropy binding of different peptides to p300 (80 nM 
FITC-peptide, 40 mM sodium phosphate, 100 mM NaCl, 1 mM DTT, 5% 
glycerol). Error bars represent the standard deviation of 3 repeats. 
 
2.2.7 Exploration of Cooperativity 
Of the two helical regions investigated here, helix 3 has the higher affinity but the 
disparity between the two helical regions separately compared to when linked 
suggested that other factors might be important. Cooperativity between the two 
helical regions could explain some of the observations. To explore any potential 
allosteric cooperativity, the fluorescently-labelled helix 3 peptide was titrated into a 
solution containing both the protein and a high concentration (3 mM) of the 
unlabelled helix 2 peptide. No increase in affinity was observed compared to that 
observed for binding of helix 3 in the absence of helix 2 as can be seen in Figure 29. 
Allosteric cooperativity by a different region of the HIF-1α CTAD cannot be ruled 
out but the presence of helix 2 did not appear to increase the affinity of helix 3. 
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Figure 29 - Fluorescence anisotropy binding of helix 3 in the presence and absence 
of helix 2. (80 nM FITC-HIF-1α CTAD, 3 mM helix 2 peptide, 40 mM sodium 
phosphate, 100 mM NaCl, 1 mM DTT, 5% glycerol). Error bars represent the 
standard deviation of 3 repeats. 
 
The significant increase in binding when the helix 2 and 3 peptides are linked 
suggest that either a previously unidentified hotspot residue may exist in the linking 
region or that the chelate effect is crucial for this interaction. The chelate effect 
arises from an increase in effective molarity and a reduced entropic penalty for 
sequential binding events. Inspection of the ensemble of NMR structures suggests 
that this loop is relatively unstructured as shown in Figure 30. The chelate effect can 
significantly increase binding of two weak interactions via  increasing the effective 
molarity.
99, 100
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Figure 30 - Ensemble NMR structures of helix 2 to helix 3 linker region. 1 
backbone representation shown for clarity. 
To investigate the importance of the chelate effect on the binding between HIF-1α 
and p300, a series of peptide conjugates was proposed. By linking the helical 
domains of the HIF-1α CTAD with a polyethylene glycol (PEG) linker, the effect of 
chelation could be explored without the linker region making specific interactions 
with the protein. PEG linkers have previously been incorporated into unstructured 
loop regions of proteins without perturbing binding.
101
 The design of these 
constructs was challenging as calculating the required length for the PEG linker is 
non-trivial. Achieving the correct length is crucial, as if it is too short then both 
helices could not bind simultaneously.
102
 To this end, the length of the native 
sequence and the linear distance between the helices was measured computationally 
(Table 1). For a PEG chain to span the same distance it must undergo a random 3D 
walk so longer lengths were required.
103
 The commercially available monodisperse 
PEG lengths chosen along with the lengths supplied by the manufacturers are shown 
in Table 1. 
Table 1 – Distances from helix 2-3 and PEG linker lengths.  
 Length (Å) 
Linear distance 21 
Native linker sequence 40 
PEG8 40 
PEG12 53 
PEG24 95 
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Peptide constructs were prepared, consisting of a fluorophore (FITC), the helix 2 
binding region, a PEG linker and then the helix 3 binding region as shown in Figure 
31. The PEG-peptide conjugates were synthesised via standard Fmoc-SPPS utilising 
an Fmoc-amino-carboxy-PEG building block and N-terminally labelled with 
fluorescein to allow direct binding measurements (see Appendix I for alternative 
approaches). 
 
 
Figure 31 - PEG linked peptide sequences 
Titration of p300 protein against the PEG conjugates showed a significant 
dependency on the length of the PEG linker. As the PEG chain was lengthened the 
binding to p300 increased (Figure 32 and Table 2). 
 
Figure 32  - Binding curves for FITC peptide PEG conjugates (80 nM FITC-
Peptide, 40 mM sodium phosphate, 100 mM NaCl, 1 mM DTT, 5% glycerol). 
Error bars represent the standard deviation of 3 repeats. 
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Table 2 - Binding constants for PEG linked constructs determined by fluorescence 
anisotropy protein titrations  
Linker Length  Estimated Kd/μM 
PEG8 827 ± 99 
PEG12 423 ± 17 
PEG24 144 ± 13 
 
The PEG24 construct binds tightest and is the only construct to bind with higher 
affinity than the helix 3 region alone (cf. 198 μM). This suggests that either the PEG 
length is not long enough or that interactions between the linker region and p300 are 
crucial. By applying a variation of the Kuhn length model, the average distance of a 
random walk by a polymer can be estimated. Using the published characteristics of 
PEG polymers
104, 105
 and the self-avoiding random walk model, it can be estimated 
that a PEG72 linker would be required for an average distance of random walk of >40 
Å suggesting that, despite the linear lengths of the linkers used above were 
sufficient, further elongation of the linker may continue to result in increased 
affinity.  
Nevertheless, the results reported hear tentatively suggest that the chelate effect is 
important for the high affinity interaction between the HIF-1α CTAD and p300. 
Whilst an increase in affinity was not observed when both Helix 2 and 3 peptides 
were present but separate, an increase in affinity was observed when the same two 
peptides were linked by a non-peptidic linker.  
2.2.8 Peptide Inhibitor Screening 
Since the objective of the project was to design and prepare inhibitors of this PPI, a 
more complete series of peptide fragments of the HIF-1α CTAD was prepared and 
tested for inhibition. Despite the fact that peptide-based inhibitors are unfavourable 
in terms of cell permeability and instability to degradation, the identification of 
peptides capable of inhibiting the full length CTAD binding could inform inhibitor 
design. 
106
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Figure 33 - Sequences of peptides used to explore inhibitory ability of HIF-1α 
CTAD regions 
Nine additional peptides, the sequences of which are shown in Figure 33, were 
synthesised or purchased and tested in the competition assay discussed in Chapter 2.  
In these competition experiments, only 2 peptides, in addition to the unlabelled 
CTAD, were able to inhibit to any extent (Figure 34). The peptide comprising the 
helices 2 and 3 (denoted helix 2-3) in agreement with the direct binding 
measurement described above and the peptide comprising helix 1 and 2 (denoted 
helix 1-2). This result again suggests that the helix 1 region may be relevant for the 
recognition between HIF-1α and p300. 
 
Figure 34 - Competition assay with peptide portions of HIF-1α against FITC HIF-
1α CTAD. (80 nM FITC-HIF-1α CTAD, 0.1 µM p300, 40 mM sodium 
phosphate, 100 mM NaCl, 1 mM DTT, 5% glycerol, 0.1% triton).  Error bars 
represent the standard deviation of 3 repeats. 
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Unfortunately these competition assays did not reveal a key pharmacophore or even 
provide a ranking of the peptides in affinity order. Instead, suggesting that, at least 
for peptidic inhibitors, 2 helical regions are the minimum requirement for inhibitory 
activity. This is potentially due to the format of the assay which relies on competing 
with a particularly high affinity peptide (Kd ~ 40 nM).  
2.2.9 Conclusions on HIF-1α/p300 binding requirements 
Whilst the results presented in this section do not offer conclusive proof it led to the 
proposal of a hypothesis: that the helix 3 region of the peptide provides the majority 
of the affinity whilst the rest of the peptide, particularly the previously identified 
hotspots, impart specificity. This would be in line with previous reports carried out 
on much more complex biological systems. It is conceivable that mutation of the 
Cys800
 
or Asn804 residues led to decreased activity in cells due to off target binding 
which is not observed in the isolated recombinant system discussed here. They are 
also key sites for post-translational modifications as discussed in Chapter 1. Further 
work is clearly required in this area to more thoroughly investigate, using more 
sensitive biophysical techniques, the recognition features between the binding 
partners. 
The proposed hypothesis suggests that the helix 3 binding region of p300 would be a 
good starting point to target inhibitors, giving them the best chance to abrogate the 
binding between the HIF-1α CTAD and p300. 
2.3 eIF4E/eIF4G Assay Development 
2.3.1 Direct binding of eIF4G peptide to eIF4E 
As for the assay system developed above, a fluorescence anisotropy assay was 
developed for the eIF4E/eIF4G interaction. A peptide derived from the helical 
region of the eIF4G protein that binds to eIF4E was synthesised using conventional 
Fmoc solid phase peptide synthesis on 0.1 mmol scale as both the fluorescein-
labelled and acetylated analogue (see experimental section).  
 
 
Figure 35 - eIF4G peptide sequences 
Titration of increasing protein concentrations (prepared by recombinant expression 
by H. Kyle) into a solution of the fluorescein-labelled peptide provided a binding 
curve as the peptide bound to the protein and tumbled less rapidly in solution as 
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shown in Figure 36. Fitting of this data to a Kd model (described in experimental 
section) gave a Kd of 1.76 ± 0.17 µM which is in good agreement with the 
literature.
80, 82
 
 
Figure 36 - Binding curve for FITC-eIF4G/eIF4E (80 nM FITC-eIF4G, 40 mM 
sodium phosphate, 200 mM NaCl, 1 mM DTT, 5% glycerol, 0.1% triton). 
Error bars represent the standard deviation of 3 repeats 
Since the eIF4e protein had been expressed as a small ubiquitin-like modifier 
(SUMO) fusion protein and the fact that a larger size difference between the bound 
and unbound states (high and low anisotropy respectively) gives a higher dynamic 
range for the assay, binding of the labelled eIF4G peptide to eIF4E-SUMO fusion 
protein was compared to the binding to eIF4E alone. The presence of the SUMO 
increases the molecular weight significantly and thus the rate of tumbling but the 
binding constant was unchanged as can be seen in Figure 37. Additionally, as a 
control, it was confirmed that no binding of the labelled eIF4G peptide to SUMO 
could be measured in the absence of eIF4E. This enabled easier protein preparation 
(no SUMO cleavage step) and gave an improved dynamic range for the assay.  
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Figure 37 - Comparison of labelled eIF4G binding to eIF4E and eIF4E-SUMO by 
anisotropy (80 nM FITC-eIF4G, 40 mM sodium phosphate, 200 mM NaCl, 1 
mM DTT, 5% glycerol, 0.1% triton). Error bars represent the standard 
deviation of 3 repeats.  
 
2.3.2 Time and Temperature Dependence of eIF4E/eIF4G Interaction 
Incubation time was assessed as shown in Figure 38 and indicated that 40 minutes 
was an adequate time to reach equilibrium as very little change was observed after 5 
hours. It also appears that the protein is unstable as the data begins to deviate and 
become less consistent at 18 hours of incubation. 
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Figure 38 - Incubation time dependence on fluorescence anisotropy assays between 
eIF4G and eIF4E (80 nM FITC-eIF4G, 40 mM sodium phosphate, 200 mM 
NaCl, 1 mM DTT, 5% glycerol, 0.1% triton). Error bars represent the standard 
deviation of 3 repeats 
Similarly, temperature dependence studies were performed. Again the increased 
temperature increased the general rate of tumbling in solution causing a decrease in 
the apparent maximum anisotropy which can be seen in Figure 39. The binding 
constants increased slightly as the temperature increased and performing a Van’t 
Hoff analysis (Figure 40) showed a slightly negative slope – suggesting a slightly 
endothermic interaction. The magnitude of the gradient suggests the interaction is 
mostly driven by entropic contribution. This effect may potentially stem from the 
displacement of ordered water both in the binding site and surrounding the peptide 
in solution.
107
 
 
- 39 - 
 
Figure 39 - Temperature dependence of eIF4G/eIF4G interaction (80 nM FITC-
eIF4G, 40 mM sodium phosphate, 200 mM NaCl, 1 mM DTT, 5% glycerol, 
0.1% triton). Error bars represent the standard deviation of 3 repeats 
 
Figure 40 - Van't Hoff Analysis for the eIF4E/eIF4G interaction 
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2.3.3 Cap dependence of eIF4E/eIF4G interaction 
Since the eIF4E/eIF4G interaction is key to the regulation of 5′ cap mRNA 
translation (discussed in Chapter 1) it was also assessed if the presence of cap or a 
cap analogue, structures shown in Figure 41, would affect the interaction.  
 
Figure 41 - Structures of 5' Cap and Cap Analogue used in binding investigation 
The assay was performed in the presence of 1 mM cap or its analogue but no 
significant change in affinity was observed as shown in Figure 42. Given this result 
no cap or analogue was included in subsequent screening experiments. This result 
was subsequently corroborated by others.
71
 
 
Figure 42 - Effect of cap or cap analogue on eIF4E/eIF4G binding interaction (80 
nM FITC-eIF4G, 40 mM sodium phosphate, 200 mM NaCl, 1mM Cap or 
Analogue, 1 mM DTT, 5% glycerol, 0.1% triton). Error bars represent the 
standard deviation of 3 repeats 
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2.3.5 Competition assay for inhibitors of the eIF4E/eIF4G interaction 
Subsequently, a competition assay was developed whereby the unlabelled eIF4G 
peptide was titrated into a mixture of the labelled peptide and the eIF4E protein. It 
was shown that the unlabelled peptide could disrupt the interaction with an IC50 of 
36 ± 4.5 µM  (Figure 43) which when converted to an inhibition constant (Ki) gives 
2.36 ± 0.63 µM.
93
 
 
Figure 43 - Competition titration of eIF4G vs FITC-eIF4G with eIF4E followed by 
fluorescence anisotropy (80 nM FITC-eIF4G, 3 µM eIF4E, 40 mM sodium 
phosphate, 200 mM NaCl, 1 mM DTT, 5% glycerol, 0.1% triton). Error bars 
represent the standard deviation of 3 repeats. 
This positive control experiment validated this fluorescent anisotropy assay for the 
identification of inhibitors of the eIF4E/eIF4G protein-protein interaction and a 
further control experiment showed that the assay was uneffected by DMSO up to 
20% v/v in buffer as a mock inhibitor. 
 
Figure 44 - Structure of known eIF4E/eIF4G inhibitors 
Finally, as several compounds have been reported in the literature as inhibitors of 
eIF4E/eIF4G, the assay was validated by titration with known inhibitors (Figure 44). 
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4EGI-1
80
 was found to have intrinsic fluorescence which interefered with the assay 
but 41R-Cat inhibitied the interaction with a IC50 value of 7.7 ± 0.4 μM (Figure 45) 
which is in good agreement with the reported value of ~4 μM.82 
 
Figure 45 - Competition titration of 41R-Cat vs FITC-eIF4G with eIF4E followed 
by fluorescence anisotropy (80 nM FITC-eIF4G, 3 µM eIF4E, 40 mM sodium 
phosphate, 200 mM NaCl, 1 mM DTT, 5% glycerol, 0.1% triton). Error bars 
represent the standard deviation of 3 repeats. 
2.4 Summary and Conclusions 
In summary, the interaction between the HIF-1α CTAD and the CH1 domain of 
p300 was assessed by both fluorescence anisotropy and ITC. These experiments 
gave a Kd of approximately 40 nM which is in good agreement across both 
techniques and the relevant literature.
29, 33, 108
 The effects of time, temperature and 
DMSO co-solvent were assessed. Furthermore, an investigation into the 
requirements for HIF-1α/p300 binding revealed the importance of the Helix 3 region 
and the role of chelation. 
The interaction between a peptide derived from eIF4G and eIF4E protein was 
assessed by fluorescence anisotropy. The Kd was determined to be approximately 
1.7 μM which is in good agreement the relevant literature.80, 109 The effects of time, 
temperature, protein construct, assay additives and DMSO co-solvent were assessed. 
A known ligand was also used to validate the assay. 
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Subsequently this information was utilised to develop robust fluorescence 
anisotropy assays for both interactions which could allow the identification of 
inhibitors of these PPIs (see Chapters 3 and 4). 
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Chapter 3 – Computational Approaches to Inhibitors 
The candidate confirms that the work submitted is his own, except where work 
which has formed part of jointly authored publications has been included. The 
contribution of the candidate and the other authors to this work has been explicitly 
indicated below. The candidate confirms that appropriate credit has been given 
within the thesis where reference has been made to the work of others. 
 
Portions of the work described in this chapter were submitted as part of a research 
paper describing the synthesis of 1,3-amino alcohols (I. Colomer, O. Adeniji, G.M. 
Burslem, P. Craven, M.O. Rasmussen, A. Willaume, T. Kalliokoski, R. Foster, S. 
Marsden, A. Nelson, Bioorganic and Medicinal Chemistry, 2014). G.M.B. and P.C. 
proposed the synthetic approach, I.C., O.A. and G.M.B. performed the initial 
synthesis validation,  M.O.R and A.W. performed the library synthesis, T.K. 
performed the chemoinformatics, R.F., S.M. and A.N. supervised the project. I.C. 
prepared a draft manuscript which was then edited into its present from (attached) 
by A.N. with comments from all authors. Selected examples prepared by GMB are 
included in this chapter. 
The de novo compound library was enumerated by Adam Nelson (University of 
Leeds). Paul Faulder (AstraZeneca) performed the initial docking of the de novo 
library against p300 which was repeated by G.M.B. The X-ray crystal structure was 
solved by Chris Pask (University of Leeds).  
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3.1 Computational Chemistry in Lead Discovery 
Computational drug design has become an important tool in recent years
110
 and can 
provide valuable information for medicinal chemistry efforts. Whilst the main 
advantage of computational modelling has previously been ligand optimisation and 
structure-based drug design using  X-ray structures, it has increasingly been used to 
identify lead compounds as a complementary method to high-throughput 
screening.
111
 
Molecular docking of proposed ligand structures into known protein structures
112
 is 
the most common form of computational lead discovery; either docking of 
commercially-available compounds or by de novo design of putative inhibitors.
113
 
Both approaches were employed in this project as discussed below. 
3.2 Identification of Commercially Available Inhibitors 
To allow the identification of inhibitors of the HIF-1α/p300 and eIF4E/eIF4G PPIs, 
a virtual library of commercially available compounds was provided by 
AstraZeneca. The virtual library was derived from the eMolecules collection of 
commercially available compounds (www.emolecules.com), from which duplicates 
and compounds with undesirable functionalities were removed by AstraZeneca staff. 
Two approaches were employed to computationally identify compounds to be 
purchased and tested for inhibitory activity in the assays described in Chapter 2. One 
approach was to employ docking in a helix accepter/protein-centric approach whilst 
the other was to employ a helix donor/ligand-centric approach using the known 
pharmacophore from the peptide/protein complex. 
3.3 Docking Virtual Libraries 
Prior to docking, the protein receptor must be prepared and putative binding sites 
identified. The proteins were prepared using the protein preparation wizard in 
Maestro 9.3 (Schrodinger) by removing the helix donor binding partner, defining the 
binding site and setting any relevant constraints, optimising the hydrogen bonding 
within the remaining protein, removing any non-hydrogen bonding residual water 
molecules and performing a restrained minimisation.
114
  
3.3.1 HIF-1α/p300 Docking 
For the HIF-1α/p300 system, two docking sites were prepared from the complex 
NMR structure (PDB ID: 1L8C)
30
 using Glide (Schrodinger)
114, 115
 – one comprising 
the helix 2 binding region, the other the helix 3 binding region.  
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Figure 46 - Helix 2 binding region 
For the helix 2 binding cleft, shown in Figure 46, the grid comprised the region in 
which the helical portion binds and also specifies two key interactions made 
between HIF-1α and p300. Ligands must interact favourably with protein, fit within 
the defined space and make at least one of two key interactions; a hydrogen bond 
made by the key asparagine residue of HIF-1α and/or an interaction with the surface 
lysine.  
Another receptor grid was defined for the helix 3 binding region. The helix 3 
binding region makes less of an obvious pocket and is more “featureless”, as shown 
in Figure 47 and was therefore considered less tractable for docking.  
 
Figure 47 - Helix 3 binding region 
The virtual library for docking was prepared by generating up to 200 low energy 3D 
conformations for each compound using Omega (OpenEye)
116
 and physiologically 
relevant protonation states using LigPrep (Schrodinger).
117
 Low energy conformers 
were generated in advance of the docking to allow rigid docking to be performed. 
This approach can give more realistic docked poses and reduces the computational 
time required to dock large libraries.
118
 
Initial runs were performed using virtual high-throughput screening settings and the 
top compounds were then subjected to higher precision docking to give greater 
confidence in the results. Compounds were inspected visually and selected for 
screening based on the docking score, recapitulation of important peptide features 
and consistency of pose across multiple iterations. For example, if the highest 
scoring compound was only observed once in the top 50 hits, but another compound 
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was observed 5 times in similar poses in the top 20, then the latter compound was 
prioritised for screening (Table 3).  
3.3.2 eIF4E/eIF4G Docking 
 
Figure 48 – eIF4G binding region 
A similar approach was employed to dock into the helix binding region of eIF4E – a 
receptor grid was generated from the co-crystal structure (PDB ID:2W97)
68
 using 
Glide (Schrodinger)
114, 115
 A docking grid was defined based upon the location of 
binding of the eIF4G peptide in the crystal structure, shown in Figure 48. As there is 
a known inhibitor 4EGI-1,
80
 discussed in Chapter 1 and shown in Figure 49, for the 
eIF4E/eIF4G interaction this compound was used to validate the docking model – at 
the time of receptor preparation the ligand-protein complex was not known. 
 
Figure 49 - Structure of known eIF4E/eIF4G inhibitor, 4EGI-1 used in docking 
validation 
To validate docking results from this system, the known ligand was docked into the 
system and, by incorporating a hydrophobic receptor constraint, the known ligand 
docked in a consistent pose which matched with the HSQC shifts reported in the 
literature for this compound binding to eIF4E.
80
 The hydrophobic constraint ensures 
a non-polar region of the molecule binds into a small depression in the surface of 
eIF4E and is consistent with the HSQC shifts. Figure 50 shows the overlay of 10 
different docked poses with relatively little difference between them and the nitro-
aryl ring bound into the hydrophobic depression. This receptor grid was then used 
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for all subsequent docking. Unfortunately it was subsequently shown by X-ray 
crystallography that this inhibitor has an allosteric mode of action.
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Figure 50 - Ten overlaid structures of known eIF4E/eIF4G inhibitor, 4EGI-1 
3.4 Shape-Based Screening 
Another approach utilised in medicinal chemistry is pharmacophore modelling 
whereby a known inhibitor/binder is used to define a model of what is required to 
bind to the protein of interest.
119
 This approach is often used in “scaffold-hopping” 
to switch to a different chemical structure which is still capable of making the same 
interactions.
120
 It was envisioned that this approach could be used to identify PPI 
inhibitors based on the pharmacophore of the helix donor protein/peptide in the case 
of HIF-1α/p300 or eIF4E/eIF4G. To do this, the helical donor regions were 
extracted from the complex structures and used as queries for Rapid Overlay of 
Chemical Shape (ROCS) analysis.
121
 Similar approaches have previously been 
applied to PPIs by the groups of Arora
8
 and Burgess
122, 123
. 
After optimisation, it was found that the best results were achieved by excising the 
donor region of interest, removing side chains from non-bonding residues and 
converting the peptide backbone to an all carbon chain whilst maintaining the 3D 
structure: an example of this process for the helix 3 region of HIF-1α is shown in 
Figure 51. This approach allows only the desired sidechains to be included in the 
pharmacophore model and prevented overemphasis of the amide functionality in the 
backbone.  
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Figure 51 - ROCS query preparation. From left to right: helical region of peptide 
extracted from 1L8C, helical region with non-bonding sidechains removed, 
helical region with backbone converted to carbon chain. 
This approach to query preparation was employed for helix 2 and 3 of HIF-1α and 
the eIF4G helix. Important contacts were also highlighted as desired features 
providing the structures shown in Figure 52. For helix 2 of HIF-1α, two hydrophobic 
residues were highlighted along with a hydrogen bond donor and acceptor analogous 
to the docking constraints defined above. The helix 3 query highlights the i, i+4 and 
i+7 residues thought to be crucial as key hydrophobic regions. For the eIF4G query 
the key hydrophobic rings identified in the literature were defined as well as a 
potential hydrogen bond donor/acceptor on tyrosine.  
 
Figure 52 - ROCS queries employed in pharmacophore searching. From left to 
right: HIF-1α helix 2, HIF-1α helix 3, eIF4G 
These structures were then employed as ROCS queries and screened against the 
commercially available eMolecules library, discussed above, to identify potential 
inhibitors for screening.  The top 100 scoring matches for each query were visually 
inspected and compounds of interest selected based on their ability to match the 
defined pharmacophores as well as the flexibility of the ligand. Compounds with 
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more rigid structures that matched the query well were prioritised over flexible 
compounds capable of matching the query (Table 3) 
3.5 Compound Selection 
From both of the above approaches, docking and pharmacophore searching, large 
sets of compounds were suggested as potential inhibitors. A small set of compounds 
which met the defined criteria were selected and purchased. The compound 
structures  selected for screening along with the method and target used to select 
them are shown below in Table 3. 
Table 3 – Compounds selected for screening from commercially available libraries 
Compound Structure Method Target 
3 
 
Docking eIF4E 
4 
 
Docking eIF4E 
5 
 
Docking eIF4E 
6 
 
ROCS eIF4E 
7 
 
ROCS eIF4E 
8 
 
Docking p300 Helix 3 
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9 
 
Docking p300 Helix 3 
10 
 
ROCS p300 Helix 3 
11 
 
Docking p300 Helix 2 
 
3.6 Compound Screening 
The compounds detailed in Table 3 were screened in the competition assays 
discussed in Chapter 2. All of the compounds were tested in both competition assays 
(HIF-1α/p300 and eIF4E/eIF4G) despite being selected separately to allow an 
assessment of selectivity. 
3.6.1 HIF-1α/p300 Screening 
Screening of the compounds in the HIF-1α/p300 assay identified only one 
compound that showed a decrease in anisotropy consistent with inhibition: 
compound 10. This compound showed an apparent IC50 value of 67 ± 13 μM from 
the inhibition curve shown in Figure 53. 
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Figure 53 - Competition Assay of Compound 10 against HIF-1α/p300 (80 nM 
FITC-HIF-1α CTAD, 0.1 µM p300, 40 mM sodium phosphate, 100 mM NaCl, 
1 mM DTT, 5% glycerol, 0.1% triton).  Error bars represent the standard 
deviation of 3 repeats. 
 
Whilst initially exciting, comparison with the data for the eIF4E/eIF4G interaction 
for this compound showed a similar IC50 value. Inspection of the structure of 
compound 10 suggests it might possess the ability to act as a covalent inhibitor and 
the fact it inhibits both interactions assayed suggest it is a non-selective covalent 
inhibitor. To confirm this, the protein was subjected to mass spectrometry after 
incubation with the compound. The analysis showed a time dependent increase in 
molecular weight as shown in Figure 54. Prior to treatment with compound 10, mass 
spectrometry of the protein gives a series of peaks representing different charge 
states. After 30 minutes of treatment, with compound 10, another set of peaks 
appeared indicating covalent labelling of the protein whilst the initial unlabelled 
protein peaks are still observed. This most likely occurs through the reaction of a 
nucleophilic residue on p300 reacting with the Michael accepter within compound 
10. 
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Figure 54 – Mass spectrometric analysis of p300 (100 μM) and compound 10. Top 
panel – protein mass spectrum with no compound, Bottom panel – after 
treatment for 30 minutes with 100 uM compound 10 for 30 minutes. Blue 
diamonds denote protein peaks, red squares denote protein-compound complex 
 
Having shown the only compound eliciting an effect in the HIF-1α/p300 
competition assay was both non-selective and a competitive inhibitor, compound 10 
was not progressed further. The approaches discussed above did not provide any 
other inhibitors for further investigation. 
3.6.2 eIF4E/eIF4G Screening 
Screening of the compounds described in Table 3 in the fluorescence anisotropy 
competition assay previously described, identified compound 10 (which was 
discarded as discussed above) and compound 4. The assay was repeated and 
compound 4 was shown to have an IC50 of 612 ± 59 μM (Figure 55).   
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Figure 55 - Competition curve for compound 4 in the eIF4E/eIF4G competition 
assay. IC50 - 612 ± 59 μM. 80 nM FITC-eIF4G, 3 µM eIF4G, 40 mM sodium 
phosphate, 200 mM NaCl, 1 mM DTT, 5% glycerol, 0.1% triton). Error bars 
represent the standard deviation of 3 repeats. 
Whilst not a high affinity compound, its relatively low molecular weight (324 Da), 
and potential for development, made it a promising starting point for further 
elaboration and optimisation. Inspection of the docked pose for this compound, 
shown in Figure 56, suggested several possible modifications of compound 4 to 
explore the structure activity relationship.  
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Figure 56 - Docked pose for compound 4 in the eIF4G binding domain of eIF4E 
with ligand interaction diagram (inset). Docking performed using Glide 
Compound 4 is structurally similar to the known inhibitor 4EGI-1 (see Figure 49) 
and binds in a similar way during docking. This may be an artefact of the docking 
procedure/validation or may suggest a common pharmacophore/chemotype for 
eIF4E binders. Both compounds contain a central aminothiazole ring flanked by two 
aromatic rings. This lead to the design of a small analogue library which is 
summarised in Figure 57. 
 
Figure 57 - Analogues of compound 4 
Initial optimisation focussed on maintaining the aminothiazole core while altering 
the pendant aromatic rings based on the docking and similarity to the known 
inhibitor. The 3,4-dichlorophenyl group was incorporated as its presence in the 
previously reported compounds provided an increase in activity.
124
 The t-butyl 
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group was selected to include a more 3D hydrophobic moiety. On the other side of 
the compound (shown in green) the length of the linker to the aromatic ring was 
varied  and the methoxy group replaced with a bromide. The bromide was included 
both as a potential inhibitor and to allow the introduction of additional aromatic 
functionality (blue) via cross-coupling reactions. 
3.6.3 Analogue synthesis 
A small series of compounds based on the design outlined in Figure 57 was prepared 
using the route shown in Scheme 1. The aminothiazoles 14-16 were prepared 
through the reaction of α-haloketones 11-13 and thiourea either under thermal 
conditions (for aryl ketones
125
) or via copper catalysis (for the t-butyl variant, 16).
126
 
The resulting aminothiazoles then underwent amide bond forming reactions, in this 
case carbodiimide mediated coupling or reaction with an acid chloride. Finally, the 
compound 18 containing an aryl bromide were further derivatized by  Suzuki-
Miyaura cross coupling
127
 reactions to introduce an additional aromatic ring. The 
library is summarized in Table 4. 
 
Scheme 1 - Preparation of aminothiazoles  
Table 4 – Compound 4 analogue library prepared 
 
Compound R
1
 R
2
 
yield 
Ar  
yield 
17 
  
52 %
(a)
 
n/a 
18 
  
n/a 
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60%
(b)
 
19 
  
36%
(b)
 
n/a 
20 
  
60%
(b)
 
 
41%
(c)
 
21 
  
60%
(b)
 
27%
(c)
 
22 
 
 
41%
(b)
 
n/a 
23 
 
 
18%
(b)
 
n/a 
24 
 
 
86%
(b)
 
n/a 
(a) prepared from amine and benzoyl chloride (1.1 eq) (b) prepared from 
amine and carboxylic acid (1.1 eq.), N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide (2 eq.), DMAP (10 mol%) and diisopropylethylamine 
(5 eq.) (c) prepared from bromide and Ar-B(OH)2 (1 eq.), Pd(PPh3)4 (5 
mol%) and caesium carbonate (3 eq.) 
 
Compounds 17-24 were then analysed for their ability to inhibit the eIF4E/eIF4G 
compared to the initial hit compound. Unfortunately all of the analogues prepared 
had IC50 values greater than 1 mM against eIF4E/eIF4G. Given this lack of 
improvement no further work was performed on this compound series. It should also 
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be noted that 2-aminothiazoles have been reported as potentially problematic 
compounds in screening collections – 2-aminothiazoles are included on lists of pan 
assay interference compounds (PAINS)
83
 and have been found to be promiscuous in 
biophysical assays.
128
 
3.7 Design of Bespoke Compound Libraries 
In parallel to screening libraries of commercially available compounds to provide a 
starting point for inhibitor optimisation, a de novo approach was employed.
113
 This 
approach was only employed for the helix 2 binding site on p300 due to the amount 
of computational time required. The helix 2 binding site was selected as it appeared 
to be the most amenable to docking.  
Initially, a virtual library of compounds, previously enumerated within the Nelson 
group, containing 80,000 diverse compounds derived from reliable chemistry 
developed or validated within the group and commercially available starting 
materials was used. This library was docked against the helix 2 binding site 
(performed by Paul Faulder, AstraZeneca). Examples of the best docked compounds 
are shown in Figure 58. From these virtual high-throughput hits a series of 
compounds were identified for further analysis.  
 
Figure 58 - Initial hits from docking of de novo library against helix 2 binding 
region 
The bicyclic system, 28 and 29, was selected for further study as it was predicted to 
make the same contacts as the peptide in the desired region as shown in Figure 60. 
To enable further computational studies, a focussed virtual library based on the 
scaffold shown in Figure 59 was enumerated. The virtual library was enumerated 
using Pipeline Pilot
129
 by programming virtual reactions and providing readily 
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available building blocks to yield compounds of the type shown in Figure 59 (full 
protocol and building block libraries are included in the experimental). 
 
Figure 59 – Core structure of enumerated bicyclic compound library. 
The enumerated libraries were then docked against the helix 2 binding region and 
the top 100 structures inspected. Examples of some of the best docked structures are 
shown Figure 60.  
 
Figure 60 - Example docked structures of de novo designed compounds in the helix 
2 binding site of p300. (a) helix 2 in the binding (b-d) docked compound 
structures 
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As the bicyclic 6,7 cis-fused ring system consistently docked with a conserved pose, 
it was decided to prepare selected analogues. An examination of the literature also 
revealed that this fused ring system containing both an amine and an amide had not 
been previously reported. Given the similarity in structure to benzodiazepines
130
 and 
the frequency at which nitrogen heterocycles appear in pharmaceuticals,
131
 this was 
surprising and provided further encouragement to develop synthetic routes to these 
compounds. 
3.7.1 Synthesis of selected scaffold 
After several routes were explored with limited success (shown in Appendix II), the 
route shown in Scheme 2 successfully provided the scaffold. This route exploited 
the aminomethyl-hydroxylation reaction initially reported by Katritsky
132
 between a 
cyclohexene 30 and N-hydroxymethylbenzamide 31 to yield the cis-oxazine 32. 
Reductive ring opening of the oxazine 32 with lithium aluminum hydride provided 
the 1,3-aminoalcohol 33. 
133
 
 
Scheme 2 – Synthetic route to bicyclic target compound 
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The N-benzyl 1,3-aminoalcohol 33 was then carried on to final compounds 
containing benzyl functionality or the alkyl group exchanged via reductive 
amination to 34 followed by debenzylation to give 35. Efforts were also made at this 
stage to convert the alcohol into a masked amine via Mitsunobu reactions with 
various nucleophiles – converting the compound to the desired trans compound. 
Unfortunately under Mitsunobu conditions the alcohol was prone to eliminate to the 
cyclohexene rather than undergo the desired substitution.
134
 
The desired alkyl-amino alcohol 33/35 was protected as the t-butyl carbamates 
(Boc) 36/37 before oxidation of the alcohol with Dess-Martin periodinane
135
 to give 
cyclohexanones 38/39. The protection of the amine was not necessary for the 
oxidation to proceed but it was found to improve yields and ease purification. The 
Boc group was removed with TFA and Boc-glycine coupled onto the resulting 
secondary amines in one operation to provide 40/41. Finally the glycine moiety was 
deprotected and underwent reductive cyclisation to give the desired scaffolds 42/43 
as a mixture of separable diastereomers. A crystal structure confirmed the identity of 
the cis isomer (Figure 61 and Appendix III). An investigation of reducing agents 
was also performed to assess control of diastereoselectivity (Appendix IV).  Finally 
the separated diastereomers were functionalised on the secondary amine via 
reductive amination with various aldehydes mediated by picoline borane 44-50 or by 
reaction with sulfonyl chlorides 51 as shown in Table 5. 
 
 
Figure 61 - X-ray crystal structure of compound cis-42 
 
3.7.2 Screening of Designed Compounds 
The library of designed compounds was screened in the HIF-1α/p300 fluorescence 
anisotropy competition assay and their IC50 values determined as shown in Table 5. 
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Unfortunately, none of these compounds were particularly active with all but one 
having IC50 values greater than 1 mM.  
Table 5 - Bicyclic compounds prepared from computationally designed library 
 
Compound R
1
 R
2
 Diastereomer IC50/μM 
44 
 
 
cis >1000 
45 
 
 
trans >1000 
46  
 
cis 689 ± 125 
47  
 
trans >1000 
48  
 
cis >1000 
49 
 
 
cis >1000 
50 
 
 
cis >1000 
51 
 
 
cis >1000 
 
Compound 46 shows a decrease in anisotropy consistent with the HIF-1α CTAD, 
albeit at much higher concentrations, suggesting it is able to inhibit the HIF-1α/p300 
interaction with an IC50 value of 689 ± 125 (Figure 62). Whilst this potency is 
modest, compound 46 provides an potentially very exciting starting point for 
inhibitor design. The low molecular weight (349 Da) and relatively high degree of 
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aqueous solubility make it very attractive. Indeed, this compound falls within the 
ideal “lead-like” parameters (cLogP between -1 and 3, number of heavy atoms 14-
26).
136
 A considerable amount of optimisation will be required to increase the 
potency of compound 46 and elucidate its mode of action. 
 
Figure 62 - Competition Assay of Compound 46 against HIF-1α/p300 (80 nM 
FITC-HIF-1α CTAD, 0.1 µM p300, 40 mM sodium phosphate, 100 mM NaCl, 
1 mM DTT, 5% glycerol, 0.1% triton).  Error bars represent the standard 
deviation of 3 repeats. 
3.8 Summary and Conclusions 
The approaches to inhibitor identification discussed in this Chapter failed to identify 
high affinity inhibitors of the interactions of interest. This may have been a result of 
the relatively small numbers of compounds selected for screening. Similar 
approaches have previously been employed successfully to identify inhibitors of 
PPIs
8, 137
 but only weak binders or covalent inhibitors were identified in this work. 
Attempts to optimise compound 4 were unsuccessful. It is also unfortunate that the 
small molecule inhibitor 4EGI-1 used in docking grid construction for eIF4E was 
later shown to act allosterically.
69
  
However, the bespoke compound library provided a potential starting point for 
inhibitor development by identifying a novel scaffold with weak inhibitory activity 
against HIF-1α/p300. Further work will focus on the preparation of larger libraries 
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based on compound 46 to optimise affinity and use of orthogonal assays to confirm 
the activity of compound 46. 
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Chapter 4 
Development of Oligobenzamide α-Helix Mimetics as Inhibitors of 
the HIF-1α/p300 protein-protein interaction 
The candidate confirms that the work submitted is his own, except where work 
which has formed part of jointly authored publications has been included. The 
contribution of the candidate and the other authors to this work has been explicitly 
indicated below. The candidate confirms that appropriate credit has been given 
within the thesis where reference has been made to the work of others. 
Elements of the work presented in this chapter formed the basis for a research article 
that was accepted for publication in February 2014 (G.M. Burslem, H.F. Kyle, A.L. 
Breeze, T. A. Edwards,
  
A. Nelson,
 
S.L. Warriner
  
and A.J. Wilson, ChemBioChem, 
2014). The contributions of the authors were as follows: GMB (the candidate) 
performed all synthetic chemistry, peptide synthesis and modelling, HFK performed 
all protein expression, GMB and HFK performed all assays jointly. ALB, TAE, AN, 
SLW and AJW supervised the project. GMB prepared a draft of the manuscript 
which was then edited into its present form (attached) by all authors. The draft 
originally prepared by GMB was then rewritten as portions of this chapter.  
A review based on the synthesis of oligobenzamides as α-helix mimetics was also 
published by the candidate in January 2014 (G.M. Burslem and A.J. Wilson, Synlett, 
2014, 25, 324). GMB prepared a draft of the manuscript which was then edited into 
its present form (attached) by AJW. Portions of the original draft have been 
rewritten and included in this chapter.  
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4.1 The Concept of Helix Mimicry 
The most common secondary structure in proteins is the α-helix and as such α-
helices are often found at the interface between proteins.
6
 Therefore, there has been 
significant interest in designing compounds which mimic α-helices as potential 
inhibitors of Protein-Protein Interactions (PPIs). These compounds, often referred to 
as proteomimetics, are attractive because truncated versions of the native peptides 
may  or may not be active due to propensity of short peptides to form random coils 
rather than more defined secondary structures due to the entropic penalties involved. 
Even if they prove to be active, peptides may not be absorbed into cells and they can 
be prone to enzymatic degradation. 
 
Figure 63 - Schematic representation of the proteomimetic concept 
Therefore, rigid small molecules capable of recapitulating the vectoral 
representation of side chains of an α-helical peptide have been sought. Several 
different scaffolds have been developed as α-helix mimetics which present the side 
chain residues of one face of the helix – the i, i+4 and i+7 residues. These scaffolds 
are sometimes referred to as foldamers – oligomers that have well defined 
conformations.
138
 The first scaffold was the Hamilton group’s terphenyl structure 
which has been shown to be efficacious as a PPI inhibitor.
139
 Since then, there have 
been several other scaffolds exemplified in the literature including oligo-
benzamides
87
, terephthalamides,
140, 141
 enaminones
142
 and benzoyl ureas
143
 the 
structures of which are shown in Figure 64. The control of the conformation 
generally arises from intramolecular hydrogen bonding. The R groups depicted can 
be altered to present  side chains which are crucial for binding depending on the 
targeted interaction. 
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Figure 64 - Structures of foldamer helix mimetics 
Two main classes of oligo-benzamide helix mimetics have been developed:  O-
alkylated
144
 analogues in which the side chain mimic is tethered to the scaffold via a 
pendant oxygen and N-alkylated
145
  analogues tethered via the amide nitrogen 
(Figure 65).The O-alkylated oligo-benzamides have 2 possible regioisomers 
depending on the building blocks used to prepare them.
146
 They also employ 
intramolecular hydrogen bonds to promote the desired conformation (Figure 65).
147
 
N-Alkylated oligobenzamides contain no such intramolecular hydrogen bonding 
capability; and as such the lowest energy conformation is the cis-amide but they 
have been shown to mimic helices, presumably by adopting the trans-amide 
confirmation when bound to a protein. Recently, N-alkylated oligobenzamides have 
been shown to be potent cellular inhibitors of PPIs.
148
 S-alkylated oligobenzamide 
analogues have been prepared and used as antibacterial compounds
149
 and C-
alkylated oligo-benzamides have been prepared and shown to act as inhibitors of 
p53/hDM2
150
 and KSHV protease dimerization.
151
 Oligo-benzamides are also 
advantageous as the synthesis is modular and can be performed on solid phase.
152, 153
 
Variations of the oligo-benzamide scaffold exist such as the oligo-pyridylamide 
scaffold which exhibits further hydrogen bonding with the ring nitrogen.
97
 
 
- 68 - 
 
Figure 65 - Structures of 3-O-alkylated oligo-benzamides, N-alkylated oligo-
benzamides and the oligopyridylamides 
Crystal structures of the oligo-pyridylamides show that the bifurcated hydrogen 
bond between the ring nitrogen and the amide N-H imparts a curve to the backbone 
– a deviation from the rod like structure of oligo-benzamides.146, 147 However the 
conformational stability of the oligo-pyridylamides is greater than that of the oligo-
benzamides and as such there is proposed to be a lower entropic penalty for binding. 
Due to this entropic advantage, the oligo-pyridylamides are more effective inhibitors 
of amyloid fibril formation than the corresponding analogous oligo-benzamides.
154
  
Terephthalamides were developed as an easily-accessible analogue of the terphenyls 
which can be synthetically challenging.
140
 They also have an advantage over the 
terphenyls because of the conformational influence of hydrogen bonding. 
Terephthalamides have been used to inhibit the interaction between Bak and Bcl-xL, 
a target implicated in cancer.
141
 
Enaminones were also developed to replace terphenyls; again they have 
intramolecular hydrogen bonds to control conformation and they are also more 
polar, aiding the solubility, due to the replacement of the central phenyl ring.
142
 
Several studies on the synthesis and conformation of enaminones as helix mimetics 
have been published but no biological data has been published so far.
155, 156
 
Benzoyl ureas were developed as a synthetically more accessible and water soluble 
alternative to terphenyls.
143
 They have a slightly shorter distance between the side 
chains and also potentially allow the mimicking of more than the just i, i+4 and i+7 
residues.
6
 Benzoyl urea foldamers have also been used to inhibit the Bak/Bcl-xL 
interaction
98
 - displaying higher affinity than the binding region of the native 
peptide. 
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Another family of important helix mimetics are β-peptides;157 peptides comprising β 
amino acids – analogues of α-amino acids with an extra methylene between the acid 
and amine groups. β-peptides adopt a similar structure to a helix based on regular α 
amino acids but are more stable to proteolytic digestion.
158
 These extended peptides 
are expected to have similar problems to α-peptides with absorption.159 However, 
there are examples of cell permeable β-peptides that inhibit the p53/hDM2 
interaction. 
160
 
Although not strictly peptidomimetics, constrained peptides should also be 
considered in the context of helix mimicry. Constrained peptides are usually based 
on the native amino acid sequence but are held in a helical conformation thus 
negating the entropic penalty for binding by pre-organising the molecule.
161
 
Constraints can also impart resistance to proteolysis by preventing unfolding.
162
 
Peptides can also be constrained in other conformations.
163
 
These molecules are generally constrained by introducing a covalent link between 
the residue aligned vertically – the i to i+4 or the i to i+7 residues.6 The previously-
discussed (Chapter 1) hydrogen bond surrogates (HBS) introduce a covalent link to 
replace the hydrogen bond between the i carbonyl and the i+4 amide N-H as shown 
in Figure 66.
164
 The HBS approach has been successfully employed for HIF-
1α/p30054, 55  and Bak/Bcl-xL interactions.
162
 
 
Figure 66 - Structures of constrained peptides 
Stapled peptides maintain the hydrogen bond but introduce conformational stability 
by linking the side chains of two unnatural amino acid residues as shown in Figure 
66.
165, 166
 These links are usually introduced by ring closing metathesis of two 
appropriately spaced alkenyl amino acid residues. There are several examples and 
variants
88
 of stapled peptides in the literature including inhibitors of the Bcl-2/BID 
interaction which promote the apoptosis of leukaemia cells in mice.
167
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4.2 Application to the HIF-1α/p300 Protein-Protein Interaction 
HIF-1α forms a key PPI with the protein p300 which leads to the hypoxic response 
cascade, as discussed in Chapter 1.
168
 Upon inspection of the NMR structure of the 
HIF-1α/p300 complex,29 it was noted that it contains helical binding regions with the 
reported key residues
 33 displayed on one face of the α-helices, making them an 
obvious target for inhibition using appropriately functionalised α-helix mimetics. 
Having developed an assay to allow the screening of inhibitors of this PPI and 
identified a potential binding site for inhibitors, putative inhibitors were designed 
based on the amino acid sequence and secondary structure of the Helix 3 region of 
HIF-1α.  
For this work, the 3-O-alkylated oligo-benzamide scaffold was chosen due to: 
(i) The robust modular synthesis which is amenable to rapid combinatorial library 
generation either in solution
169, 170
 or on solid support
152, 153
 
(ii) The ability to adopt the desired conformation in solution
89, 144
 
(iii) Proven ability to inhibit α-helix mediated PPIs.87, 89, 171  
4.2.1 Helix 3 Mimicry 
Initially two compounds, shown in Figure 67 were designed to mimic the C-terminal 
helix of HIF-1α. The compounds were based on the previously reported modular 
oligo-benzamide PPI inhibitors.
144
  
 
Figure 67 – Rational design of helix 3 mimics. From left to right: Helix mimetic 3D 
structure, Helix 3 excised from the NMR structure of  p300 in complex with 
the C-terminal transactivation domain of HIF-1α (PDB ID: 1L8C), 
superimposed 3D structures and chemical structures of designed 
oligobenzamide mimics 
1 52 
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Compounds 1 and 52, shown in Figure 67, recapitulate the Leu, Leu, Val side chains 
in both the matched and mismatched N to C direction with respect to the helix 
dipole.  Modelling studies have shown that both the parallel and anti-parallel mimics 
are potentially effective mimics.
172
 
4.2.1.1 Monomer Preparation 
Before the oligo-benzamides could be assembled in a modular fashion, the 
monomers shown in Figure 68 had to be prepared. 
 
Figure 68 - Structures of monomers 
Initially, commercially available 3-hydroxy-4-nitrobenzoic acid 57 was protected as 
the methyl ester 58 by treatment with p-toluenesulfonic acid in methanol, and then 
the appropriate side chain was introduced by alkylation. Alkyl side chains were 
introduced using the commercially available bromides as shown in Scheme 3. 
 
Scheme 3 – Preparation and alkylation of methyl 3-hydroxy-4-nitrobenzoate, 
58 
As both the amine coupling partners and the acid coupling partners were required 
for synthesis of the oligo-amides the material resulting from each alkylation step 
was split into two portions (Scheme 4). For a portion of the material, the nitro group 
was reduced to the amine whilst for the remainder the methyl ester was hydrolysed 
to the acid. The saponification was simply performed using aqueous sodium 
hydroxide in methanol and the reduction was performed with stannous chloride. 
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Scheme 4 - Monomer differentiation via either reduction or ester hydrolysis. 
4.2.2.2 Modular Assembly of Oligo-Benzamides 
The desired oligo-benzamides were constructed using iterative cycles of amide bond 
formation and reduction. Once the desired length is obtained, a final reduction and 
methyl ester hydrolysis affords the desired compound as shown below in Scheme 5.  
The couplings between the derivatized benzoic acids and anilines are more difficult 
to achieve than most amide bond formations due to the low nucleophilicity of the 
aniline. Standard amide bond forming reagents, such as those employed in peptide 
synthesis, often return only starting materials. However formation of acyl chlorides, 
either by pre-activation or in situ formation followed by subsequent attack of the 
aniline is generally more successful.  
Initially, couplings were attempted, with moderate success, using 
dichlorotriphenylphosphorane, which forms the acid chloride in situ.
173
 In light of 
the modest yields, other conditions were investigated but the initial phosphorane 
coupling proved to be the best. The use of Mukaiyama’s reagent174 consumed the 
starting materials but none of the desired product was observed by crude NMR. 
Preforming an acyl chloride using thionyl chloride followed by reaction with an 
aniline
154
 gave none of the desired product by crude NMR. The dehydration reaction 
using PCl3 under high temperature microwave reaction conditions
175
 gave ~5% 
conversion by crude NMR. Therefore the desired oligobenzamides 1 and 52 were 
successfully prepared using the dichlorotriphenylphosphorane coupling conditions.   
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Scheme 5 - Assembly of oligobenzamide helix mimetics via iterative coupling 
and reduction cycles ending with a final hydrolysis 
4.2.2.3 Biological Assessment 
Once the oligobenzamides were synthesized, they were tested in the previously 
discussed fluorescence anisotropy competition assay (See Chapter 2). Upon titrating 
the putative inhibitors, a decrease in anisotropy associated with the disruption of the 
interaction was observed (Figure 69), in a similar manner to the decrease observed 
with the unlabelled peptide. In our assay the IC50 value of the unlabelled peptide was 
0.28 ± 0.02 μM and compounds 1 and 52 gave IC50 values of 9.1 ± 0.8 and 24 µM ± 
1 respectively.  
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Figure 69 - Representative fluorescence anisotropy titration data for the 
unlabelled HIF-1α (red) and compound 1 (black). (40 mM sodium phosphate 
buffer pH 7.5, 80 nM FITC-HIF-1α, 100 nM p300) 
Encouraged by these preliminary results, a small library of compounds with 
alternative side chains was prepared to probe the relative importance of side chain 
size and polarity. The additional compounds were prepared via the same methods 
described above: alkylation of the phenol with the corresponding halide, 
reduction/hydrolysis and coupling with dichlorotriphenylphosphorane. The 
compounds and their IC50 values are summarised in Table 6. Crucially, a peptide 
derived from the helix 3 region of the HIF-1α CTAD was incapable of inhibiting 
this interaction (IC50 > 500μM) 
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Table 6 - Structures and IC50 values for Oligobenzamide library 
 
Compound R1 R2 R3 IC50 (µM) 
1 iBu 
i
Bu 
i
Pr 9.1 ± 0.8 
52 iPr 
i
Bu 
i
Bu 24 ± 1 
69 Me 
i
Pr 
i
Bu 216 ± 16 
70 
i
Bu 
i
Bu 
i
Bu 9.8 ± 1.3 
71 
i
Bu 
i
Pr 
i
Bu 13.4 ±1.5 
72 Benzyl Benzyl Benzyl 56 ± 6 
73 
i
Pr 
i
Pr 
i
Pr 39 ± 4 
74 
i
Bu 
i
Pr 
i
Pr 17 ± 1 
75 Benzyl 
i
Pr 
i
Pr 20 ± 1 
76 2-hydroxyethyl 
i
Pr 
i
Pr 416 ± 64 
 
The best compound identified from this library is the exact mimic of the helix side 
chains with the same C to N directionality as the peptide, 1. The next best 
compound, 70, has the same top and bottom residues but with a very small 
difference (
i
Bu to 
i
Pr) in the central position. Incorporation of larger aromatic side 
chains, 72 in all positions seems to have a significant negative effect on the binding 
affinity. It should also be noted that the nitro-ester precursor 65 (shown in Scheme 
5) to 1 has an IC50 greater than 1 mM suggesting that the amine, the acid or both are 
imparting significant affinity along with the improved solubility.  
- 76 - 
In an attempt to rationalise the observed SAR, the best compound was docked 
computationally into the binding site of the corresponding peptidic region. This 
simulation and the structure activity relationship studies suggest that the R1 side 
chain is important and effectively fills a hydrophobic pocket within the binding cleft 
as shown in Figure 70. This is backed up by the reduced binding of 69 as a methyl 
group is insufficient to fill the hydrophobic pocket and 76 as the introduction of 
polar functionality into a hydrophobic binding site is disfavoured. Interestingly, as 
well as suggesting our designed binding mode could be successful, computational 
docking proposed an alternative binding mode (Figure 70 B) in which the 
oligoamide inhibitors sit transverse to the native peptide binding with the N-terminal 
region bound into the Leu 141 pocket but the C-terminal portion sitting in 
hydrophobic pocket made up by Trp 403, Cys 406 and Leu 417. Both binding poses 
are consistent with the observations from experimentation.  
 
 
Figure 70 - Proposed binding modes of compound 1 in the Helix 3 binding 
cleft 
 
Having developed inhibitors of this interaction we sought to compare our 
compounds with those reported in the literature. To this end the sulfonamide 
inhibitor, KCN-1, discussed in Chapter 1, was prepared via a modified route 
(Scheme 6).  
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Scheme 6 – Synthesis of sulfonamide, KCN-1 
Alkylation of 4-hydroxybenzaldehye 77 via an Ullman type coupling
176
 followed by 
a Claisen cyclisation under thermal conditions provided the chromene 79 in 
excellent yield. Subsequent reductive amination with aniline afforded the secondary 
amine 80 which when treated with 3,4-dimethoxybenzenesulfonyl chloride gave the 
desired sulphonamide compound KCN-1 in significantly improved yields compared 
to the original preparation (cf. 15% over the first 2 steps).
177
  
KCN-1 was subsequently tested in the fluorescence anisotropy assay to give a 
comparison to the best oligoamide inhibitor 1. Due to poor solubility, the 
sulfonamide could only be tested up to a maximum concentration of 25 µM. At this 
concentration, no inhibition of the HIF-1α/p300 PPI was observed whilst at similar 
concentrations the best oligoamide compounds showed significant inhibition. Given 
the reported cellular IC50 values for this compound is between 0.6-1.6 µM this 
suggests that the effects of KCN-1 observed in cellular assays may result, at least 
partially, from off-target effects. 
The selectivity of the oligobenzamide 1 was then assessed by testing the inhibitory 
activity on another therapeutically relevant and α-helix mediated PPI, eukaryotic 
initiation factor (eIF) 4E/4G.
80
 As Figure 71 illustrates, the oligobenzamide 
compound 1 does inhibit this alternative protein-protein interaction but only weakly 
with an IC50 of approximately 1 mM, giving over 100-fold selectivity for the HIF-
1α/p300 interaction.  
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Figure 71 - Competition assay for compound 1 against the eIF4E/eIF4G 
Protein-Protein Interaction (80 nM FITC-eIF4G, 3 µM eIF4E, 40 mM sodium 
phosphate, 200 mM NaCl, 1 mM DTT, 5% glycerol, 0.1% triton). Error bars 
represent the standard deviation of 3 repeats 
Given the success of the O-alkylated oligo-benzamides as inhibitors of the HIF-
1α/p300 interaction, a compound with the requisite side chains displayed on an 
alternative proteomimetic scaffold was investigated.  An N-alkylated oligo-
benzamide 81 (prepared by K. Long
178
) should also be capable of recapitulating the 
helix 3 sidechains (Figure 72) and therefore inhibit the interaction. However, 
compound 81 was shown to be unable to disrupt the interaction between HIF-1α and 
p300 (IC50 > 250 μM) suggesting that both the sidechains and the scaffold are 
crucial for inhibition.  
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Figure 72 - N-alkylated analogues. From left to right, superimposed structures of N-
alkylated proteomimetic and the HIF-1 Helix 3 excised from the NMR 
structure of  p300 in complex with the C-terminal transactivation domain of 
HIF-1α (PDB ID: 1L8C), 3d model of N-alkylated oligo-benzamide in the 
extended conformation, structure of N-alkylated oligo-benzamide 81. 
4.2.2 Helix 2 Mimicry 
To further validate the theory that the C-terminal helix (helix 3) of the HIF-1α 
CTAD is crucial for the interaction (see Chapter 2), and that the compounds 
described above act as helix 3 mimetic inhibitors, a series of compounds was 
designed to mimic helix 2. The helix 2 regions contains two key residues, identified 
by others
108
, on one face of the helix – namely Cys800 and Asn804.  
81 
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Figure 73 – Rational design of helix 2 mimetics. Top from left to right: Helix 
mimetic 3D structure, Helix 2 excised from the NMR structure of  p300 in 
complex with the C-terminal transactivation domain of HIF-1α (PDB ID: 
1L8C), superimposed 3D structures. Bottom chemical structures of designed 
oligobenzamide mimics 
To mimic two turns of an alpha helix, only a dimeric benzamide is required. The 
compounds were designed to mimic the relevant side chains with both the matched 
82/83 and mismatched directionality 84/85 with respect to the dipole of the native 
helix (Figure 73). Also the oxy-analogue (cf serine) was incorporated 83/85 , in 
place of the cysteine mimic, to prevent any possible issues with disulfide bond 
formation.  
4.2.2.1 Monomer Preparation 
The preparation of these compounds required the synthesis of novel monomers with 
protecting groups to prevent the nucleophilic side chains from interfering with the 
coupling reactions. They were prepared in an analogous manner those described 
above. The asparagine mimic building blocks 95/98 was prepared by the reaction of 
trityl amine 86 and bromoacetyl bromide to give the protected amide moiety 87. 
This could then be used to alkylate methyl 3-hydroxy-4-nitrobenzoate 58 giving the 
nitro ester compound 92 (Scheme 7). 
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Scheme 7 - Synthesis of protected helix 2 monomers 
The cysteine mimic building block 88 was prepared via the selective trityl protection 
of mercaptoethanol
179
 using trityl chloride followed by a Mitsunobu reaction to 
introduce the side chain 89 into nitro ester 90. The serine mimic was prepared via 
the alkylation of 58 using commercially available MOM-protected bromo-ethanol. 
The nitro esters 90-92 were subsequently either reduced to the aniline building 
blocks 93-95 or hydrolysed to give the acid blocks 96-98. 
Significantly reduced yields were observed in the alkylation steps, in comparison to 
the simple alkyl chains described previously. Two-dimensional TLC showed the 
products to be unstable on silica. Switching from silica to alumina for 
chromatography led to an increase in isolated yield in later steps. 
4.2.2.3 Dimer Assembly 
With the requisite building blocks prepared, attempts were made to assemble them 
into the designed compounds. Due to the acid lability of the side chains several 
coupling conditions were trialled  as described in Table 7. 
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Table 7 – Results from coupling experiments towards helix 2 mimetics 
 
Entry R
1
 R
2
 Conditions Conversion 
by crude 
NMR 
1 
 
 HATU, 
DIPEA 
No conversion 
2 
 
 SOCl2 No conversion 
3 
 
 Ghosez’s 
Reagent 
~5% 
 
4 
 
 Cl2PPh3 No conversion 
5  
 
Ghosez’s 
Reagent 
~5% 
 
6  
 
Cl2PPh3 Complete 
conversion 
7 
 
 
Cl2PPh3 Complete 
conversion 
 
None of the coupling conditions between two exemplar helix 2 mimetic building 
blocks gave satisfactory coupling (entries 1-4). The building block side chains were 
then reversed to rule out an incompatibility with the examples chosen for the 
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screening but coupling was still insufficient (entry 5).  Finally it was shown that the 
building blocks could be coupled with other building blocks (entries 6-7) but not 
each other. 
In order to prepare the dimers for screening an alternative synthetic method was 
required. To reduce the steric effects on the amide bond forming reaction an un-
functionalised monomer unit (methyl 4-amino-3-hydroxybenzoate) 99 was coupled 
to the monomer 97 using PyBOP.
153, 180
 This gave a 9:1 mixture of the ester 101 to 
the desired amide 100. When treated with caesium carbonate, the ester undergoes a 
O- to N-acyl transfer giving the desired amide 100 in moderate yield suggesting that 
O-acylation is kinetically favoured but that the ester rearranges to the 
thermodynamically more stable amide. The desired side chain can then be 
introduced via the alkylation of the phenol to give 101. Subsequent catalytic 
hydrogenation, ester hydrolysis and side chain deprotection afforded the desired 
dimer 102 for screening. 
 
 
Scheme 8 - Synthesis of dimers via acyl transfer 
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4.2.2.3 Assessment of Inhibitory Activity  
The prepared helix 2 mimetic compound 102 was screened in HIF-1α/p300 
competition assay and no inhibitory activity observed up to 1 mM (higher 
concentrations were not screened) – given the complete lack of activity, and time 
constraints, no further analogues were prepared. This lack of potency provides 
additional evidence for the theory that helix 3 drives the binding of the HIF-1α 
CTAD to p300. Although a body of previous work shows compounds of this type 
are good mimics of α-helices there is no evidence that the compounds used here are 
capably of mimicking this particular helix. The lack of activity of these compounds, 
featuring the same backbone scaffold as the active compounds described in section 
4.2, also provides additional evidence that the side chains are crucial for the 
recognition of oligobenzamide 1 by p300.  
4.3 Late Stage Functionalization 
Late stage functionalization is important in the exploration of structure activity 
relationships (SAR) – allowing rapid access to many analogues from a single 
precursor which can be prepared on a reasonable scale. The development of 
synthetic methodology in the area of late stage functionalization has recently 
expanded
181
 particularly through the use of C-H functionalization.
182
  
In able to allow access to a larger set of oligo-benzamide compounds with more 
diverse side chains to explore the SAR of their HIF-1α/p300 inhibition, it was 
desirable to develop a late stage functionalization approach. This abrogates the 
requirement to build large sets of monomers and assemble them; whilst this 
approach is useful for library production
152
 and initial screening,
148, 170
 it disfavours 
making small changes to compound structures.  
Employing the best inhibitor identified from the initial library of HIF-1α/p300 
inhibitors 1, as a starting point for SAR studies, and with a secondary aim of 
improving the solubility, a series of compounds with cleavable protecting groups 
was prepared. Phenolic allyl ethers are readily cleaved via the formation of a π-allyl 
complex with palladium (0) but are relatively inert to other conditions. This made 
then ideal for use in the late stage functionalization of oligobenzamides.  
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Figure 74 - Allyl precursors for late stage functionalization 
The allyl side chain monomer was produced via the methods previously described 
for monomer synthesis.
144, 152
 This allyl monomer can then be carried through 
iterative trimer assembly to give the allyl protected trimers 103-105 shown in Figure 
74 which have each of the side chain positions sequentially substituted from the 
trimer 1 – the best inhibitor of HIF-1α/p300. 
The allyl group can then be cleaved by treatment with palladium tetrakis 
triphenylphosphine in the presence of a sulfinic acid scavenger as shown in Scheme 
9.
183
 This reveals the phenol which can then be functionalized via Mitsunobu
184
 or 
SN2 alkylation reactions. As well as incorporating additional functionality at the 
phenolic position, it can be left functionalised to assess the individual contributions 
of sidechains after reduction and hydrolysis. An analogous sidechain deletion 
approach was employed to elucidate the mechanism of amphotericin B activity.
185
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Scheme 9 - Example de-allylation reaction of trimer 103 
In an attempt to increase the aqueous solubility of the oligobenzamides, a variety of 
solubilising side chains were incorporated into the scaffolds. The compounds were 
then reduced and hydrolysed to provide another library of compounds with more 
diverse functionality without having to produce all the monomers separately and 
construct the compounds individually. An example of a synthetic route is shown in 
Scheme 10. 
 
Scheme 10 - Example late stage functionalization 
This approach reduces the number of synthetic steps required to make a library of 5 
trimeric compounds with variation in one position from 42  to 27 steps from 3-
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hydroxy-4-nitrobenzoic acid 58. The compounds prepared were then screened in the 
HIF-1α/p300 competition assay and the results are summarised in the table below. 
 
Compound R
1
 R
2
 R
3
 IC50 / μM 
110 H 
i
Bu 
i
Pr >500 
111 
 
i
Bu 
i
Pr 521 ± 16 
112 
i
Bu H 
i
Pr 341 ± 15 
113 
i
Bu 
 
i
Pr >500 
114 
i
Bu 
 
i
Pr 168 ± 22 
115 
i
Bu
 i
Bu H 137 ± 12 
116 
i
Bu
 i
Bu 
 
>500 
109 
i
Bu
 i
Bu 
 
322 ±15 
117 
i
Bu
 i
Bu 
 
163 ± 10 
 
Unfortunately none of the compounds exhibited activities anywhere near those of 
the previously described compounds. This provides further evidence that the 
hydrophobic nature of the sidechains is crucial for inhibition of the HIF-1α/p300 
interaction. The amine functionalized compounds were observed to be significantly 
more soluble than the previous compounds. Some of the compound appeared to 
interfere with the assay so accurate IC50 values could not be determined.  
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4.4 Photo-crosslinking Compounds 
Another advantage of the late stage functionalization approach is that sensitive 
functional groups can be incorporated later in the synthesis and therefore carried 
through fewer steps. This allowed the preparation of a trifluoromethyl diazarine 
photocrosslinking group
186
 functionalized trimer in an attempt to confirm active 
helix mimetic binding sides via covalent crosslinking and proteomics as shown in 
Figure 75. 
 
Figure 75 - Schematic representation of photo-crosslinking approach 
The trifluorodiazarine functional group extrudes nitrogen when irradiated with UV 
light and generates a singlet carbene. This carbene is highly reactive and 
promiscuously forms covalent bonds with proximal groups. It has been utilised to 
explore biological interactions, including amyloid formation
187
 and prolyl 
hydroxylase enzymes,
188
 via crosslinking then mass spectrometry. It was envisioned 
that by functionalising compound 1 with trifluoromethyl diazarines in various 
positions it would be possible to identify the binding site of the compounds by 
inducing crosslinks, digesting the protein into peptide fragments and identifying the 
crosslinked region by LC-MS/MS.   
The trifluoromethyl diazarine moiety was prepared according to a literature 
procedure
189
 as shown in Scheme 11. Briefly, 4-bromobenzyl alcohol 118 was silyl 
protected 119 then  lithiated and trapped with diethyltrifluoroacetamide to introduce 
the trifluoromethyl ketone functionality 120. The ketone was sequentially converted 
to the oxime 121, tosyl-oxime 122 and finally the diaziridine 123. The diaziridine 
123 was oxidised to the diazarine 124 with iodine, the alcohol deprotected to 125 
and converted to the iodide 126.  
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Scheme 11 - Synthesis of trifluoromethyldiazarine building block 
The fragile diazarine would likely not survive the harsh coupling conditions required 
to prepare the oligobenzamide backbone and would certainly not be stable to the 
reductive conditions required to reduce the nitro groups. It would also significantly 
lengthen the number of linear steps required to produce the compounds. However 
using the late stage methodology described above, the aryl trifluoromethyl diazarine 
can be incorporated after all the required reductions as shown in Scheme 12. 
 
Scheme 12 - Late stage one-pot synthesis of photocrosslinking helix mimetic 
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By selectively, and irreversibly, deprotonating the phenol with sodium hydride then 
treating with the iodide, the desired functionality could be introduced. Final ester 
hydrolysis was performed in situ by treating the reaction mixture with sodium 
hydroxide. This afforded the compounds shown in Figure 76 with the aryl group in 
the middle 128 and bottom positions 129 but failed to produce the compound 
functionalized in the top position – possibly due to the proximity of the aniline to the 
phenol.  
 
Figure 76 - Structure of cross linking compounds prepared 
The photo-crosslinking compounds were screened for activity in the HIF-1α/p300 
competition assay and unfortunately, although not surprisingly, the presence of the 
cross-linking functionality impaired the ability to inhibit the interaction. The degree 
of impairment was position dependant and consistent with the models provided in 
Figure 70. Incorporation in the middle position, compound 128, was particularly 
poorly tolerated with an estimated IC50 of 985 ± 102 μM. Functionalization at the C-
terminal position 129 was tolerated considerably better with an IC50 of 136 ± 8.7 
μM. Compound 129 was therefore selected for preliminary crosslinking studies.  
4.4.1 Protein Digestion Analysis 
To enable the identification of protein-compound cross links an unlabelled protein 
digestion and analysis was required as background. The p300 protein was dialysed 
into ammonium bicarbonate buffer, denatured thermally and disulfides reduced prior 
to the cysteines being alkylated with iodoacetamide. The protein was then treated 
with trypsin for 4 hours, quenched with TFA and analysed by LC-MS/MS. The LC 
trace and example MS/MS data are shown below in Figure 77. This analysis 
provided approximately 70% coverage of the p300 primary sequence without further 
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optimisation suggesting that it was likely the binding sites could be identified using 
this method.  
 
Figure 77 - LC trace and example MS/MS for p300 digestion 
Compound 129 was incubated with p300 protein (100 μM) at 150 μM, a 
concentration above its IC50 value for HIF-1α/p300 inhibition, and irradiated with 
360 nM light for 1 hour. Crosslinking was initially monitored by intact protein 
electrospray mass spectrometry and LC-MS. Prior to UV irradiation, samples 
containing protein only, compound 129 only and the protein/compound mixture 
were analysed by LC-MS. These samples were then irradiated with 365 nm UV light 
for 1 hour whilst cooled in an ice bath and reanalysed. LC-MS analysis showed that 
that compound 129 had been almost completely consumed in both the compound 
only sample and the protein/compound sample however mass spectrometry showed 
no protein adducts (Figure 78).  
- 92 - 
 
Figure 78 - Analytical data for photo-crosslinking experiments. (a) Chromatogram 
of 150 μM compound 129 in buffer prior to UV irradiation. The peak 
corresponding to compound 129 is denoted by the asterisk (b) Chromatogram 
of 150 μM compound 129 in buffer post UV irradiation (365 nm, 1 hour) (c) 
mass spectrum of protein before UV irradiation (365 nm, 1 hour)  (d) mass 
spectrum of protein after UV activation (365 nm, 1 hour)  
Upon further inspection, several additional peaks were evident in the LC-MS trace 
corresponding to various degradation products arising from carbene formation and 
reaction with water. The water quenched carbene products and the lack of 
crosslinking observed suggest that the trifluoromethyl diazarine is exposed to 
solvent when compound 129 is bound to p300 rather than buried in the protein 
surface. This could explain why incorporation at the bottom position is tolerated 
better than in the middle position. Unfortunately, this approach did not provide any 
further information about the binding mode of these oligoamides as hoped. 
- 93 - 
4.5 Protein Prosthesis 
A long term goal in chemical biology and synthetic biology is the incorporation of 
non-natural functionality into biomolecules such that the natural function of the 
original molecule is enhanced (protein prosthesis).
190
 There are many ways in which 
this has been attempted; chemical mutagenesis of enzyme active sites,
191, 192
 the 
synthesis of all mirror image proteins
193
 and the replacement of canonical amino 
acids with β-peptides.194 Nature, for the most part, uses the 20 canonical amino acids 
but protein prosthesis allows the incorporation of any number of unnatural 
functionalities.  
Often in this field, biomolecules are engineered to either improve stability
195
 or to 
change substrate specificity.
196
 It is rare for the activity to be equal to the wild type 
but there are examples where activity is retained
197
 or only mildly depleted
198
 when 
unnatural functionality is incorporated. A common approach to protein prosthesis is 
the replacement of individual residues
199
 or small sections
198
 of the protein primary 
structure with unnatural amino acids. β-turns have also been replaced by small 
molecules with locked conformations.
200
  There are examples of β-peptide 
sequences replacing helical regions of proteins without complete loss of activity
201
 
but, so far, no examples of helix mimetic small molecule incorporation have been 
reported. 
4.5.1 Oligobenzamide-Peptide Hybrids 
Having observed that the oligobenzamide proteomimetic compounds, discussed in 
Chapter 5, provided better inhibitors that the short (helix 3) peptide that they mimic, 
it was envisaged that incorporation of the helix mimetic into a longer peptide 
sequence could provide an inhibitor with enhanced affinity that retained the 
specificity imparted by a long peptide sequence. To this end, synthetic methodology 
to develop oligobenzamide helix mimetic/peptide hybrids was developed based on 
the previously developed solid phase oligobenzamide synthesis shown in Scheme 
13.
152
 Fluorenylmethoxy carbamate (Fmoc)-protected monomers were activated as 
the acid chloride then added to glycine loaded Wang resin. The Fmoc can then be 
subsequently removed with piperidine and additional monomers added to the 
growing chain in an method analogous to standard Fmoc-SPPS.  
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Scheme 13 - Previously developed iterative solid phase synthesis of 
oligobenzamides
152
 
4.5.2 Method Development 
Previously developed solid-phase synthesis methods for the preparation of 
oligobenzamides allows the rapid preparation of helix mimetic trimers (Scheme 
13)
152
 but the conditions were not suitable for the preparation of peptide-conjugates. 
The poor nucleophilicity of the anilines requires harsh acid chloride mediated 
conditions likely to racemize and/or deprotect conventional amino acid building 
blocks. Attempts were made to couple Fmoc-glycine to the top of a trimer 130 using 
either HATU or via Fmoc-glycine acid chloride, but no coupling product 131 was 
observed (Scheme 14).  
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Scheme 14 - Attempted coupling of Fmoc-Glycine to the N-terminus of an 
oligobenzamide trimer 
To circumvent the poor nucleophilicity of trimer anilines, Fmoc-glycine was 
coupled to an isobutyl monomer 134 using dichlorotriphenylphosphorane (Scheme 
15). The use of an allyl ester facilitated the ester cleavage in the presence of the base 
labile Fmoc protecting group as shown in Scheme 15. 
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Scheme 15 - Synthesis of Fmoc-Gly iBu monomer, 136 
Synthesis of key monomer 136, began with Fischer esterification of nitro acid 58 
with allyl alcohol to give ester 132 before alkylation with isobutyl bromide to give 
alkoxy nitro ester 133. The aryl nitro group was reduced to the aniline 134 using 
stannous chloride. The aniline 134 was then acylated with Fmoc-glycine via in situ 
acid chloride formation with dichlorotriphenylphosphorane. Finally the ester 135 
was revealed with palladium (0) tetrakis triphenylphosphine and sodium 
toluenesulfinate scavenger
183
 to give the final building block 136 in good yield. 
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Scheme 16 - Solid phase synthesis of oligobenzamide peptide hybrids 
 
- 98 - 
4.5.3 Application to HIF-1α/p300 
The Fmoc-Gly-
i
Bu monomer 136 was then used in the modified oligomer synthesis 
depicted in Scheme 16. Initially the method is the same as the one shown in Scheme 
13, however when the terminal benzamide residue was reached, the glycine 
conjugated monomer was included. Deprotection of the glycine amine with 
piperidine provided a handle for standard solid phase peptide synthesis. The pendant 
peptide was then extended using coupling reagent HCTU in a conventional manner.  
This methodology was applied to the helix 2 and 3 region of the C-terminal 
transactivation domain (CTAD) of HIF-1α. The helix 3 region was replaced with the 
previously identified helix mimetic (see Chapter 5) and the rest of the amino acids 
kept unchanged as shown in Figure 79. The preparation of compound 137 was 
performed in a single run on an automated peptide synthesiser (CEM Liberty). 
 
Figure 79 - Structure of oligobenzamide peptide hybrid 137 
The hybrid compound 137 was prepared via the methods discussed above and 
purified by preparative-HPLC three times, however each time it was unstable and 
could not be stored for any amount of time thus precluding the testing of its 
inhibitory activity. Due to the instability of hybrid 137, several structural 
modifications were proposed to increase stability. The N-terminal amine was 
acetylated to curtail reactivity and the cysteine residue was replaced with a serine 
residue to give hybrid 138 (Figure 80). Hybrid 138 was prepared via the same 
methodology, purified by HPLC and exhibited significantly improved stability. 
137 
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Figure 80 - Structure of oligobenzamide peptide hybrid 138 
4.5.4 Assessment of Inhibitory Activity 
The increased stability of hybrid 138 allowed it to be tested in the HIF-1α/p300 
fluorescence anisotropy competition assays (described in Chapter 1). The hybrid 
was able to inhibit the interaction to almost exactly the same extent as the helix 2-3 
peptide (Chapter 2) as shown in Figure 81. The similar IC50 values (Hybrid: 83 ± 1.8 
μM; peptide: 89 ± 2.8 μM) were encouraging, despite the fact that they were not as 
potent as the helix mimetics alone (cf. 10 μM), because no potency is lost when 11 
residues were replaced with a small molecule. Crucially, the peptide does not bear 
the cysteine to serine modification. As the mutation of this cysteine residue to a 
serine has been shown to reduce activity by approximately 10-fold,
35
 it is 
conceivable that the hybrid has improved potency provided by the unnatural portion 
but reduced potency from the serine residue. Further compounds in this series could 
further elucidate this effect and a direct comparison with the cysteine to serine 
modified peptide should be performed. It should also be noted that this affinity does 
not come from the peptidic region alone as the “Helix 2 plus linker” peptide 
comprises the same residues and shows no inhibitory activity (Chapter 4). 
138 
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Figure 81 - Fluorescence anisotropy inhibitor curves for hybrid 138 and the helix 2-
3 peptide 
The decreased affinity, compared to the helix mimetics portion alone, implies that 
the peptide chain may be forcing the compound to bind in a suboptimal position or  
in a different position all together. Optimisation of the spacing/linker between the 
small molecule and the peptide sequence could be performed, especially if 
crystallographic data could be acquired. Molecular modelling of the complex 
(Figure 82), based on the previously docked oligoamide compound, suggests that 
further truncating the peptide in the region between helix 2 and 3 may provide a 
better fit. By beginning the peptide region at the indicated leucine residue rather than 
glycine, a higher affinity binder could conceivably be achieved.  
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Figure 82 - Overlaid NMR structure and docked pose showing mismatch at the N-
terminus of helix 3 
4.6 Summary and Conclusions 
This chapter introduced the concept of helix mimicry and then goes on to  describe 
the design, synthesis and screening of small molecule helix mimetic inhibitors of the 
HIF-1α/p300 with low micromolar activity. The effect of scaffold is considered 
followed by a novel synthetic procedure for the preparation of oligobenzamides 
featuring designed against  a different region of the interaction. Additionally a late 
stage functionalization procedure capable of incorporating diverse functionality is 
described and applied to developing analogues with increase solubility and 
photocrosslinking potential. Finally, synthetic methodology to provide novel 
peptide-oligobenzamide hybrid molecules has been developed. This methodology 
was then applied to the CTAD of HIF-1α to provide a compound with equivalent 
potency to the native peptide sequence it replaces. This provides further evidence 
that oligobenzamides can successfully mimic helices. 
The work presented in this chapter demonstrated the applicability of helix mimetic 
strategies to a new target and provided the first biophysically characterised 
inhibitors of a therapeutically relevant PPI. Whilst the extended SAR studies and 
photo-crosslinking analogues failed to further elucidate the binding mode, the 
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methodology reported herein will hopefully prove useful for other targets/projects. 
Further work could focus on further increasing affinity and increasing solubility in a 
fashion which does not reduce activity. 
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Thesis Summary and Future Work 
This thesis began with a description of two biological pathways featuring α-helix 
mediated protein-protein interactions, both of which provide potential points for 
therapeutic intervention during cancer progression. The HIF-1α/p300 interaction is 
crucial for oxygen homeostasis and provides solid tumours a pathway through which 
hypoxia can be lifted. The eIF4E/eIF4G interaction provides control over expression 
of proteins by limiting the recruitment of mRNA to the ribosome. Overexpression of 
eIF4E is a common feature of cancers and allows the overexpression of anti-
apoptotic proteins, thus preventing programmed cell death. The currently available 
inhibitors of these interactions were reviewed and discussed. 
Seeking to identify and develop new inhibitors of the HIF-1α/p300 and eIF4E/eIF4G 
interactions, binding assays were developed and the requirements for binding 
investigated. It was found that the complete CTAD of HIF-1α was required for high 
affinity binding to p300 but that the C-terminal Helix 3 provided a significant 
amount of this affinity and could be a potential target for inhibitor design. An 
investigation into cooperativity between the Helix 2 and Helix 3 binding regions was 
carried out and the effect of the chelate effect investigated. Some of the results in 
Chapter 2 hint at the importance of the previously disregarded Helix 1 region which 
requires further investigation. A full alanine scan of the HIF-1α CTAD followed by 
biophysical analysis of the binding to p300 has been proposed. 
The requirements for eIF4E/eIF4G binding are better known in the literature but the 
studies reported here suggest that the binding is independent of m7G Cap binding at 
a distal position. Further work is warranted to fully understand the reported binding 
of both 4E-BP and 4EGI-1 at an allosteric site and the potential of this allosteric site 
for inhibitor development. 
Subsequently, competition assays capable of identifying inhibitors were developed 
for both PPIs of interest. These screening assays should allow the discovery of 
potent inhibitors and future work may focus on the high-throughput screening of 
compound libraries. These assays were used to screen compounds identified from 
virtual libraries of commercially available and bespoke diverse compound libraries. 
Both docking and pharmacophore modelling were used to identify compounds for 
purchase or further virtual enumeration. Purchased compounds were screened and a 
non-selective covalent inhibitor 10 identified as well as a weak inhibitor of the 
eIF4E/eIF4G interaction, 4. A small library of compounds based on compound 4 
was prepared but no clear SAR could be determined. Further work could focus on 
the further exploration of this compound, particularly moving away from the 
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aminothiazole core. Additional docking and screening could also provide more 
starting points for inhibitor development. 
A novel, drug like, small molecule scaffold emerged from the docking of bespoke 
libraries against HIF-1α/p300 and underwent optimisation by iterative virtual library 
enumeration and docking before compounds were selected for synthesis. A small 
library of novel compounds was prepared and screened against HIF-1α/p300 
resulting in the identification of a potential starting point for a medicinal chemistry 
campaign. Further work will focus on optimising the potency, screening for 
selectivity and elucidating the binding mode.  
A proteomimetic approach was also employed for HIF-1α/p300. Oligobenzamides 
capable of recapitulating the Helix 3 sidechains were prepared and screened, thus 
identifying small molecule inhibitors of the HIF-1α/p300 interaction. A library of 
analogues was prepared to explore the SAR and a binding model proposed based on 
docking and the results from the library screening. A literature compound, KCN-1, 
was also prepared via an improved route and found not to inhibit the HIF-1α/p300 
interaction. Further work would focus on improving the potency and physical 
properties of the oligobenzamide inhibitor 1. This would be aided hugely by 
structural studies of the compounds in complex with p300, either by NMR or X-ray 
crystallography. 
New methodology was developed to allowed the mimicry of the Helix 2 region of 
the HIF-1α CTAD, however this compound proved to be inactive. A late stage 
functionalization protocol for oligobenzamides was developed to allow easier access 
to large libraries for SAR studies and the incorporation of delicate functionalities. 
The late stage functionalization protocol was employed to provide another set of 
oligobenzamide analogues with amine sidechains which proved to be weaker 
inhibitors, albeit with increased aqueous solubility. The late stage functionalization 
procedure also allowed the incorporation of a trifluoromethyl diazarine moiety for 
photo-crosslinking. Unfortunately, no photo-crosslinking could be observed to p300. 
Despite the fact that the late stage functionalization protocol failed to produce 
improved inhibitors or crosslinking compounds, the methodology should provide 
useful for the preparation of larger libraries for SAR studies for this and other targets 
in the future. Incorporation of the photocrosslinking capabilities in other positions 
should be carried out to attempt to validate the binding mode of these compounds.  
Finally, a new hybrid compound containing both a helix mimetic compound and a 
peptide was proposed and prepared. New solid phase methodology was employed to 
prepare two examples of this type. Screening of the hybrid compounds revealed 
them to be as potent as the peptide they were designed to mimic but not as potent as 
the small molecule alone. This provides further evidence that oligobenzamides are 
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capable of mimicking helices. However, further work is clearly required to improve 
the potency to the level of the small molecules and potentially beyond. 
In summary, binding requirements for two PPIs were investigated allowing the 
development of screening assays. These assays were used, alongside computational 
approaches, to identify several small molecule inhibitors which may provide useful 
starting points for inhibitor development. An secondary structure mimicry approach 
also provided inhibitors of the HIF-1α/p300 interaction. New methodology was 
developed to further explore these proteomimetic inhibitors. 
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Chapter 5 – Experimental Section 
The candidate confirms that the work submitted is his own, except where work 
which has formed part of jointly authored publications has been included. The 
contribution of the candidate and the other authors to this work has been explicitly 
indicated below. The candidate confirms that appropriate credit has been given 
within the thesis where reference has been made to the work of others. 
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5.1 General Experimental 
All commercial solvents and reagents were used without further purification unless 
stated otherwise. All non-aqueous reactions were performed under an atmosphere of 
nitrogen and using anhydrous solvents. Water-sensitive reactions were performed in 
oven-dried glassware, cooled under nitrogen before use, or flame dried and cooled, 
under vacuum if stated. Solvents were removed under reduced pressure using a 
Büchi rotary evaporator. Ether refers to diethyl ether and petrol refers to petroleum 
spirit (b.p. 40-60 °C). Flash column chromatography was carried out using silica 
(35-70 μm particles) or alumina (neutral, Brockman activity 1), with crude reaction 
mixtures loaded in the initial solvent system or its least polar constituent. Thin layer 
chromatography was carried out on commercially available silica pre-coated 
aluminium plates (Kieselgel 60 F254, Merck) or commercially available alumina 
pre-coated glass plates (neutral, Brockman activity 1). Strong cation exchange 
columns  were carried out using SCX, 5.0 g pre-packed cartridge, Supelco. 
Proton and carbon NMR spectra were recorded on a Bruker Avance 500, Avance 
DPX300 or DRX500 spectrophotometer with an internal deuterium lock. Carbon 
NMR spectra were recorded with composite pulse decoupling using the waltz 16 
pulse sequence. Chemical shifts are quoted in parts per million downfield of 
tetramethylsilane, and coupling constants (J) are given in Hz. NMR spectra were 
recorded at 300 K unless otherwise stated. Infra-red spectra were recorded using a 
Perkin–Elmer Spectrum One FT-IR spectrophotometer. Melting points were 
determined using a Griffin and George melting point apparatus and are uncorrected. 
Nominal mass spectrometry was routinely performed on a Bruker HCT Ultra 
spectrometer using electrospray (+) ionization. Nominal and accurate mass 
spectrometry using electrospray ionisation was carried out by staff or the candidate 
in the School of Chemistry using a Micromass LCT-KA111, Bruker MicroTOF or 
Bruker MaXis Impact TOF mass spectrometer. Mass-directed HPLC purifications 
were run on an Agilent 1260 Infinity Preparative HPLC system equipped with a 
Waters XBridge™ Prep C18 19 × 100 mm column, 5 μm particle size, on an 
acetonitrile or methanol/water gradient (5-95% acetonitrile or methanol over 8 
minutes) and an Agilent 6120 Quadrupole system equipped with a quadrupole MS 
detector, using electrospray ionisation (ESI).  
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5.1.1 Oligobenzamide Nomenclature 
To simplify the numbering and NMR assignment of 
oligobenzamides, we have devised a sequential 
nomenclature, where each of the monomer building 
blocks is considered separately. The monomers are 
numbered from 1 to 3 starting from the N-terminal. 
Within each monomer, the numbering is the same: the 
carbons from the aminobenzoic acid are numbered 
using the standard system (the aromatic carbon bearing 
the carboxylic acid is C1, the one bearing the amine is 
C4). Then, the lateral chain is numbered: the carbon 
attached to the oxygen is the Cα, and the numbering of 
the aliphatic part of the side chain continues with Cβ, 
etc. In the case of aromatic side chains, the aromatic 
carbons are numbered CAr1, CAr2, etc. The numbering of the protons is based on 
the carbon numbering. To differentiate each individual carbon/proton, the monomer 
number is added as a prefix to the carbon/proton number representative examples 
are given above. 
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5.2 Experimental for Chapter 2 
5.2.1 HIF-1α CTAD Peptides 
The HIF-1α C-terminal transactivation domain (CTAD) peptides were purchased 
from Proteogenix, France. The sequence is shown below. 
Ac-SMDESGLPQLTSYDCEVNAPIQGSRNLLQGEELLRALDQVN-NH2 
The labelled analogue has the same sequence with an additional aminohexanoic acid 
(Ahx) residue as the N-terminus was functionalised with fluorescein isothiocyanate 
(FITC). 
FITC-Ahx-SMDESGLPQLTSYDCEVNAPIQGSRNLLQGEELLRALDQVN-NH2 
5.2.2 Determination of the Binding of Labelled HIF-1α Peptide to p300 
Protein 
Protein was serially diluted into a solution of labelled peptide (80 nM) and the plates 
incubated for 30 minutes at room temperature. Each experiment was run in triplicate 
and the fluorescence anisotropy measured using a EnVision 2103 MultiLabel plate 
reader (Perkin Elmer) with excitation at 480 nm and emission at 535 nm (5 nm 
bandwidths). The Intensity was calculated for each point using Eq. 1 and used to 
calculated anisotropy using Eq. 2. From a plot of anisotropy against protein 
concentration, the minimum and maximum anisotropies were obtained using a 
logistic sigmoidal fit in OriginPro 8.6. 
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Determination of minimum and maximum anisotropy (80 nM FITC-HIF-1α CTAD, 
40 mM sodium phosphate, 100 mM NaCl, 1 mM DTT, 5% glycerol). Error bars 
represent the standard deviation of 3 repeats. 
These values were used to convert anisotropy into amount of bound labelled peptide 
using Eq. 3. This data was then fitted using Eq. 4 in OriginPro 8.6 to determine the 
dissociation constant, KD.  
𝐼 = (2𝑃𝐺) + 𝑆  (Eq.1) 
𝑟 =
𝑆−𝑃𝐺
1
 (Eq. 2) 
𝐿𝑏 =
𝑟−𝑟𝑚𝑖𝑛
𝜆(𝑟𝑚𝑎𝑥−𝑟)+𝑟−𝑟𝑚𝑖𝑛
   (Eq. 3) 
𝑦 =
(𝐾𝐷+𝑥+[𝐹𝐿])−√〖{(𝐾𝐷+𝑥+[𝐹𝐿])〗2−4𝑥[𝐹𝐿]}
2
  (Eq. 4) 
R= anisotropy, I= total intensity, P=perpendicular intensity, S= parallel intensity, G 
= an instrument factor set to 1, Lb = fraction ligand bound, λ = Ibound/Iunbound = 1, 
[FL] = concentration of fluorescent peptide, KD = dissociation constant, y = Lb 
multiplied by [FL], x = protein concentration 
 
Direct titration of p300 into FITC-HIF-1α C-TAD followed by fluorescence 
anisotropy KD = 37.4 ± 4.4 nM (80 nM FITC-HIF-1α CTAD, 40 mM sodium 
phosphate, 100 mM NaCl, 1 mM DTT, 5% glycerol). Error bars represent the 
standard deviation of 3 repeats. 
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Isothermal Titration Calorimetry 
The HIF-1α peptide (100 μM) was titrated into p300 protein (10 μM) in matched 
ITC buffer (40 mM sodium phosphate, 100 mM sodium chloride and 5% glycerol). 
An initial injection of 10 μL peptide was made followed by 10 μL injections, over 
20 seconds, made every 300 seconds for 30 injections. Peptide was also titrated in to 
buffer to give a baseline integration. This baseline was then subtracted to give a 
baseline-subtracted thermogram. The thermogram was then modeled by one-site 
interaction ITC data analysis, performed with Origin 5.0 software (MicroCal Inc.) 
The titration was conducted at 25 °C using a VP-ITC titration calorimeter from 
MicroCal Inc. All solutions were degassed prior to use. 
5.2.3 Competition Assays 
Compounds to be tested were serially diluted across a 384 well plate in buffer 
containing the minimum DMSO (final concentration <5%) before labelled peptide 
and protein were added sequentially. In parallel, a control experiment was 
performed in which no labelled peptide was added and the volume made up with 
additional buffer. Each experiment was performed in triplicate using a EnVision 
2103 MultiLabel plate reader (Perkin Elmer) with excitation at 480 nm and emission 
at 535 nm (5 nm bandwidths) at 25 °C. Intensity and anisotropy were calculated as 
above using Eq. 1 and Eq. 2 respectively. Plots of anisotropy against compound 
concentration were fitted to a logistic sigmoidal dose response model to determine 
IC50 values. This procedure was used for all screening described below. 
A positive control was performed with the unlabelled version of the labelled tracer 
peptide which is shown below. 
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Competition titration of p300/HIF-1α with HIF-1α CTAD followed by fluorescence 
anisotropy IC50 = 228 ± 25 nM (80 nM FITC-HIF-1α CTAD, 0.1 µM p300, 40 mM 
sodium phosphate, 100 mM NaCl, 1 mM DTT, 5% glycerol, 0.1% triton).  Error 
bars represent the standard deviation of 3 repeats. 
5.2.4 Calculation of occluded surface area 
Using PyMol, the 1L8C protein structure (downloaded from the PDB) was separated 
into component parts. The solvent accessible surface area for each component was 
measured using the command: 
get_area, object 
The settings for this command were as follows: 
dot_solvent, 1 (calculates solvent accessible surface area rather than molecular 
surface area) 
dot_density, 4 (the highest level of density) 
solvent_radius, 1.4 (approximates water with a radius of 1.4 Å) 
The difference between the sum of the surface areas of the individual components 
and the surface area of the complex gives an approximation of the occluded surface 
area. The results are summarised in the table below. 
  
- 113 - 
Component Solvent accessible surface area / Å
2
 
p300 CH1 domain 7929 
HIF-1α CTAD 5585 
Complex 9304 
Occluded surface area 4210 
 
5.2.5 Peptide Synthesis 
Peptides were synthesized by manual or automated Fmoc solid phase peptide 
synthesis methods on Rink Amide MBHA resin. For each coupling step 5 
equivalents of the Fmoc-Amino acid in DMF was added to the resin along with 5 
equivalents of HCTU and 5 equivalents of DIPEA in DMF and mixed for 2 hours 
followed by washing the resin 3 times for 2 minutes with DMF. For the Fmoc 
deprotection the resin was treated with an excess of 20% Piperidine in DMF 5 times 
for 2 minutes each followed by washing 5 times with DMF for 2 minutes each.  
Acetylation 
The resin bound peptide was treated with 10 equivalents of acetic anhydride and 10 
equivalents of DIPEA and mixed overnight.  
Fluorescein Labelling 
Fmoc-amino hexanoic acid was coupled to the resin bound peptide and deprotected 
as before and it was then treated with fluorescein isothiocyanate (1.2 equivalents) 
overnight in the minimum volume of 12:7:5 pyridine/DMF/CH2Cl2. The pyridine 
was distilled over CaH2 immediately before use.  
Deprotection and Cleavage 
The resin was washed with DMF 3 times and DCM 3 times prior to cleavage and 
deprotection. The peptides were globally deprotected and cleaved from the resin 
with TFA/thioanisole/water/phenol/EDT (83:5:5:5:2) [Reagent K], concentrated in 
vacuo, precipitated with ice cold ether, washed 3 times with ice cold ether and dried 
in vacuo. Peptides were purified by reverse phase HPLC as required. 
  
- 114 - 
Helix 2 Peptides 
Ac-GTQLTSYDCEVNAAAG-NH2 
LC-MS m/z (ES) 1640.6 [M+H]
+
, 821.6 [M+2H]
2+
. HRMS Found: 1662.7046; 
C67H105N19NaO27S requires [M+ Na]
+
 1662.7046. 
 
FITC-Ahx-GTQLTSYDCEVNAAAG-NH2 
LC-MS m/z (ES) 1051.3 [M+2H]
2+
; MS Found: 2100.79: C92H125N21O32S2 require 
[M+H]
+
 2100.82 (outside calibration range for HRMS)  
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Helix 3 Peptides 
Ac-GTEELLRALDQVNAAG-NH2 
LC-MS m/z (ES) 1697.7 [M+H]
+
, 849.8 [M+2H]
2
 HRMS Found: 849.4462, 
1697.8843; C70H120N22O26 requires [M+2H]
2+
 849.4444, [M+H]
+
 1697.8851 
 
FITC-Ahx-GTEELLRALDQVNAAG-NH2 
LC-MS m/z (ES) 1079.8 [M+2H]
2+
, 720.2 [M+3H]
3+
 HRMS Found: 1080.0015 
C96H140N24O31S requires [M+2H]
2+
 1080.0008 
 
5.2.6 Peptide-PEG Conjugates 
Fmoc-Amino-PEG8/12/24-COOH 
Amino-PEG8/12/24-COOH (100 mg) was dissolved in 1:1 water/dioxane (6 ml) and 
sodium carbonate (3 eq.) was added followed by Fmoc-Cl (1.2 eq) and the reaction 
stirred overnight. The reaction mixture was then acidified with conc. HCl and 
extracted with ethyl acetate (3 × 5 ml). The combined organic layers were dried over 
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MgSO4 and concentrated in vacuo. The product was checked by LC-MS and used 
without further purification. 
 
Fmoc-Amino-PEG8-COOH 
 
LC-MS m/z (ES) 664.5 [M+H]
+
 
Fmoc-Amino-PEG12-COOH 
 
LC-MS m/z (ES) 840.7 [M+H]
+
 
Fmoc-Amino-PEG24-COOH 
 
LC-MS m/z (ES) 1391.1 [M+Na]
+
 
Peptide-PEG Conjugates 
The C-terminal portion of the peptide was synthesised using standard Fmoc-SPPS as 
above on 0.3 mmol scale and checked by cleaving a small amount and performing 
LC-MS analysis. The resin was then split into 3 equal portions. 
To each portion was added the Fmoc-Amino-PEG-COOH monomer (PEG8 – 2 eq., 
PEG12 – 1.6 eq. and PEG24 – 1.1 eq.), HCTU (5 eq.) and DIPEA (5 eq.) in DMF (2 
ml). The reaction mixture was agitated for 16 hours and drained. The resin was 
washed 5 × 2 minutes with DMF and the remainder of the peptide synthesised using 
standard Fmoc-SPPS.  
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FITC-Ahx-QLTSYDCEVAN-PEG8-EELLRALDQVN 
LC-MS m/z (ES) 1150.7 [M+3H]
3+
, 872 [M+4H]
4+
 HRMS Found: 1724.2922 
C152H231N33O54S2 requires [M+2H]
2+
 1724.2922 
 
FITC-Ahx-QLTSYDCEVAN-PEG12-EELLRALDQVN 
LC-MS m/z (ES) 1813.1 [M+2H]
2+
, 1209 [M+3H]
3+
 HRMS Found: 1813.3517 
C160H247N33O58S2 requires [M+2H]
2+
 1813.3411 
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FITC-Ahx-QLTSYDCEVAN-PEG24-EELLRALDQVN 
LC-MS m/z (ES) 1385.5 [M+3H]
3+
, 1039.5 [M+4H]
4+
 HRMS Found: 2077.4836 
C184H295N33O70S2 requires [M+2H]
2+
 2077.4984 
 
 
5.2.7 eIF4G Peptide Synthesis 
Ac-RYDREFLLGFQ-NH2 
LC-MS m/z (ES) 1484.7 [M+H]
+
, 743.0 [M+2H]
2+
;  HPLC r.t. 2.49 min  (5-95% 
H2O-MeCN + 0.1% TFA, 5.40 min, 0.5ml/min, Ascentis Peptide). HRMS Found: 
742.8860; C69H101N19O18 requires [M+2H]
2+
 742.8786. 
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Fluorescein-Ahx-RYDREFLLGFQ-NH2 
LC-MS m/z (ES) 1945.6 [M+H]
+
,  973.4 [M+2H]
2+
, 649.7 [M+3H]
3+
; HRMS 
Found: 1966.8350; C94H121N21NaO23S requires [M+Na]
+
 1966.8557. 
 
5.2.8 Determination of the Binding of Labelled eIF4G Peptide to eIF4E 
Protein 
Development of a fluorescence anisotropy binding assay for eIF4E/eIF4G was 
performed as for the HIF-1a/p300 interaction described above. 
 
Determination of minimum and maximum anisotropy values by direct titration of 
eIF4E into FITC-eIF4G followed by fluorescence anisotropy KD = 1.76 ± 0.17 µM 
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(80 nM FITC-eIF4G, 40 mM sodium phosphate, 200 mM NaCl, 1 mM DTT, 5% 
glycerol, 0.1% triton). Error bars represent the standard deviation of 3 repeats. 
 
Direct titration of eIF4E into FITC-eIF4G followed by fluorescence anisotropy KD = 
1.76 ± 0.17 µM (80 nM FITC-eIF4G, 40 mM sodium phosphate, 200 mM NaCl, 1 
mM DTT, 5% glycerol, 0.1% triton). Error bars represent the standard deviation of 3 
repeats. 
5.2.9 Competition Assays 
The assay was validated for identification of competitive inhibitors through 
competition titration with unlabelled peptide as described for the HIF-1α/p300 
interaction above. 
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Competition titration of eiF4E/FITC-eIF4G with eIF4G followed by fluorescence 
anisotropy IC50 = 36 ± 4.5 µM (80 nM FITC-eIF4G, 3 µM eIF4E, 40 mM sodium 
phosphate, 200 mM NaCl, 1 mM DTT, 5% glycerol, 0.1% triton). Error bars 
represent the standard deviation of 3 repeats. 
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5.3 Experimental for Chapter 3 
5.3.1 Docking 
Compound libraries generated in Pipeline Pilot 8.5 (Accelrys) were converted to 3D 
conformer libraries of up to 200 conformers per compound using Omega 
(OpenEye). The proteins were prepared using the protein preparation wizard in 
Maestro 9.3 (Schrodinger) by removing the helix donor binding partner, defining the 
binding site and setting any relevant constraints, optimising the hydrogen bonding 
within the remaining protein, removing any non-hydrogen bonding residual water 
molecules and performing a restrained minimisation.  
Conformer libraries were then prepared using Ligprep (Schrodinger) and docked 
rigidly into binding sites of interest using Glide (Schrodinger). Compounds were 
selected based on docking score, recapitulation of important residues and 
consistency of pose.  
eIF4E preparation – PDB ID: 2W97 
Two hydrophobic constraints were defined based on peptide binding and known 
molecule NMR 
15
N-HSQC shifts. 
 
p300 preparation – PDB ID: 1L8C 
Helix 2 binding site – two hydrogen bonding constraints were defined based on 
peptide protein interactions observed in the NMR structure and residues thought to 
be important from the literature. 
Asp – hydrogen bond acceptor – polar hydrogen 
Lys – hydrogen bond acceptor – polar hydrogen 
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Helix 3 binding site – no constraints applied 
 
5.3.2 Pharmacophore modelling 
Helical regions of the peptide donor binding partner were excised from the NMR or 
crystal structure using Maestro 9.3 (Schrodinger), the side chains on the non-binding 
faces of the helix were removed and the backbone converted to carbon whilst 
retaining the structural integrity of the helix. These structures were then imported 
into vROCs (Openeye) and used to generate queries based on matching the relevant 
important side chains which are shown below.  
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Multi-conformer libraries generated using Omega (Openeye) from the eMolecules 
collection of commercially available compounds were used as the database for 
ROCS analysis using the manually generated queries to search for molecules from a 
database which could match the desired structural elements. The top 100 scoring 
matches for each query were visually inspected and compounds of interest selected 
based on their ability to match the defined pharmacophores as well as the flexibility 
of the ligand. Compounds with more rigid structures that matched the query well 
were prioritised over flexible compounds capable of matching the query. 
5.3.3 Library Enumeration 
Virtual libraries were enumerated and manipulated using Accelrys Pipeline Pilot 
version 8.5 (Pipeline Pilot v8.5.0.200, Accelrys© Software Inc., 2011). A virtual 
library was enumerated based on the route shown in Scheme 17. The protocol 
(Figure 83) and building blocks used are shown below (Figures 2-5). 
 
Scheme 17 - Route for virtual enumeration 
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Figure 83 - Library enumeration protocol 
 
 
Figure 84 - Starting cyclic sulfamidate for bicyclic core enumeration 
 
Figure 85 - Alkylating groups for bicyclic core enumeration 
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Figure 86 - Protected amino esters for bicyclic core enumeration 
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Figure 87 - Capping groups for bicyclic core enumeration 
5.3.4 Synthesis of Compound 4 analogues  
4-phenyl-1,3-thiazol-2-amine, 11 
 
Following a literature procedure, 
125
 bromoacetophenone (1 g, 5 mmol) and thiourea 
(425 mg, 5.58 mmol) were heated to reflux in ethanol (50 ml) for 1 hour. The 
reaction mixture was then allowed to cool to r.t. and concentrated in vacuo, 
suspended in saturated aqueous sodium bicarbonate (30 ml) and extracted with 
DCM (3 × 20 ml). The combined organic layers were washed with brine, dried with 
MgSO4 and concentrated in vacuo. The residue was stirred in petrol for 30 minutes 
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and the solid collected by filtration and dried in vacuo to give the desired product as 
an off-white solid (672 mg, 76%).
1
H NMR (500 MHz, d
6
-DMSO) δ 7.78 (m, 2H, 
Ar-H), 7.38 – 7.30 (m, 2H, Ar-H), 7.26 – 7.22 (m, 1H, Ar-H), 7.02 (br s, 2H, NH2), 
6.98 (s, 1H, 5-CH); 
13
C NMR (125 MHz, d
6
-DMSO) δ 168.14, 149.84, 134.91, 
128.41, 127.12, 125.50, 101.44; LC-MS: 177.0 [M+H] 
4-(3,4-dichlorophenyl)-1,3-thiazol-2-amine, 12
125
 
 
Following a literature procedure, 
125
 2-bromo-1-(3,4-dichlorophenyl)ethan-1-one 
(600 mg, 2.25 mmol) and thiourea (188 mg, 2.47 mmol) were heated to reflux in 
ethanol (50 ml) for 1 hour. The reaction mixture was then allowed to cool to r.t. and 
concentrated in vacuo, suspended in saturated aqueous sodium bicarbonate (30 ml) 
and extracted with DCM (3 × 20 ml). The combined organic layers were washed 
with brine, dried with MgSO4 and concentrated in vacuo. The residue was stirred in 
petrol for 30 minutes and the solid collected by filtration and dried in vacuo to give 
the desired product as an off-white solid (420 mg, 76%). 
1
H NMR (500 MHz, 
CDCl3) δ 7.82 (d, J = 1.8 Hz, 1H, 2’C-H), 7.52 (dd, J = 8.4, 1.8 Hz, 1H, 6’C-H), 
7.36 (d, J = 8.4 Hz, 1H, 5’C-H), 6.68 (s, 1H, 5-CH), 4.97 (br s, 2H, NH2); 
13
C NMR 
(125 MHz, CDCl3) δ 167.28, 149.02, 134.61, 132.76, 131.44, 130.50, 127.92, 
125.10, 104.23; LC-MS: 244.9 [M+H] 
4-tert-butyl-1,3-thiazol-2-amine, 13 
 
Following a literature procedure,
126
  copper (II) acetate (120 mg, 0.65 mmol) was 
added to a solution of 1-bromopinacolone (0.88 ml, 6.57 mmol) and thiourea (500 
mg, 6.57 mmol) in ethanol (50 ml) and stirred at r.t. for 30 minutes. The reaction 
was then diluted with water (30 ml) and extracted with ethyl acetate (3 × 20 ml). 
The combined organic layers were washed with brine, dried over MgSO4 and 
concentrated in vacuo.  The residue was purified by column chromatography eluting 
with 10% ethyl acetate/petrol to give the desired product as an off-white solid (680 
mg, 66%). Data matches literature.
202
 Rf  0.2 (10% ethyl acetate/petrol); 
1
H NMR 
(500 MHz, CDCl3) δ 6.11 (s, 1H, 5-CH), 5.16 (br s, 2H, NH2), 1.28 (s, 9H, t-butyl); 
13
C NMR (125 MHz, CDCl3) δ 166.95, 162.60, 99.86, 34.53, 29.70; LC-MS: 157.0 
[M+H] 
N-(4-phenyl-1,3-thiazol-2-yl)benzamide, 17 
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Benzoyl chloride (78 μl, 0.68 mmol) was added dropwise to a cooled solution (0 °C) 
of 4-phenyl-1,3-thiazol-2-amine (100 mg, 0.57 mmol) and diisopropylethylamine 
(0.3 ml, 1.7 mmol) in THF (5 ml) and allowed to warm to r.t. overnight with stirring. 
Reaction mixture concentrated in vacuo and purified by mass-directed 
chromatography to give the title compound as an off-white amorphous solid (83.4 
mg, 52%). νmax/cm
-1
 (solid state) 3126, 2780, 1667; 
1
H NMR (500 MHz, CDCl3) δ 
10.86 (s, 1H, Amide NH), 7.84 (d, J = 7.7 Hz, 2H, Ar-H), 7.77 (d, J = 7.7 Hz, 2H, 
Ar-H), 7.51 (t, J = 7.4 Hz, 1H, Ar-H), 7.42 – 7.32 (m, 4H, Ar-H), 7.31 – 7.25 (m, 
1H, Ar-H), 7.22 (s, 1H, 5C-H); 
13
C NMR (125 MHz, CDCl3) δ 165.17, 158.94, 
150.21, 134.14, 132.75, 131.89, 128.79, 128.70, 128.07, 127.43, 126.06, 108.09; 
HRMS Found: 281.0745; C16H12N2OS [M+H]
+
 requires 281.0743. 
2-(2’-bromophenyl)-N-[4-(3’’,4’’-dichlorophenyl)-1,3-thiazol-2-yl]acetamide, 18   
 
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide (481 mg, 2.52 mmol), DMAP (15 
mg, 0.12 mmol) and diisopropylethylamine (1 ml, 6.3 mmol) were added 
sequentially to a solution of 2-bromophenylacetic acid (300 mg, 1.39 mmol) in 
DCM (20 ml). The reaction was stirred for 30 minutes at r.t. followed by the 
addition of 4-(3,4-dichlorophenyl)-1,3-thiazol-2-amine (310 mg, 1.26 mmol) after 
which the reaction was stirred overnight. The reaction mixture was washed with 2M 
HCl (aq.) (2 × 20 ml) and saturated aqueous sodium bicarbonate (2 × 20 ml), dried 
over MgSO4 and concentrated in vacuo. The residue was purified by column 
chromatography eluting with 10% ethyl acetate/petrol to give the desired compound 
as a colourless amorphous solid (337 mg, 60%). Rf  0.3 (10% ethyl acetate/petrol); 
νmax/cm
-1
 (solid state) 3172, 3077, 2997, 1697; 
1
H NMR (500 MHz, d
6
-DMSO) δ 
12.62 (s, 1H, Amide NH), 8.15 (d, J = 1.9 Hz, 1H, 2’’C-H), 7.89 (dd, J = 8.4, 1.9 
Hz, 1H, 6’’C-H), 7.83 (s, 1H, 5C-H), 7.70 (d, J = 8.4 Hz, 1H, 5’’C-H), 7.63 (d, J = 
7.9 Hz, 1H, 3’C-H), 7.45 (d, J = 7.5 Hz, 1H, 6’C-H), 7.38 (t, J = 7.4 Hz, 1H, 5’C-
H), 7.26 (t, J = 7.7 Hz, 1H, 4’C-H), 4.03 (s, 2H, acetamide CH2); 
13
C NMR (126 
MHz, d
6
-DMSO) δ 168.53, 158.21, 146.22, 134.81, 134.69, 132.42, 132.32, 131.55, 
131.01, 130.02, 129.11, 127.70, 127.32, 125.68, 124.52, 110.14, 41.90; HRMS 
found 442.9205; C17H12BrCl2N2OS [M+H]
+
 requires 442.9205 
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N-[4-(3’’,4’’-dichlorophenyl)-1,3-thiazol-2-yl]-2-(2’-methoxyphenyl)acetamide, 
19 
 
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide (156 mg, 0.82 mmol), DMAP (5 
mg, 0.04 mmol) and diisopropylethylamine (0.35 ml, 2.05 mmol) were added 
sequentially to a solution of 2-methoxyphenylacetic acid (136 mg, 0.82 mmol) in 
DCM (20 ml). The reaction was stirred for 30 minutes at r.t. followed by the 
addition of 4-(3,4-dichlorophenyl)-1,3-thiazol-2-amine (100 mg, 0.41 mmol) after 
which the reaction was stirred overnight. The reaction mixture was concentrated in 
vacuo, re-dissolved in ethyl acetate, washed with 2M HCl (aq.) (2 × 20 ml) and 
saturated aqueous sodium bicarbonate (2 × 20 ml), dried over MgSO4 and 
concentrated in vacuo. The residue was purified by column chromatography eluting 
with 10% ethyl acetate/petrol and triturated with hexane to give the desired 
compound as a colourless amorphous solid (58 mg, 36%). Rf  0.25 (10% ethyl 
acetate/petrol); νmax/cm
-1
 (solid state) 3187, 1655, 1549; 
1
H NMR (500 MHz, 
CDCl3) δ 9.25 (s, 1H, Amide NH), 7.91 (d, J = 2.0 Hz, 1H, 2’’C-H), 7.61 (dd, J = 
8.4, 2.0 Hz, 1H, 6’’C-H), 7.45 (d, J = 8.4 Hz, 1H, 5’’C-H), 7.36 (td, J = 8.0, 1.7 Hz, 
1H, 6’C-H), 7.30 (dd, J = 7.4, 1.7 Hz, 1H, 4’C-H), 7.12 (s, 1H, 5C-H), 7.01 (m, 2H, 
3’C-H and 5’C-H), 3.97 (s, 3H, OMe), 3.84 (s, 2H, acetamide CH2); 
13
C NMR (125 
MHz, CDCl3) δ 169.06, 157.98, 157.04, 147.27, 134.20, 132.91, 131.80, 131.51, 
130.62, 129.68, 127.93, 125.11, 121.58, 111.21, 108.93, 55.81, 38.84; HRMS 
Found: 393.0236; C18H14Cl2N2O2S [M+H]
+
 requires 393.0225 
N-[4-(3’’,4’’-dichlorophenyl)-1,3-thiazol-2-yl]-2-(2’-phenylphenyl)acetamide, 20  
 
A microwave reaction vessel was charged with 2-(2-bromophenyl)-N-[4-(3,4-
dichlorophenyl)-1,3-thiazol-2-yl]acetamide (20 mg, 0.045 mmol), phenylboronic 
acid (5.4 mg, 0.045 mmol), tetrakis(triphenylphosphine) palladium (2.6 mg, 5 
mol%), caesium carbonate (44 mg, 0.135 mmol) and dioxane (3 ml). The reaction 
was then sealed and heated to 120 °C for 1 hour in the microwave, filtered through 
Celite, concentrated in vacuo and purified by mass directed chromatography (8 mg, 
41%). νmax/cm
-1
 (solid state) 3425, 2926, 2853, 1750; 
1
H NMR (500 MHz, CDCl3) δ 
8.52 (s, 1H, Amide NH), 7.92 (d, J = 1.9 Hz, 1H, Ar-H), 7.62 (dd, J = 8.4, 2.0 Hz, 
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1H, Ar-H), 7.50 – 7.38 (m, 8H, Ar-H), 7.34 – 7.30 (m, 2H, Ar-H), 7.15 (s, 1H, 5’C-
H), 3.84 (s, 2H, acetamide CH2); HRMS Found 439.0440, C23H16Cl2N2OS [M+H]
+
 
requires 439.0433. 
N-[4-(3’’,4’’-dichlorophenyl)-1,3-thiazol-2-yl]-2-[2’-(2’’’,6’’’-dimethoxypyridin-
3-yl)phenyl]acetamide, 21 
 
A microwave reaction vessel was charged with 2-(2-bromophenyl)-N-[4-(3,4-
dichlorophenyl)-1,3-thiazol-2-yl]acetamide (20 mg, 0.045 mmol), 2,6-Dimethoxy-3-
pyridineboronic acid (10 mg, 0.054 mmol), tetrakis(triphenylphosphine) palladium 
(2.6 mg, 5 mol%), caesium carbonate (44 mg, 0.135 mmol) and dioxane (3 ml). The 
reaction was then sealed and heated to 120 °C for 1 hour in the microwave, filtered 
through Celite, concentrated in vacuo and purified by mass directed chromatography 
to give the title compound as a yellow solid (6 mg, 27 %). νmax/cm
-1
 (solid state) 
3303, 2906, 1678, 1532; 
1
H NMR (500 MHz, CDCl3) δ 9.07 (s, 1H, Amide N-H), 
7.90 (d, J = 2.0 Hz, 1H, Ar-H), 7.60 (dd, J = 8.4, 2.1 Hz, 1H, Ar-H), 7.44 (d, J = 8.4 
Hz, 1H, Ar-H), 7.43 – 7.40 (m, 3H, Ar-H), 7.39 (d, J = 8.0 Hz, 1H, Ar-H), 7.13 (s, 
1H, Thiazole-CH), 6.42 (d, J = 8.0 Hz, 1H, Ar-H), 3.97 (s, 3H, OMe), 3.94 (s, 3H, 
OMe), 3.69 (s, 2H, acetamide CH2); 
13
C NMR (125 MHz, CDCl3) δ 169.21, 163.04, 
158.95, 157.81, 147.53, 142.43, 137.53, 134.39, 132.89, 132.38, 131.68, 130.61, 
130.05, 128.73, 128.29, 127.88, 125.03, 113.93, 108.82, 101.80, 53.76, 53.67, 
41.29; HRMS Found: 500.06062; C24H19Cl2N3O3S [M+H]
+
 requires 500.0597 
2-(2-bromophenyl)-N-(4-phenyl-1,3-thiazol-2-yl)acetamide, 22 
 
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide (1.3 g, 6.8 mmol), DMAP (20 
mg, 0.17 mmol) and diisopropylethylamine (1.5 ml, 8.5 mmol) were added 
sequentially to a solution of 2-bromophenylacetic acid (400 mg, 1.87 mmol) in 
DCM (30 ml). The reaction was stirred for 30 minutes at r.t. followed by the 
addition of 4-phenyl-1,3-thiazol-2-amine (300 mg, 1.7 mmol) after which the 
reaction was stirred overnight. The reaction mixture was washed with 2M HCl (aq) 
(2 × 20 ml) and saturated aqueous sodium bicarbonate (2 × 20 ml), dried over 
MgSO4 and concentrated in vacuo. The residue was purified by column 
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chromatography eluting with 10% ethyl acetate/petrol to give the desired compound 
as a colourless amorphous solid (261 mg, 41%). Rf  0.3 (10% ethyl acetate/petrol); 
νmax/cm
-1
 (solid state) 3290, 1635, 1539; 
1
H NMR (500 MHz, CDCl3) δ 10.21 (s, 
1H, Amide NH), 7.84 (d, J = 7.9 Hz, 2H, Ar-H), 7.60 (d, J = 7.9 Hz, 1H, Ar-H), 
7.44 (t, J = 7.6 Hz, 2H, Ar-H), 7.39 – 7.24 (m, 3H, Ar-H), 7.24 – 7.15 (m, 2H, Ar-
H), 3.75 (s, 2H, acetamide CH2); 
13
C NMR (125 MHz, CDCl3) δ 167.91, 158.78, 
149.81, 134.28, 133.31, 133.10, 131.78, 129.46, 128.95, 128.28, 127.92, 126.24, 
125.03, 108.16, 43.12; HRMS Found: 373.0011; C17H13BrN2OS [M+H]
+
 requires 
373.0004 
2-(2’-methoxyphenyl)-N-(4-phenyl-1,3-thiazol-2-yl)acetamide, 23 
 
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide (435 mg, 2.28 mmol), DMAP (7 
mg, 0.057 mmol) and diisopropylethylamine (0.5 ml, 2.85 mmol) were added 
sequentially to a solution of 2-(2-methoxyphenyl)acetic acid (104 mg, 0.625 mmol) 
in DCM (20 ml). The reaction was stirred for 30 minutes at r.t. followed by the 
addition of 4-phenyl-1,3-thiazol-2-amine (100 mg, 0.57 mmol) after which the 
reaction was stirred overnight. The reaction mixture was washed with 2M HCl (aq) 
(2 × 20 ml) and saturated aqueous sodium bicarbonate (2 × 20 ml), dried over 
MgSO4 and concentrated in vacuo. The residue was purified by column 
chromatography eluting with 10% ethyl acetate/petrol to give the desired compound 
as a colourless amorphous solid (33 mg, 18%). Rf  0.2 (10% ethyl acetate/petrol) 
νmax/cm
-1
 (solid state) 3168, 3069, 2970, 1650; 
1
H NMR (500 MHz, CDCl3) δ 9.39 
(s, 1H, Amide NH), 7.82 (d, J = 7.4 Hz, 2H, Ar-H), 7.42 (t, J = 7.6 Hz, 2H, Ar-H), 
7.38 – 7.30 (m, 3H, Ar-H), 7.13 (s, 1H,5-CH), 7.01 (dd, J = 15.5, 7.9 Hz, 2H, Ar-H), 
3.95 (s, 3H, OMe), 3.82 (s, 2H, Acetamide CH2); 
13
C NMR (125 MHz, CDCl3) δ 
169.03, 157.72, 157.11, 149.85, 134.42, 131.50, 129.56, 128.72, 127.98, 126.06, 
121.74, 121.44, 111.09, 107.76, 55.71, 38.72; HRMS Found: 325.1007; 
C18H16N2O2S [M+H]
+
 requires 325.1005 
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N-(4-tert-butyl-1,3-thiazol-2-yl)-2-(2-methoxyphenyl)acetamide, 24 
 
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide (1.0 g, 5.12 mmol), DMAP (16 
mg, 0.128 mmol) and diisopropylethylamine (1.1 ml, 6.4 mmol) were added 
sequentially to a solution of 2-(2-methoxyphenyl)acetic acid (637 mg, 3.84 mmol) in 
DCM (30 ml). The reaction was stirred for 30 minutes at r.t. followed by the 
addition of 4-t-butyl-1,3-thiazol-2-amine (200 mg, 1.28 mmol) after which the 
reaction was stirred overnight. The reaction mixture was washed with 2M HCl (aq) 
(2 × 20 ml) and saturated aqueous sodium bicarbonate (2 × 20 ml), dried over 
MgSO4 and concentrated in vacuo. The residue was purified by column 
chromatography eluting with 10% ethyl acetate/petrol to give the desired compound 
as a colourless amorphous solid (335 mg, 86%). Rf  0.3 (10% ethyl acetate/petrol); 
νmax/cm
-1
 (solid state) 3183, 2962, 1683; 
1
H NMR (500 MHz, CDCl3) δ 7.42 – 7.23 
(m, 2H, Ar-H), 7.09 – 6.92 (m, 2H, Ar-H), 6.52 (s, 1H, 5-CH), 3.92 (s, 3H, OMe), 
3.83 (s, 2H, CH2), 1.30 (s, 9H, t-butyl); 
13
C NMR (125 MHz, CDCl3) δ 168.93, 
157.22, 131.46, 129.38, 121.88, 121.25, 110.95, 104.98, 55.60, 38.55, 34.29, 29.77; 
HRMS Found: 305.1327; C16H20N2O2S [M+H]
+
 requires 305.1318. 
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5.3.5 Synthesis of designed compounds 
cis-2-Phenyl-4a,5,6,7,8,8a-hexahydro-4H-1,3-benzoxazine, 32 
 
Following a literature procedure,
132
 cyclohexene (1.0 ml, 10 mmol) and N-
hydroxymethyl benzamide (1.5 g, 10 mmol) were stirred in acetic acid (10 ml) at r.t. 
for 10 minutes then cooled to 10 °C and a sulphuric acid (1.5 ml) in acetic acid (12.5 
ml) was added dropwise maintaining a temperature between 10-15 °C. After the 
addition was complete, the reaction was heated to 70 °C for 1 hour, allowed to cool 
then poured into ice water (300 ml). The resulting solution was washed with ether (2 
× 50 ml) and the organics discarded. The remaining aqueous layer was adjusted to 
pH 7.5 by the addition of 25 % aqueous sodium carbonate with vigorous stirring 
then extracted with ether (3 × 30 ml). The combined organics were washed with 
saturated aqueous sodium bicarbonate (3 × 20 ml), dried over MgSO4 and 
concentrated in vacuo to a pale yellow oil (1.3 g, 61%). Analytical data matches 
literature. IR (νmax /cm
-1
) 3300, 2931, 1655; 
1
H NMR (500 MHz; CDCl3) δ 7.86 (2 
H, d, J = 7.3, Ar-H), 7.30 (3 H, m, Ar-H), 4.31 (1H, m, 8a-H), 3.57 (1 H, dd, J  = 17, 
5.5, 4-Ha), 3.30 (1 H, dd, J = 17, 2.3, 4-Hb), 1.98 (1 H, m, 8-H), 1.79 (1 H, m, 4a-H), 
1.61 (1 H, m, Cy-CH), 1.45 (5 H, m, Cy-CH), 1.25 (1 H, m, Cy-CH); 
13
C NMR (125 
MHz; CDCl3) δ 155.0, 134.1, 130.1, 127.9, 126.9, 72.7, 48.9, 32.1, 30.5, 25.4, 24.4, 
20.3; HRMS found: 216.1392; C14H18NO [M+H]
+
 requires 216.1383. 
Cis-2-(benzylamino)methyl cyclohexan-1-ol, 33 
 
Following a literature procedure
133
, cis-2-Phenyl-4a,5,6,7,8,8a-hexahydro-4H-1,3-
benzoxazine (5 g, 23 mmol) was added  dropwise as a solution in tetrahydrofuran 
(10 ml) to a stirred suspension of lithium aluminium hydride (1.8 g, 46 mmol) in 
anhydrous tetrahydrofuran (200 ml) under N2. The reaction was heated to reflux 
overnight then cooled to 0°C and quenched by the dropwise addition of water (2 
ml). The resulting precipitate was removed by filtration, the filtrate dried over 
MgSO4 and concentrated in vacuo to give the title compound as a yellow oil (3.33 g, 
66%). 
1
H NMR (500 MHz; CDCl3) δ 7.28 (4 H, d, J = 4.6, Ar-H), 7.22 (1 H, m, Ar-H), 4.1 
(1 H, br s, NH), 3.97 (1 H, m, 1-H), 3.73 (2 H, s, 1’-H2), 2.92 (1 H, dd, J  = 12.0, 
6.4, 7-Ha), 2.66 (1 H, dd, J =  12.0, 3.4, 7-Hb), 1.72 – 1.44 (6 H, m, Cy-CH2), 1.36 – 
1.21 (3 H, m, CH2 and 2-H); 
13
C NMR C (125 MHz; CDCl3) δ 138.9, 128.4, 126.2, 
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127.2, 70.7, 54.1, 52.4, 39.8, 32.4, 25.5, 24.6, 21.1; IR (νmax /cm
-1
): 3299, 2931, 
2856, 1655; HRMS found: 220.1698; C14H22NO [M+H]
+
 requires 220.1696. 
Cis-2-[benzyl(2-methylpropyl)amino]methyl cyclohexan-1-ol, 34 
 
Isobutyraldehyde (0.6 ml, 6.4 mmol) and picoline borane complex (670 mg, 6.4 
mmol) were added sequentially to a solution of cis-2-(benzylamino)methyl 
cyclohexan-1-ol (700 mg, 3.2 mmol) in methanol (30 ml) and stirred at r.t. 
overnight. Upon completion the reaction was quenched with water (20 ml) and 
acidified to pH 2 with 2M aqueous HCl, washed with ethyl acetate (3 × 10 ml), 
neutralised with saturated aqueous sodium bicarbonate and extracted with ethyl 
acetate (3 × 15 ml). Final extractions were combined, washed with brine, dried over 
MgSO4 and concentrated in vacuo to yield the title compound as a colourless oil 
(585 mg, 66%). IR (νmax /cm
-1
): 2930, 2865, 2801, 1452; 
1
H NMR (500 MHz; 
CDCl3) δ 7.35 (4 H, m, Ar-H), 7.31 – 7.27 (1 H, m, Ar-H), 3.94 – 3.88 (2 H, m, 1’-
CH2), 3.22 (1H, d, J = 11.9, 7-Ha), 2.89 (1H, t, J = 11.5, 7-Hb), 2.39 – 2.32 (1H, m, 
1-H), 2.19 – 2.10 (3H, m, 2”CH2 and Cy-CH ), 1.93 – 1.91 (1H, m, 2”CH), 1.63 – 
1.56 (2H, m, Cy-CH), 1.48 – 1.43 (3H, m, Cy-CH), 1.37 – 1.26 (3H, m, Cy-CH), 
0.93 (6H, dd, J = 19.2, 6.4, 2 × 3”-H3); 
13
C NMR (125 MHz; CDCl3): δ 129.5, 
126.4, 127.3, 70.79, 63.6, 59.4, 56.5, 36.5, 31.6, 27.6, 26.0, 22.9, 21.2, 20.7; HRMS 
Found: 276.2335 C18H30NO [M+H]
+
 requires 276.2322. 
Cis-2-[[(2-methylpropyl)amino]methyl]cyclohexan-1-ol, 35 
 
Cis-2-[benzyl(2-methylpropyl)amino]methyl cyclohexan-1-ol (1 g, 3.6 mmol) was 
dissolved in methanol (50 ml) under an N2 atmosphere. Pd/C (100 mg, 10 wt%) was 
added followed by ammonium formate (1.15 g, 18.1 mmol) and the reaction heated 
to reflux for 2 hours. The reaction was allowed to cool to RT and filtered through 
Celite and concentrated in vacuo. The residue was triturated with acetonitrile and 
purified by strong cation exchange (SCX) column chromatography eluting with 
saturated ammonia in methanol to give the title compound as a colourless oil (461 
mg, 70%). νmax/cm
-1
 (solid state) 3318, 2927, 1589; 
1
H NMR (500 MHz, CDCl3) δ 
4.07 – 3.93 (m, 1H, 1-CH), 2.97 (dd, J = 12.0, 6.0 Hz, 1H, 7-CHa), 2.67 (dd, J = 
12.0, 2.9 Hz, 1H, 7-CHb), 2.39 (app. qd, J = 11.5, 6.7 Hz, 2H, 1’-CH2, rot.), 1.79 – 
1.61 (m, 4H, Cy-Ch and 2’-CH), 1.60 – 1.46 (m, 2H, Cy-CH), 1.42 – 1.22 (m, 3H, 
Cy-CH), 0.89 (d, J = 4.3 Hz, 6H, rot. 2 × 3’-CH3); 
13
C NMR (125 MHz, CDCl3) δ 
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71.74, 58.32, 53.68, 39.65, 32.38, 28.15, 25.62, 24.57, 21.30, 20.57, 20.52; HRMS 
Found 186.1860 C11H23NO [M+H]
+
 requires 186.1852  
tert-butyl N-([cis-2-hydroxycyclohexyl]methyl)-N-(2-methylpropyl)carbamate, 
36 
 
2-{[(2-methylpropyl)amino]methyl}cyclohexan-1-ol (1.12 g, 6.1 mmol) was 
dissolved in THF (50 ml). (Boc)2O (1.46 g, 6.7  mmol) and diisopropylethylamine 
(2.6 ml, 15.25 mmol) were added and the reaction stirred overnight and concentrated 
in vacuo. The residue was purified by column chromatography eluting with 10% 
ethyl acetate in petrol to give the title compound as a colourless oil (1.42 g, 87%). Rf  
0.25 (10% ethyl acetate/petrol); νmax/cm
-1
 (solid state) 3446, 3186, 2932, 1656; 1H 
NMR (500 MHz, CDCl3) δ 4.22 (s, 1H, 1-CH), 3.66 (m, 2H, 2-CH and 7-CHa), 3.17 
(dd, J = 13.9, 7.6 Hz, 1H, 1’-CHa), 2.70 (dd, J = 14.0, 7.3 Hz, 1H, 1’-CHb), 2.55 (dd, 
J = 14.5, 4.1 Hz, 1H, 7-CHb), 1.90 (m, 2H, Cy-CH and 2’-CH), 1.73 – 1.46 (m, 3H, 
Cy-CH), 1.43 (s, 6H, t-butyl), 1.40 – 1.08 (m, 4H, Cy-CH), 0.88 (d, J = 6.7 Hz, 3H, 
3’-CH3), 0.85 (d, J = 6.9 Hz, 3H, 3’-CH3); 
13
C NMR (125 MHz, CDCl3) δ 157.53, 
79.90, 64.44, 54.55, 49.22, 40.17, 32.16, 28.33, 27.57, 25.83, 24.46, 20.21, 20.09, 
20.06; HRMS Found 308.2205 C16H31NO3 [M+Na] requires 308.2196 
tert-butyl N-(2-methylpropyl)-N-{[-2-oxocyclohexyl]methyl}carbamate, 38 
 
tert-butyl N-{[(1S,2S)-2-hydroxycyclohexyl]methyl}-N-(2-methylpropyl)carbamate 
(1 g,  3.51 mmol) was dissolved in DCM (30 ml) and Dess-Martin Periodinane (1.6 
g, 3.86 mmol) was added. The reaction was stirred at r.t. for 3 hours then quenched 
with saturated sodium thiosulfate solution (10 ml) and saturated sodium hydrogen 
carbonate solution (10 ml). The organic layer was separated, and the aqueous layer 
extracted with DCM (3 × 10 ml). The organic layers were combined, dried over 
MgSO4 and concentrated in vacuo to a pale yellow oil (990 mg, quant). νmax/cm
-1
 
(solid state) 2960, 2868 1693, 
1
H NMR (500 MHz, CDCl3) δ 3.51 (m, 1H, 7-CHa), 
3.30 – 3.17 (m, 1H, 7-CHb), 3.13 – 2.93 (m, 2H, 1’-CH2), 2.88 – 2.57 (m, 1H, 2-
CH), 2.41 (d, J = 13.1 Hz, 1H, Cy-CH), 2.32 (m, 1H, Cy-CH), 2.10 (dd, J = 44.3, 
5.7 Hz, 2H, Cy-CH), 2.01 – 1.80 (m, 2H, 2’-CH and Cy-CH), 1.66 (tt, J = 11.9, 5.9 
Hz, 2H, Cy-CH), 1.45 (s, 9H, t-butyl), 1.43 – 1.29 (m, 1H, Cy-CH), 0.87 (app. t, J = 
7.2 Hz, 6H, 2 × 3’-CH3); 
13
C NMR (125 MHz, CDCl3) δ 212.79, 156.04, 79.21, 
55.67, 54.70, 50.37, 49.72, 47.57, 46.89, 42.11, 32.04, 28.46, 27.96, 27.11, 24.68, 
20.10; HRMS found 284.2217, C16H29NO3 requires [M+H]
+
 284.2217 
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tert-butyl N-{[(2-methylpropyl)({[(1S)-2-oxocyclohexyl] methyl})carbamoyl] 
methyl}carbamate, 40 
 
tert-butyl N-(2-methylpropyl)-N-{[-2-oxocyclohexyl]methyl}carbamate  (990 mg, 
3.8 mmol) was dissolved in 10% TFA in DCM (40 ml) and stirred overnight and 
concentrated in vacuo. The crude TFA salt was then re-dissolved in DCM (30 ml) to 
which was added Boc-glycine (798 mg, 4.56 mmol), HATU (1.7 g, 4.56 mmol) and 
diisopropylethylamine (1.9 ml, 11.4 mmol) and the reaction stirred overnight. The 
reaction mixture was then washed with H2O (20 ml) and 1M HCl (20 ml), dried over 
MgSO4 and concentrated in vacuo. The residue was purified by column 
chromatography eluting with 20% ethyl acetate in petrol to give the title compound 
as a colourless oil (1.13 g, 87%). Rf  0.3 (20% ethyl acetate/petrol); νmax/cm
-1
 (solid 
state) 3228, 1699, 1626; 
1
H NMR (500 MHz, C2Cl4D2) δ 3.95 (d, J = 3.3 Hz, 1H, 
2”-CH2), 3.55 (dd, J = 13.7, 6.9 Hz, 1H, 7-CHa), 3.35 (dd, J = 13.8, 6.0 Hz, 1H, 7-
CHb), 3.25 (dd, J = 14.7, 7.4 Hz, 1H, 2’-CHa), 2.97 (dd, J = 14.7, 7.9 Hz, 1H, 2’-
CHb), 2.84 (m, 1H, 2-CH), 2.37 (m, 1H, Cy-CH), 2.16 – 2.03 (m, 2H, 2’-CH and 
Cy-CH), 1.94 (m, 2H, Cy-CH), 1.67 (m, 2H, Cy-CH), 1.46 (s, 9H, t-butyl), 1.41 – 
1.32 (m, 1H, Cy-CH), 0.95 (d, J = 6.6 Hz, 3H, 3’-CH3) 0.92 (d, J = 6.6 Hz, 3H, 3’-
CH3); 
13
C NMR (125 MHz, C2Cl4D2) δ 212.09, 169.02, 155.63, 79.60, 55.22, 49.31, 
46.95, 42.64, 42.13, 41.13, 32.38, 28.54, 27.76, 24.85, 23.99, 21.01, 20.14, 17.60; 
HRMS Found 341.24429 C18H32N2O4 [M+H]
+
 requires 341.2434. 
4-(2-methylpropyl)-decahydro-1H-1,4-benzodiazepin-3-one, 42 
 
tert-butyl N-{[(2-methylpropyl) ({[-2-oxocyclohexyl] methyl})carbamoyl] 
methyl}carbamate (200 mg, 0.58 mmol) was dissolved in 20% TFA in DCM (20 ml) 
and stirred at r.t. for 1 hour. The reaction mixture was then concentrated in vacuo 
and the residue re-suspended in methanol (20 ml) and picoline borane complex (75 
mg, 0.70 mmol) added and reaction stirred for 3 hours, concentrated in vacuo and 
residue purified by column chromatography eluting with DCM then 10% methanol 
in DCM to give the title compound as a mixture of diastereomers (125 mg, 83%).  
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The diastereomers were separated by column chromatography eluting with 1.5% 
saturated NH3 in methanol in DCM. 
HRMS found 225.1968, C13H24N2O [M+H]
+
 requires 225.1961 
νmax/cm
-1
 (solid state) 2923, 2853, 1639 
cis-4-(2-methylpropyl)-decahydro-1H-1,4-benzodiazepin-3-one, cis-42 
 
1
H NMR (500 MHz, CDCl3) δ 3.82 – 3.71 (m, 1H, 1’-CHa), 3.72 – 3.60 (m, 2H, 2-
CHa and 5-CHa), 3.54 (d, J = 14.8 Hz, 1H, 2-CHb), 3.26 (d, J = 11.1 Hz, 1H, 5-CHb), 
3.02 (q, J = 3.4 Hz, 1H, 7-CH), 2.62 (br, s, 1H, 1’-CHb), 2.07 – 1.87 (m, 1H, 2’-CH), 
1.84 – 1.67 (m, 3H, Cy-CH), 1.69 – 1.54 (m, 2H, Cy-CH), 1.44 (ddd, J = 16.8, 9.9, 
3.4 Hz, 3H, Cy-CH), 1.33 (tdd, J = 16.3, 12.5, 4.0 Hz, 1H, Cy-CH), 0.93 (d, J = 6.7 
Hz, 3H, 3’-CH3), 0.88 (d, J = 6.7 Hz, 3H, 4’-CH3); 
13
C NMR (125 MHz, CDCl3) δ 
175.98, 60.10, 57.89, 54.67, 54.04, 40.63, 33.18, 28.31, 26.41, 24.74, 21.61, 20.55, 
20.24. 
trans-4-(2-methylpropyl)-decahydro-1H-1,4-benzodiazepin-3-one, trans-42 
 
1
H NMR (500 MHz, d
4
-MeOD) δ 3.58 (d, J = 14.6 Hz, 1H, 2-CHa), 3.49 (dd, J = 
15.1, 10.1 Hz, 1H, 5-CHa), 3.34 (d, J = 14.6 Hz, 1H, 2-CHb), 3.21 (m, 1H, 2’-CHa), 
2.99 (dd, J = 13.2, 7.6 Hz, 1H, 2’CHb), 2.87 (dd, J = 15.1, 1.4 Hz, 1H, 5-CHb), 2.24 
(ddd, J = 11.3, 9.6, 3.4 Hz, 1H, 7-CH), 1.81 (dp, J = 13.9, 6.9 Hz, 1H, 2’-CH), 1.73 
– 1.60 (m, 3H, Cy-CH), 1.57 – 1.40 (m, 1H, Cy-CH), 1.32 – 1.16 (m, 3H, Cy-CH), 
1.16 – 1.06 (m, 1H, Cy-CH), 0.94 (qd, J = 12.8, 3.7 Hz, 1H, Cy-CH), 0.84 (d, J = 
6.7 Hz, 3H, 3’CH3), 0.79 (d, J = 6.7 Hz, 3H, 4’CH3); 
13
C NMR (125 MHz, d
4
-
MeOD) δ 176.10, 67.05, 56.92, 56.69, 54.66, 45.60, 34.26, 31.24, 28.34, 26.72, 
26.24, 20.45, 20.37. 
tert-butyl N-benzyl-N-{[cis-2-hydroxycyclohexyl]methyl}carbamate, 37 
 
Cis-2-(benzylamino)methyl cyclohexan-1-ol (1.0 g, 4.56 mmol) was dissolved in 
THF (30 ml). (Boc)2O (1.1 g, 5.02  mmol) and diisopropylethylamine (1.98 ml, 11.4 
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mmol) were added and the reaction stirred overnight and concentrated in vacuo. The 
residue was purified by column chromatography eluting with 10% ethyl acetate in 
petrol to give the title compound as a colourless oil (832 mg, 57%). Rf  0.3 (10% 
ethyl acetate/petrol); νmax/cm
-1
 (solid state) 3446, 2930, 2857, 1657; 
1
H NMR (500 
MHz, CDCl3) δ 7.35 (m, 2H, Ar-H), 7.32 – 7.17 (m, 3H, Ar-H), 4.69 (d, J = 15.6 
Hz, 1H, 1’-CHa), 4.14 (m, 2H, 1’-CHb and 1-CH), 3.78 (s, 1H, OH), 3.73 – 3.65 (m, 
1H, 7-CHa), 2.61 (dd, J = 14.5, 4.0 Hz, 1H, 7-CHb), 1.96 (d, J = 13.3 Hz, 1H, 2-CH), 
1.77-1.69 (m, 1H, Cy-CH), 1.67 – 1.51 (m, 3H, Cy-CH), 1.47 (s, 9H), 1.41 – 1.30 
(m, 2H), 1.28 – 1.17 (m, 1H), 0.97 – 0.84 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 
157.30, 138.13, 128.52, 127.28, 127.20, 80.60, 64.57, 50.79, 48.65, 39.93, 32.17, 
28.41, 28.32, 25.78, 24.40, 20.06; HRMS found 320.2221, C19H29NO3 requires 
[M+H]
+
 320.2220. 
tert-butyl N-benzyl-N-{[2-oxocyclohexyl]methyl}carbamate, 39 
 
tert-butyl N-benzyl-N-{[cis-2-hydroxycyclohexyl]methyl}carbamate (832 mg, 2.6 
mmol) was dissolved in DCM (40 ml) and Dess-Martin Periodinane (1.2g, 2.86 
mmol) was added. The reaction was stirred at r.t. for 3 hours then quenched with 
saturated sodium thiosulfate solution (10 ml) and saturated sodium hydrogen 
carbonate solution (10 ml). The organic layer was separated, and the aqueous layer 
extracted with DCM (3 × 10 ml). The organic layers were combined, dried over 
MgSO4 and concentrated in vacuo to a pale yellow oil (506 mg, 61%). νmax/cm
-1
 
(solid state) 2934, 2863, 1696; 
1
H NMR (500 MHz, d
4
-MeOD) δ 7.19 (m, 2H, Ar-
H), 7.13 (m, 3H, Ar-H), 4.42 – 4.19 (m, 2H, 1-CH2), 3.39 (dd, J = 14.3, 5.9 Hz, 1H, 
7-CHa), 3.23 – 3.02 (m, 1H, 7-CHb), 2.60 (s, 1H, 2-CH), 2.31 – 2.10 (m, 2H, Cy-
CH), 2.00 – 1.90 (m, 1H, Cy-CH), 1.92 – 1.84 (m, 1H, Cy-CH), 1.72 (dd, J = 9.0, 
4.5 Hz, 1H, Cy-CH), 1.61 – 1.45 (m, 2H, Cy-CH), 1.34 (s, 9H, t-butyl), 1.23 (m, 1H, 
Cy-CH); 
13
C NMR (125 MHz, d
4
-MeOD) δ 214.06, 157.73, 139.59, 129.59, 127.75, 
81.25, 52.55, 51.33, 50.80, 48.18, 47.66, 47.51, 42.84, 33.35, 28.87, 25.77; HRMS 
found 340.1877, C19H27NO3 requires [M+Na]
+
 318.2063 
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tert-butyl N-{[benzyl({[2-oxocyclohexyl]methyl})carbamoyl]methyl}carbamate, 
41 
 
 tert-butyl N-benzyl-N-{[2-oxocyclohexyl]methyl}carbamate (500 mg, 1.6 mmol) 
was dissolved in 20% TFA in DCM (20 ml) and stirred overnight then concentrated 
in vacuo. The crude TFA salt was then re-dissolved in DCM (30 ml) to which was 
added Boc-glycine (332 mg, 1.89 mmol), HATU (722 mg, 1.89 mmol) and 
diisopropylethylamine (0.82 ml, 4.73 mmol) and the reaction stirred overnight. The 
reaction mixture was then washed with H2O (20 ml) and 1M HCl (20 ml), dried over 
MgSO4 and concentrated in vacuo. The residue was purified by column 
chromatography eluting with 40% ethyl acetate in petrol to give the title compound 
as a colourless oil (490 mg, 83%). Rf  0.2 (40% ethyl acetate/petrol); νmax/cm
-1
 (solid 
state) 3418, 2934, 2863, 1704, 1647; 
1
H NMR (500 MHz, d
4
-MeOD) δ 7.27 (m, 1H, 
Ar-H), 7.23 – 7.08 (m, 4H, Ar-H), 4.69 (s, 2H, 2”-CH2), 4.61 (dd, J = 15.9, 6.6 Hz, 
1H, 1’-CHa), 4.47 (dd, J = 33.3, 16.1 Hz, rot. 1’-CHb) 4.00 (dd, J = 63.2, 16.9 Hz, 
1H, rot. 7-CHa), 3.81 (dd, J = 39.7, 16.8 Hz, 1H, rot, 7-CHa), 3.62 (dd, J = 15.2, 6.6 
Hz, 1H, 2-CH), 3.44 – 3.30 (m, 1H, Cy-CH), 3.26 – 2.98 (m, 1H, Cy-CH), 2.83 – 
2.60 (m, 1H, Cy-CH), 2.31 – 2.08 (m, 2H, Cy-CH), 2.07 – 1.86 (m, 2H, Cy-CH), 
1.74 (d, J = 8.5 Hz, 1H, Cy-CH), 1.66 – 1.47 (m, 2H, Cy-CH), 1.35 (d, J = 16.9 Hz, 
9H, t-butyl), 1.27 – 1.10 (m, 1H, Cy-CH); 13C NMR (125 MHz, d4-MeOD) δ 
214.45, 214.10, 171.93, 158.11, 138.11, 129.95, 129.54, 128.82, 128.63, 127.68, 
80.64, 52.43, 50.50, 47.32, 43.48, 42.72, 33.25, 28.75, 25.62; HRMS found 
375.2275, C21H30N2O4 requires [M+H]
+
 375.2278. 
4-benzyl-decahydro-1H-1,4-benzodiazepin-3-one, 43 
 
 (400 mg, 1.1 mmol) was dissolved in 20% TFA in DCM (20 ml) and stirred at r.t. 
for 1 hour. The reaction mixture was then concentrated in vacuo and the residue re-
suspended in DCM and stirred with MgSO4 overnight. The mixture was then 
filtered, concentrated in vacuo and re-dissolved in methanol (30 ml). Sodium 
borohydride (58 mg, 1.57 mmol) was added and the reaction stirred for 3 hours, 
concentrated in vacuo and residue purified by SCX column chromatography eluting 
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with saturated ammonia in methanol to give the title compound as a 50:50 mixture 
of diastereomers (246 mg, 86%).  
The diastereomers were separated by column chromatography eluting with 3% 
saturated NH3 in methanol in DCM. 
HRMS Found 259.1803; C16H22N2O [M+H]
+
 requires 259.1804 
νmax/cm
-1
 (solid state) 2935, 2848, 1637 
Cis-4-benzyl-decahydro-1H-1,4-benzodiazepin-3-one, cis-43 
 
1
H NMR (500 MHz, CDCl3) δ 7.37 – 7.30 (m, 2H, Ar-H), 7.30 – 7.23 (m, 3H, Ar-
H), 5.16 (d, J = 14.6 Hz, 1H, benzyl CHa), 4.01 (d, J = 14.6 Hz, 1H benzyl CHb), 
3.75 (d, J = 15.0 Hz, 1H, 2-CHa), 3.58 (d, J = 15.0 Hz, 1H, 2-CHb), 3.51 (d, J = 15.1 
Hz, 1H, 5-CHa), 3.22 (dt, J = 16.8, 8.5 Hz, 1H, 5-CHb), 2.99 (dd, J = 6.8, 3.4 Hz, 
1H, 7-CH), 1.78 – 1.51 (m, 5H, Cy-CH), 1.50 – 1.39 (m, 2H, Cy-CH), 1.35 – 1.18 
(m, 2H, Cy-CH); 
13
C NMR (126 MHz, CDCl3) δ 174.28, 137.57, 137.56, 128.54, 
128.22, 127.36, 59.10, 53.96, 52.34, 52.08, 39.47, 32.85, 25.45, 23.77, 20.72 
Trans-4-benzyl-decahydro-1H-1,4-benzodiazepin-3-one, trans-43 
 
1
H NMR (500 MHz, CDCl3) δ 7.38 – 7.32 (m, 2H, Ar-H), 7.32 – 7.24 (m, 3H, Ar-
H), 4.80 (d, J = 14.7 Hz, 1H, benzyl CHa), 4.41 (d, J = 14.7 Hz, 1H benzyl CHb), 
3.74 (d, J = 14.8 Hz, 1H, 2-CHa), 3.68 (d, J = 14.8 Hz, 1H, 2-CHa), 3.40 (dd, J = 
15.2, 10.0 Hz, 1H, 5-CHa), 2.88 (dd, J = 15.2, 1.0 Hz, 1H, 5-CHa), 2.29 (ddd, J = 
11.2, 9.6, 3.5 Hz, 1H, 7-CH), 1.86 – 1.72 (m, 2H, Cy-CH), 1.67 (d, J = 14.5 Hz, 1H, 
Cy-CH), 1.47 – 1.39 (m, 1H, Cy-CH), 1.37 – 1.06 (m, 4H, Cy-CH), 0.91 (qd, J = 
12.8, 3.7 Hz, 1H, Cy-CH); 
13
C NMR (125 MHz, CDCl3) δ 174.44, 137.52, 128.58, 
128.17, 127.41, 66.12, 54.52, 54.36, 53.44, 51.36, 45.34, 34.03, 30.27, 25.64, 25.39 
Standard Procedure A – Reductive amination 
Amine (1 eq.) was dissolved in MeOH (10 ml per mmol) and the relevant aldehyde 
(2 eq.) added followed by picoline borane complex (2 eq.) and the reaction stirred at 
r.t. until LC-MS confirmed completion. The reaction mixture was then concentrated 
in vacuo and the residue purified by mass-directed HPLC. 
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Standard Procedure B – Sulfonamide formation 
Triethylamine (2 eq.) and the relevant sulfonyl chloride (1.2 eq.) were added to a 
solution of the amine (1 eq.) in DCM (10 ml per mmol) and the reaction stirred at r.t. 
until LC-MS confirmed completion. The reaction mixture was then concentrated in 
vacuo and the residue purified by mass-directed HPLC. 
 
Cis-4-(2’-methylpropyl)-1-(pyridin-3-ylmethyl)-decahydro-1H-1,4-
benzodiazepin-3-one, 44  
 
Prepared using general procedure A (16.2 mg 53%). 
1
H NMR (500 MHz, CDCl3) δ 
8.58 (s, 1H, 2-pyridyl CH), 8.52 (d, J = 4.2 Hz, 1H, 6-pyridyl CH), 7.77 (d, J = 7.8 
Hz, 1H, 4-pyridyl CH), 7.33 (dd, J = 7.7, 4.9 Hz, 1H, 5-pyridyl CH), 4.01 (dd, J = 
14.7, 10.6 Hz, 1H, 2-CHa), 3.90 (dd, J = 14.6, 10.5 Hz, 2H, 5-CHa), 3.83 (d, J = 14.3 
Hz, 1H,7-CH), 3.33 (dd, J = 13.2, 6.9 Hz, 1H, 1’CHb), 3.29 – 3.11 (m, 2H, 1’CHa 
and 5-CHb), 2.85 (d, J = 15.2 Hz, 1H,2-CHb), 2.82 – 2.66 (m, 1H, Cy-CH), 2.28 (d, 
J = 5.8 Hz, 1H, Cy-CH), 1.97 – 1.81 (m, 3H, 2’C-H and Cy-CH), 1.75 (d, J = 13.3 
Hz, 1H, Cy-CH), 1.61 (d, J = 11.1 Hz, 1H, Cy-CH), 1.52 – 1.41 (m, 2H, Cy-CH), 
1.35 – 1.24 (m, 1H, Cy-CH), 1.16 (t, J = 13.6 Hz, 1H, Cy-CH), 1.00 (d, J = 6.6 Hz, 
3H, 3’-CH3), 0.94 (d, J = 6.7 Hz, 3H, 4’-CH3); HRMS Found: 316.2393; C19H29N3O 
[M+H]
+
 requires 316.2383. 
Trans-4-(2’-methylpropyl)-1-(pyridin-3-ylmethyl)-decahydro-1H-1,4-
benzodiazepin-3-one, 45 
 
Prepared using general procedure A (9.2 mg, 58%). 
1
H NMR (500 MHz, CDCl3) δ 
8.63 (s, 1H, 2-pyridyl CH), 8.53 (d, J = 4.9 Hz, 1H, 6-pyridyl CH), 7.83 (d, J = 7.7 
Hz, 1H, 4-pyridyl CH), 7.36 (dd, J = 7.7, 4.9 Hz, 1H, 5-pyridyl CH), 3.98 (d, J = 
14.4 Hz, 1H, benzylic CHa), 3.67 (d, J = 15.5 Hz, 1H, 2-CHa), 3.53 – 3.38 (m, 3H, 
benzylic C-Hb, 2-CHb and 5-CHa), 3.34 – 3.23 (m, 2H, 1’CH2), 2.93 (d, J = 14.8 Hz, 
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1H, 5-CHb), 2.60 (td, J = 11.6, 3.0 Hz, 1H, 7-CH), 2.00 – 1.81 (m, 3H, 2’CH and 
Cy-CH), 1.81 – 1.62 (m, 3H, Cy-CH), 1.60 – 1.42 (m, 1H, Cy-CH), 1.29 (tt, J = 
25.5, 12.7 Hz, 2H, Cy-CH), 1.00 (d, J = 6.6 Hz, 3H, 3’-CH3), 0.95 (d, J = 6.6 Hz, 
3H, 4’-CH3); HRMS found 316.2390; C19H29N3O [M+H]
+
 requires 316.2383. 
 
Cis-4-benzyl-1-(pyridin-3-ylmethyl)-decahydro-1H-1,4-benzodiazepin-3-one, 46 
 
Prepared using general procedure A (13.5 mg, 50%). 
1
H NMR (500 MHz, CDCl3) δ 
8.57 (s, 1H, Ar-H), 8.54 (d, J = 4.1 Hz, 1H, Ar-H), 7.77 (d, J = 7.8 Hz, 1H, Ar-H), 
7.42 – 7.31 (m, 6H, Ar-H), 4.65 (s, 2H, pyridyl CH2), 4.00 – 3.85 (m, 3H, 2-CHa, 
benzyl-CHa and 5-CHa), 3.80 (d, J = 14.3 Hz, 1H, benzyl-CHb), 3.33 (d, J = 15.4 Hz, 
1H, 2-CHb), 2.87 (d, J = 15.1 Hz, 1H, 5-CHb), 2.77 – 2.65 (m, 1H, 7-CH), 2.04 (d, J 
= 6.5 Hz, 1H, Cy-CH), 1.92 – 1.72 (m, 2H, Cy-CH), 1.57 (app. t, J = 11.7 Hz, 2H, 
Cy-CH), 1.46 – 1.18 (m, 3H, Cy-CH), 1.05 (q, J = 13.3 Hz, 1H, Cy-CH); HRMS 
Found 350.2232; C22H27N3O [M+H]
+
 requires 350.2226. 
Trans-4-benzyl-1-(pyridin-3-ylmethyl)-decahydro-1H-1,4-benzodiazepin-3-one, 
47 
 
Prepared using general procedure A (16.5 mg, 61%. 
1
H NMR (500 MHz, CDCl3) δ 
8.61 (s, 1H, 2-pyridyl CH), 8.53 (d, J = 4.9 Hz, 1H,6-pyridyl CH), 7.80 (d, J = 7.8 
Hz, 1H, 4-pyridyl CH), 7.41 – 7.31 (m, 6H, Ar-H), 4.67 (d, J = 6.5 Hz, 2H, benzylic 
CH2), 3.94 (d, J = 14.3 Hz, 1H, pyridylmethyl CHa), 3.70 (d, J = 15.8 Hz, 1H, 2-
CHa), 3.60 – 3.49 (m, 2H, pyridylmethyl CHb and 2-CHb), 3.39 (dd, J = 14.8, 10.1 
Hz, 1H, 5-CHa), 2.96 (d, J = 14.8 Hz, 1H, 5-CHb), 2.60 – 2.51 (m, 1H, 7-CH), 1.85 
(t, J = 12.0 Hz, 2H, Cy-CH), 1.69 (d, J = 13.5 Hz, 1H, Cy-CH), 1.60 – 1.38 (m, 3H, 
Cy-CH), 1.33 – 1.22 (m, 1H, Cy-CH), 1.21 – 1.10 (m, 1H, Cy-CH), 0.94 (qd, J = 
12.6, 3.8 Hz, 1H, Cy-CH); HRMS Found 350.2235; C22H27N3O [M+H]
+
 requires 
350.2226. 
- 144 - 
cis-4-benzyl-1-(1H-imidazol-4-ylmethyl)-decahydro-1H-1,4-benzodiazepin-3-
one, 48 
 
Prepared using general procedure A, with 1-Tritylimidazole-4-carboxyaldehyde, 
followed by treatment with 20% TFA in DCM, concentrated in vacuo and the 
residue purification by mass directed HPLC (13.5 mg, 52%). 
1
H NMR (500 MHz, 
CDCl3) δ 7.64 (s, 1H, Ar-H), 7.50 – 7.34 (m, 3H, Ar-H), 7.30 (d, J = 7.5 Hz, 3H, Ar-
H), 4.66 (s, 2H, imidazol-4-ylmethyl CH2), 4.39 (dd, J = 31.4, 14.4 Hz, 2H, benzylic 
CH2), 4.27 (d, J = 14.6 Hz, 1H, 2-CHa), 4.02 (dd, J = 14.8, 10.9 Hz, 1H, 5-CHa), 
3.67 (d, J = 14.7 Hz, 1H, 2-CHb), 3.35 (d, J = 9.6 Hz, 1H, 7-CH), 3.04 (d, J = 15.4 
Hz, 1H, 5-CHb), 2.28 (d, J = 8.0 Hz, 1H, 6-CH), 2.07 – 1.80 (m, 3H, Cy-CH), 1.65 
(d, J = 12.1 Hz, 1H, Cy-CH), 1.58 – 1.39 (m, 2H, Cy-CH), 1.40 – 1.25 (m, 1H, Cy-
CH), 1.24 – 0.98 (m, 1H, Cy-CH); HRMS Found: 339.2185; C20H26N4O [M+H]
+
 
requires 339.2179. 
 
cis-1-(furan-2-ylmethyl)-4-(2-methylpropyl)-decahydro-1H-1,4-benzodiazepin-
3-one, 48 
 
Prepared using general procedure A (9.9 mg, 36%). 
1
H NMR (500 MHz, CDCl3) δ 
7.42 – 7.39 (m, 1H, 5-furanyl CH), 6.35 (dd, J = 3.0, 1.9 Hz, 1H, 4-furanyl CH), 
6.31 (d, J = 3.1 Hz, 1H, 3-furanyl CH), 4.01 (d, J = 14.7 Hz, 1H, furanyl methyl 
CHa), 3.87 (t, J = 17.7 Hz, 3H, furanyl methyl CHb, 2-CHa and 5-CHa), 3.43 (d, J = 
15.4 Hz, 1H, 2-CHb), 3.25 (s, 2H, 1’CH2), 2.90 (d J = 11.3, 1H, 5-CHb), 2.83 (d, J = 
10.0 Hz, 1H, 7-CH), 2.22 (d, J = 18.2 Hz, 1H, 6-CH), 2.01 – 1.73 (m, 4H, 2’-CH 
and Cy-CH), 1.68 (d, J = 11.9 Hz, 1H, Cy-CH), 1.47 (dd, J = 17.9, 8.4 Hz, 2H, Cy-
CH), 1.42 – 1.10 (m, 2H, Cy-CH), 0.97 (d, J = 6.7 Hz, 3H, 3’-CH3), 0.93 (d, J = 6.7 
Hz, 3H, 4’-CH3); HRMS Found 305.2230; C18H28N2O2 [M+H]
+
 requires 305.2223. 
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Cis-1-[(4-fluorophenyl)methyl]-4-(2-methylpropyl)-decahydro-1H-1,4-
benzodiazepin-3-one, 50  
 
Prepared using general procedure A (26 mg, 87%). 
1
H NMR (500 MHz, CDCl3) δ 
7.35 – 7.27 (m, 2H, Ar-H), 7.07 – 6.96 (m, 2H, Ar-H), 4.00 (dd, J = 14.6, 10.8 Hz, 
1H, 5-CHa), 3.94 – 3.82 (m, 2H, benzylic CHa and 2-CHa), 3.76 (d, J = 13.8 Hz, 1H, 
benzylic CHb), 3.38 – 3.17 (m, 3H, 2-CHb and 2’CH2), 2.84 (d, J = 15.0 Hz, 1H, 5-
CHb), 2.78 (dt, J = 11.6, 3.8 Hz, 1H, 7-CH), 2.27 (d, J = 5.4 Hz, 1H, 6-CH), 1.99 – 
1.79 (m, 3H, 2’CH and Cy-CH), 1.74 (d, J = 12.8 Hz, 1H, Cy-CH), 1.65 – 1.53 (m, 
1H, Cy-CH), 1.52 – 1.39 (m, 2H, Cy-CH), 1.36 – 1.22 (m, 1H, Cy-CH), 1.16 (t, J = 
13.5 Hz, 1H, Cy-CH), 1.00 (d, J = 6.6 Hz, 3H, 3’-CH3), 0.94 (d, J = 6.7 Hz, 3H, 4’-
CH3); HRMS Found: 333.2347; C20H29N2FO [M+H]
+ 
requires 333.2336. 
cis-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(2-methylpropyl)-decahydro-1H-
1,4-benzodiazepin-3-one, 51 
 
Prepared using general procedure B (23 mg, 69%). 
1
H NMR (500 MHz, CDCl3) δ 
7.49 (d, J = 1.2 Hz, 1H, Ar-H), 7.45 (s, 1H, Ar-H), 4.49 (dt, J = 9.2, 4.2 Hz, 1H, 7-
CH), 4.24 (d, J = 16.3 Hz, 1H, 2-CHa), 4.08 – 3.90 (m, 2H, 2-CHb and 5-CHa), 3.73 
(s, 3H, NMe), 2.98 (ddd, J = 20.3, 13.3, 7.4 Hz, 2H, diastereomeric 1’CH2), 2.80 (d, 
J = 15.3 Hz, 1H, 5-CHb), 2.29 (d, J = 10.7 Hz, 1H, 6-CH), 1.98 – 1.81 (m, 2H), 1.80 
– 1.61 (m, 4H, 2’CH and Cy-CH), 1.46 (dd, J = 30.0, 13.0 Hz, 2H, Cy-CH), 1.18 – 
0.99 (m, 1H, Cy-CH), 0.84 (d, J = 6.7 Hz, 3H, 3’-CH3), 0.78 (d, J = 6.6 Hz, 3H, 4’-
CH3). HRMS Found: 369.1961; C17H28N4O3S [M+H]
+
 requires 369.1954 
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5.4 Experimental for Chapter 4 
Methyl 3-hydroxy-4-nitrobenzoate, 58 
 
Following a literature procedure, Para-toluene sulphonic acid (pTSA) (415 mg, 2.18 
mmol, 20 mol%) was added to a suspension of 3-hydroxy-4-nitrobenzoic acid (2 g, 
10.9 mmol) in methanol (40 ml) and the reaction heated at reflux for 18 hours. After 
which time the reaction was concentrated in vacuo to afford a yellow solid which 
was then partitioned between H2O (20 ml) and ethyl acetate (40 ml), the organic 
layer was washed with H2O (2 × 20 ml) and saturated sodium bicarbonate solution 
(20 ml), dried over MgSO4 and concentrated in vacuo to yield the title compound as 
yellow needles (1.8 g, 87%); Rf 0.3 (20% EtOAc in Petrol); δH (500 MHz; CDCl3) 
10.50 (1H, s (broad), OH),  8.16 (1H, d, J = 8.7 Hz, Ar-H), 7.83 (1H, d, J  = 1.6 Hz, 
Ar-H), 7.62 (1H, dd, J =  8.7, 1.6 Hz, Ar-H), 3.95 (3H, s, OCH3), δC (125 MHz; 
CDCl3) 164.8, 154.6, 137.9, 135.8, 125.3, 121.6, 120.5, 52.9; m/z (ES) [M+H]
+
 197.  
Methyl 3-isopropyloxy-4-nitrobenzoate 59 
 
Potassium carbonate (2.1 g, 15.2 mmol) was added to a solution of methy-3-
hydroxy-4-nitrobenzoate (600 mg, 3.04 mmol) in DMF (5 ml), followed by 2-
bromopropane (0.40 ml, 4.26 mmol) and the reaction was stirred at 50 °C. After 20 
hours the reaction was diluted with ethyl acetate (50 ml), washed with H2O (2 × 50 
ml) and brine (50 ml), dried over MgSO4 and concentrated in vacuo to a pale yellow 
oil. The resulting residue was purified by flash column chromatography eluting with 
1:1 Petrol‒DCM to give the title compound as a yellow oil which crystallized on 
standing – yellow needles (396 mg, 54%), m.p. 54-56 °C (DCM); Rf 0.3 (1:1 Petrol‒
DCM); νmax/cm
-1
 (solid state) 3437, 3119, 2990, 2516, 2159; δH (500 MHz; CDCl3) 
7.70 (2H, m, ArH), 7.59 (1H, dd, J = 8.4, 1.4 Hz, ArH), 4.74 (1H, spt, J = 6.2 Hz, 
CαH), 3.91 (3H, s, OCH3), 1.36 (6H, d, J = 6.2 Hz, CβH3 and CγH3); δC (125 MHz; 
CDCl3) 165.2, 150.6, 143.6, 134.4, 124.9, 121.0, 116.8, 72.9, 52.6, 21.6; HRMS m/z 
(ESI) Found 262.0686, C12H15NO5 [M+Na]
+
 requires 262.0691. 
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Methyl 3-(2-methyl-propyloxy)-4-nitrobenzoate, 60 
 
Potassium carbonate (4.20 g, 30.50 mmol) was added to a solution of methy-3-
hydroxy-4-nitrobenzoate 2 (1.20 g, 6.09 mmol) in DMF (10 ml), followed by 1-
bromo-2-methylpropane (0.93 ml, 8.52 mmol) and the reaction was stirred at 50 °C. 
After 20 hours a further aliquot of 1-bromo-2-methylpropane (0.93 ml, 8.52 mmol) 
was added and the reaction stirred at 50 °C for a further 24 hours. After this time the 
reaction was diluted with ethyl acetate (100 ml), washed with H2O (2 × 100ml) and 
brine (100ml), dried over magnesium sulphate and concentrated in vacuo to an 
orange oil which crystallised on standing. The resulting mixture was purified by 
flash column chromatography eluting with 1:1 Petrol‒DCM to give the title 
compound (964 mg, 63%) as a yellow crystalline solid; m.p. 69-71 °C (from DCM‒
Petrol); Rf  0.3 (1:1 Petrol‒DCM); νmax/cm
-1
 (solid state) 3101, 2469, 2159, 1727; δH 
(500 MHz; CDCl3) 7.78 (1H, d, J = 8.2 Hz, Ar-H), 7.69 (1H, s, Ar-H), 7.62 (1H, d, J 
= 8.2 Hz, Ar-H), 3.94 (3H, s, CO2CH3), 3.90 (2H, d, J = 6.3 Hz, CαH2), 2.13 (1H, 
sept, J = 6.7 Hz, CβH), 1.03 (6H, d, J = 6.7 Hz, CγH3 and CδH3); δC (125 MHz; 
CDCl3) 165.1, 151.9, 142.3, 134.6, 125.7, 125.0, 120.9, 115.3, 52.6, 28.1, 18.8 (2C); 
m/z (ESI) 276.1 (100%, [M+Na]
+
); HRMS Found: 276.0835; C12H15NO5[M+Na]
+
  
requires 276.0842. 
 
5.4.1 Synthesis of Oligobenzamides 
Standard Procedure C - Ester Hydrolysis 
An aqueous sodium hydroxide solution (2 M, 1 ml per 100 mg of ester) was added 
to a solution of the ester in methanol (~5 ml per 100 mg of ester) and stirred at room 
temperature until the starting material had been consumed, as observed by TLC. The 
reaction mixture was concentrated by half in vacuo then adjusted to pH 3 by the 
addition of 1M HCl (aq.); the resulting precipitate was isolated by filtration, dried in 
vacuo and used without further purification in subsequent steps. 
Standard Procedure D – Tin mediated nitro reduction 
Tin (II) chloride dihydrate (5 equivalents) was added in one portion to a solution of 
the nitro compound in ethyl acetate (5 ml per 100 mg) and the reaction stirred at 50 
°C under a calcium chloride drying tube for 24 hours. The reaction was then allowed 
to cool to room temperature and poured into 2 M sodium hydroxide solution (5 ml 
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per 100 mg of starting material). The organic layer was separated, washed with 2 M 
sodium hydroxide solution (2 × 5 ml per 100 mg of starting material) and brine (5 
ml per 100 mg of starting material), dried over MgSO4 and concentrated in vacuo. 
The residue was purified by flash column chromatography to give the desired 
compound.  
Standard Procedure E – Nitro reduction by hydrogenation 
Palladium on charcoal (10 %) was added against a flow of nitrogen to a solution of 
the nitro compound in methanol  (10 ml per 100 mg) under a nitrogen atmosphere, 
the atmosphere was then replaced with hydrogen and the reaction stirred vigorously 
until complete by TLC (typically 2 hours). The hydrogen atmosphere was vented 
and the reaction mixture filtered through a pad of Celite with methanol, concentrated 
in vacuo and purified by flash column chromatography.  
Standard Procedure F - Coupling 
Dichlorotriphenylphosphorane (4.5 equivalents) was added to a solution of nitro-
acid compound (1.2 equivalents) in chloroform (5 ml per 100 mg of amine) and the 
reaction heated to reflux with stirring under nitrogen. After 2 hours at reflux, the 
amine ester compound (1 equivalent) was added as solution in chloroform (1 ml) 
and the reaction was heated to reflux for a further 24 hours. The reaction mixture 
was then concentrated in vacuo and partitioned between ethyl acetate (5 ml per 100 
mg of amine) and H2O (5 ml per 100 mg of amine). The organic layer was separated 
and washed with saturated aqueous sodium bicarbonate solution (5 ml per 100 mg of 
amine), dried over magnesium sulphate and concentrated in vacuo. The resulting 
residue was purified by flash column chromatography to give the desired compound.   
3-Isopropyloxy-4-nitrobenzoic acid, 55 
 
Prepared using procedure C from 3-isopropyloxy-4-nitrobenzoate (100mg, 0.42 
mmol) to give pale yellow needles (41.5 mg, 44%); Rf  0.2 (DCM);  m.p. 166-170 °C 
(H2O); νmax/cm
-1
 (solid state) 2970, 2534, 2159, 1737; δH (500 MHz; CDCl3) 7.80 
(1H, m, Ar-H), 7.78 (1H, s, Ar-H), 7.74 (1H, m, Ar-H), 4.79 (1H, spt, J = 6.0 Hz, 
CαH), 1.43 (6H, d, J = 6.4 Hz, CβH3 and CγH3); δC (125 MHz; CDCl3) 170.1, 150.8, 
144.4, 133.2, 125.1, 121.8, 117.3, 73.1, 21.7; HRMS Found:
 
225.0622;  C10H11NO5 
[M+H]
+  
requires 225.0637 
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3-(2-Methyl-propyloxy)-4-nitrobenzoic acid, 56 
 
Prepared using procedure C from methyl 3-(2-methyl-propyloxy)-4-nitrobenzoate 
(400mg, 1.58 mmol) to give pale yellow needles (345 mg, 73%); Rf  0.2 (DCM);  
m.p. 188-191 °C (MeOH); νmax/cm
-1
 (solid state) 2962 (broad), 1715, 1610; δH (500 
MHz; CDCl3) 7.87 (1H, d, J = 8.3 Hz, ArH), 7.81 (1H, d, J = 1.4 Hz, ArH), 7.78 
(1H, dd, J = 8.3, 1.4 Hz, ArH), 3.97 (2H, d, J = 6.4 Hz, CαH2), 2.20 (1H, sept, J=  
6.4 Hz, CβH), 1.10 (6H, d, J = 6.7 Hz, CγH3 and CδH3); δC (125 MHz; CDCl3) 169.6, 
152.1, 143.2, 133.6, 125.3, 121.8, 115.8, 91.9, 28.2, 19.0; HRMS Found: 239.0805; 
C12H15NO5 [M+Na]
+
 requires 239.0794. 
Methyl 3-isopropyloxy-4-aminobenzoate, 53 
 
Prepared using procedure D from methyl 3-isopropyloxy-4-nitrobenzoate (100mg, 
0.42 mmol) and purified by flash column chromatography eluting with DCM to give 
a pale orange oil (72 mg, 77%); νmax/cm
-1
 (solid state) 3488, 3371, 2978, 1703; δH 
(500 MHz, CDCl3) 7.55 (dd, J = 8.15, 1.8 Hz, 1 H, Ar-H), 7.49 (d, J = 1.6 Hz, 1 H, 
Ar-H), 6.69 (d, J = 7.9 Hz, 1 H, Ar-H), 4.66 (spt, J = 6.0 Hz, 1 H, CαH),  1.39 (d, J 
= 5.9 Hz, 6 H, CβH3 and CγH3); δC (125 MHz, CDCl3) 167.6, 144.1, 142.2, 123.8, 
119.4, 114.0, 113.4, 70.8, 51.6, 22.1; HRMS Found: 210.1122; C11H16NO3 [M+H]
+
 
requires 210.1125. 
Methyl 3-(2-methyl-propyloxy)-4-amino-benzoate, 54 
 
Prepared using procedure D from methyl 3-(2-methyl-propyloxy)-4-nitrobenzoate 
(200mg, 0.79 mmol) to give a pale yellow oil which crystallized on standing (125 
mg, 71%). Rf  0.5 (DCM); m.p. 61-62 °C (from DCM); νmax/cm
-1
 (solid state) 3462, 
3341, 3202, 2951; δH (500 MHZ; CDCl3) 7.45 (1H, dd, J = 8.2, 1.8 Hz, ArH) 7.35 
(1H, d, J = 1.7 Hz, ArH), 6.58 (1H, d, J = 8.2 Hz, ArH), 4.18 (2H, s, broad, NH2), 
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3.77 (3H, s, OCH3), 3.73 (2H, d, J = 6.5 Hz, CαH2), 2.04 (1H, sept, J = 6.7 Hz, 
CβH), 0.96 (6H, d, J = 6.7 Hz, CγH3 and CδH3); δC (125 MHz, CDCl3) 167.4, 145.6, 
141.4, 123.9, 119.3, 113.1, 74.7, 51.6, 28.3, 19.3; HRMS Found: 223.1212; 
C11H16NO3 [M+H]
+
  requires 223.1208. 
O2N-[ O-
i
Bu(3-HABA)]-[O-
i
Pr (3-HABA)]-COOMe, 61 
 
Prepared using procedure F on a 0.34 mmol scale to give a pale yellow oil (94 mg, 
46%); Rf  0.25 (DCM); νmax/cm
-1
 (film) 3421, 2979, 2504, 2159, 2030, 1976, 1717; 
δH (500 MHz; CDCl3) 8.80 (1H, s, Amide NH), 8.59 (1H, d, J = 8.2 Hz, Ar-H), 7.93 
(1H, d, J = 8.2 Hz, Ar-H), 7.74 (1H, dd, J = 8.5, 1.6 Hz, Ar-H), 7.68 (1H, d, J = 1.4 
Hz, Ar-H), 7.61 (1H, d, J = 1.8 Hz, Ar-H), 7.37 (1H, dd, J = 8.2, 1.4 Hz, Ar-H), 4.78 
(1H, spt, J = 6.1 Hz, 2-CαH), 3.97 (2H, d, J = 6.4 Hz, 1-CαH2), 3.32 (3H, s, OMe), 
2.19 (1H, spt, J = 6.6 Hz, 2-CαH), 1.44 (6H, d, J = 6.0 Hz, 2-CβH3 and 1-CγH3), 
1.07 (6H, d, J = 6.4 Hz, 1-CγH3 and 1-CδH3); δC (125 MHz; CDCl3) 166.6, 163.0, 
152.7, 145.6, 141.6, 139.7, 132.1, 125.8, 123.2, 118.8, 117.2, 114.9, 114.0, 113.1, 
76.1, 71.8, 52.1, 28.1, 21.8, 18.9; HRMS Found 431.1816, C22H26N2O7 [M+H]
+
 
requires 431.1813. 
O2N-[ O-
i
Bu(3-HABA)]-[O-
i
Bu (3-HABA)]-COOMe, 62 
 
Prepared using procedure F  on a 0.42 mmol scale to give pale yellow needles (92.3 
mg, 49%); Rf  0.2 (DCM); m.p. 146-149 °C (DCM); νmax/cm
-1
 (solid state) 3431, 
3085, 2971, 1722; δH (500 MHz; CDCl3) 8.70 (1H, s, Amide N-H), 8.50 (1H, d, J = 
8.7 Hz, Ar-H), 7.83 (1H, d, J = 7.9 Hz, Ar-H), 7.66 (1H, d, J = 8.3 Hz, Ar-H), 7.56 
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(1H, s, Ar-H), 7.50 (1H, s, Ar-H), 7.31 (1H, d, J = 7.9 Hz, Ar-H), 3.87 (4H, m, 1-
CαH2 and 2- CαH2), 3.84 (3H, s, OMe), 2.12 (2H, m, 1-CβH and 2-CβH), 1.03 (6H, d, 
J = 6.8 Hz, 1-CγH3 and 1-CδH3), 0.99 (6H, d, J = 6.8 Hz, 2-CγH3 and 2-CδH3); δC 
(125 MHz; CDCl3) 166.5, 163.0, 152.8, 147.1, 141.6, 139.7, 131.4, 125.9, 125.8, 
123.3, 118.6, 117.3, 113.7, 111.6, 76.1, 75.1, 52.1, 28.3, 28.2, 19.3, 19.0; HRMS 
Found  467.1789, C23H28N2O7 [M+Na]
+
 requires 467.1789. 
H2N-[ O-
i
Bu(3-HABA)]-[O-
i
Pr(3-HABA)]-COOMe, 63 
 
Prepared using procedure D from O2N-[ O-
i
Bu(3-HABA)]-[O-
i
Pr (3-HABA)]-
COOMe (94 mg, 0.22 mmol) to give a colourless oil (47 mg, 53%); Rf  0.3 (2% Et2O 
in DCM); νmax/cm
-1
 (film) 3490, 3430, 3370, 2959, 1713; δH (500 MHz; CDCl3) 
8.79 (1H, s, Amide NH), 8.65 (1H, d, J = 8.2 Hz, Ar-H), 7.74 (1H, dd, J = 8.7 Hz, 
1.4, Ar-H), 7.61 (1H, s, Ar-H), 7.45 (1H, d, J = 1.8 Hz, Ar-H), 7.31 (1H, d, J = 1.4 
Hz, Ar-H), 6.76 (1H, d, J = 8.2 Hz, Ar-H), 4.78 (1H, spt, J = 6.0 Hz, 2-CαH), 4.27 
(2H, s, NH2), 3.93 (3H, s, OMe), 3.89 (2H, d, J  = 6.4 Hz, 1-CαH2), 2.19 (1H, spt, J 
= 6.6 Hz, 1-CβH), 1.46 (6H, d, J = 6.0 Hz, 2-CβH3 and 2-CγH3),1.09 (6H, d, J = 6.9 
Hz, 1-CγH3 and 1-CδH3); δC (125 MHz; CDCl3) 166.9, 165.0, 146.2, 145.5, 140.5, 
133.5, 124.4, 124.1, 123.4, 119.8, 118.4, 113.3, 113.1, 111.5, 74.7, 71.7, 52.0, 28.2, 
19.3, 19.2; HRMS Found 423.1897, C22H28N2O5 [M+Na]
+
 requires 423.1890. 
H2N-[ O-
i
Bu(3-HABA)]-[O-
i
Bu (3-HABA)]-COOMe, 64 
 
Prepared using procedure D from O2N-[O-
i
Bu(3-HABA)]-[O-
i
Bu (3-HABA)]-
COOMe (63 mg, 0.14 mmol) to give off-white needles (41.4 mg, 71%); Rf  0.3 (10% 
- 152 - 
MeOH in DCM); m.p. 147-148 °C (DCM); νmax/cm
-1
 (solid state) 3461, 3435, 3335, 
2961, 2529, 2159, 2028; δH (500 MHz; CDCl3) 8.73 (1H, s, Amide NH), 8.63 (1H, 
d, J 8.7, Ar-H), 7.72 (1H, dd, J = 8.8, 1.6 Hz, Ar-H), 7.55 (1H, d, J = 1.8 Hz, Ar-H), 
7.40 (1H, d, J = 1.8 Hz, Ar-H), 7.30 (1H, dd, J = 8.2, 1.8 Hz, Ar-H), 6.73 (1H, d, J 
= 7.8 Hz, Ar-H), 4.23 (2H, s (broad), NH2), 3.92 (2H, d, J = 6.4 Hz, 2-CαH2), 3.91 
(3H, s, OMe), 3.85 (2H, d, J = 6.4 Hz, 2-CαH2), 2.18 (2H, m, 1-CβH and 2-CβH), 
1.11 (6H, d, J = 6.9 Hz, 1-CγH3 and 1-CδH3), 1.06 (6H, d, J = 6.9 Hz, 2-CγH3 and 2-
CδH3); δC (125 MHz; CDCl3) 166.9, 165.1, 146.85 146.2, 140.5, 132.8, 124.4, 124.1, 
123.5, 120.1, 118.2, 113.4, 111.4, 110.3, 75.0, 74.7, 52.0, 28.3, 28.3, 19.4, 19.3; 
HRMS Found: 437.2042; C23H30N2O5 [M+Na]
+
 requires 437.2047.  
O2N-[ O-
i
Bu(3-HABA)]-[O-
i
Bu (3-HABA)]-[ O-
i
Pr(3-HABA)]-COOMe, 65 
 
Prepared using procedure F on a 0.11 mmol scale to give a yellow solid (21.3 mg, 
30%); Rf  0.25 (2% Et2O in DCM); m.p. 189-191 °C (DCM); νmax/cm
-1
 (solid state) 
2966, 2514, 2159, 2026, 1706, 1680; δH (500 MHz; CDCl3) 8.90 (1H, s, Amide 
NH), 8.81 (1H, s, Amide NH), 8.69 (1H, d, J = 8.2 Hz, Ar-H), 8.65 (1H, d, J = 8.7 
Hz, Ar-H), 7.96 (1H, d, J = 8.2 Hz, Ar-H), 7.76 (1H, dd, J = 8.7, 1.4 Hz, Ar-H), 7.69 
(1H, s, Ar-H), 7.64 (2H, d, J = 6.9 Hz, Ar-H), 7.46 (2H, dd, J = 12.1, 8.5 Hz, Ar-H), 
4.81 (1H, spt, J = 6.0 Hz, 3-CαH), 4.01 (4H, dd, J = 10.5, 6.4 Hz, 1-CαH2 and 2-
CαH2), 3.94 (3H, s, OMe), 2.24 (2H, m, 1-CβH and 2-CβH), 1.49 (6H, d, J = 6.4 Hz, 
3-CγH3 and 3-CδH3), 1.15 (6H, d, J = Hz 6.9, 1-CγH3 and 1-CδH3), 1.11 (6H, d, J = 
6.9 Hz, 2-CγH3 and 2-CδH3); δC (125 MHz; CDCl3) 166.7, 164.2, 163.1, 152.8, 
147.8, 145.8, 141.7, 139.6, 132.9, 130.7, 130.6, 125.9, 125.1, 123.3, 118.9, 118.9, 
118.6, 117.4, 113.7, 113.1, 110.6, 76.1, 75.2, 71.8, 52.1, 28.2, 28.2, 22.2, 19.3,19.0; 
HRMS Found: 644.2596; C33H39N3O9 [M+Na]
+
 requires 644.2579. 
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O2N-[ O-
i
Pr(3-HABA)]-[O-
i
Bu (3-HABA)]-[ O-
i
Bu(3-HABA)]-COOMe, 66 
 
Prepared using procedure F on a 0.1 mmol scale and further purified by trituration 
with hexane to give pale yellow needles (5.5 mg, 9%); Rf  0.3 (99:1 DCM–Et2O); 
m.p. 195-196 °C (Hexane); νmax/cm
-1
 (solid state) 3437, 2961, 2874, 1709, 1680; δH 
(500 MHz; CDCl3) 8.88 (1H, s, Amide NH), 8.78 (1H, s, Amide NH), 8.66 (1H, d, J 
= 8.2 Hz, Ar-H), 8.63 (1H, d, J = 8.2 Hz, Ar-H), 7.88 (1H, s, Ar-H), 7.87 (1H, s, Ar-
H), 7.75 (1H, dd, J = 8.5, 1.1 Hz, Ar-H), 7.70 (1H, s, Ar-H), 7.58 (1H, s, Ar-H), 7.46 
(1H, d, J = 7.8 Hz, Ar-H), 7.38 (1H, d, J = 8.2 Hz, Ar-H), 4.82 (1H, spt, J = 6.0 Hz, 
1-CαH), 3.98 (2H, d, J = 6.9 Hz, 1-CαH2), 3.95 (2H, d, J = 6.4 Hz, 2-CαH2), 3.92 
(3H, s, OMe), 2.23 (2H, m, 1-CβH and 2-CβH), 1.45 (6H, d, J =6.0 Hz, 3-CβH3 and 
3-CγH3), 1.13 (6H, d, J = 6.9 Hz, 1-CγH3 and 1-CδH3), 1.11 (6H, d, J = 6.9 Hz, 2-
CγH3 and 2-CδH3); δC (125 MHz; CDCl3) 166.7, 164.3, 163.2, 151.6, 147.8, 147.0, 
143.2, 143.0, 139.3, 132.1, 130.8, 130.6, 125.8, 125.1, 123.4, 118.9, 118.4, 117.1, 
115.4, 111.5, 110.5, 75.2, 75.1, 73.2, 52.1, 28.3, 28.2, 21.8, 19.38, 19.3; HRMS 
Found: 644.2567; C33H39N3O9 [M+Na]
+
 requires 644.2579. 
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H2N-[O-
i
Bu(3-HABA)]-[O-
i
Bu (3-HABA)]-[O-
i
Pr(3-HABA)]-COOMe, 67 
 
Prepared using procedure D  from O2N-[ O-
i
Bu(3-HABA)]-[O-
i
Bu (3-HABA)]-[ O-
i
Pr(3-HABA)]-COOMe (15 mg, 24 μmol) to give a colourless solid (4.4 mg, 31%). 
m.p. 197-198 °C (CH2Cl2); Rf  0.1 (2:98 Et2O–CH2Cl2); νmax/cm
-1
 (solid state) 3491, 
3436, 3350, 2960, 1714; δH (500 MHz; CDCl3) 8.88 (1H, s, Amide NH), 8.73 (1H, 
s, Amide NH), 8.70 (1H, d, J = 8.5 Hz, Ar-H), 8.63 (1H, d, J = 8.5 Hz, Ar-H), 7.73 
(1H, dd, J = 8.5 Hz, 1.7, Ar-H), 7.60 (2H, dd, J = 4.7, 1.7 Hz, Ar-H), 7.42 (2H, m, 
Ar-H), 7.33 (1H, dd, J = 8.1, 1.7 Hz, Ar-H), 6.75 (1H, d, J = 8.1 Hz, Ar-H), 4.77 
(1H, spt, J = 6.1 Hz, 3-CαH2), 4.23 (2H, br. s, NH2), 3.98 (2H, d, J = 6.4 Hz, 1-
CαH2), 3.92 (3H, s, OCH3), 3.87 (2H, d, J = 6.8 Hz, 2-CαH2), 2.23 (1H, spt, J =6.4 
Hz, 1-CβH), 2.18 (1H, spt, J = 6.8 Hz, 2-CβH), 1.46 (6H, d, J = 6.0 Hz, 3-CβH3 and 
3-CγH3), 1.13 (6H, d, J = 6.8 Hz, 1-CγH3 and 1-CδH3), 1.08 (6H, d, J = 6.4 Hz, 2-
CγH3 and 2-CδH3); δC (125 MHz; CDCl3) 166.8, 165.1, 164.6, 147.6, 146.2, 145.7, 
140.6, 133.2, 132.0, 129.1, 124.9, 124.0, 1?23.3, 120.1, 119.0, 118.5, 118.4, 113.4, 
113.1, 110.4, 110.3, 75.1, 74.8, 71.9, 52.0, 28.4, 28.3, 22.2, 19.4, 19.3; HRMS 
Found: 614.2825; C33H41N3O7 [M+Na]
+
   requires 614.2837. 
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H2N-[ O-
i
Pr(3-HABA)]-[O-
i
Bu (3-HABA)]-[ O-
i
Bu(3-HABA)]-COOMe, 68 
 
Prepared using procedure D from O2N-[ O-
i
Pr(3-HABA)]-[O-
i
Bu (3-HABA)]-[ O-
i
Bu(3-HABA)]-COOMe (89 mg, 0.14 mmol) to give a colourless solid (34 mg, 
41%). m.p. 210-212 °C (CH2Cl2); Rf  0.25 (1:99 MeOH–CH2Cl2); νmax/cm
-1
 (solid 
state) 3496, 3443, 3376, 2962, 2893, 1697, 1673; δH (500 MHz; CDCl3) 8.90 (1H, s, 
Amide NH), 8.77 (1H, s, Amide NH), 8.73 (1H, d, J = 8.7 Hz, Ar-H), 8.67 (1H, d, J 
= 8.7 Hz, Ar-H), 7.77 (1H, d, J = 8.7 Hz, Ar-H), 7.61 (2H, dd, J = 4.6, 1.4 Hz, Ar-
H), 7.49 (1H, d, J =1.4 Hz, Ar-H), 7.46 (1H, dd, J = 8.5, 1.4 Hz, Ar-H), 7.32 (2H, 
dd, J = 8.5, 1.4 Hz, Ar-H), 6.80 (1H, d, J = 8.2 Hz, Ar-H), 4.72 (1H, spt, J =6 Hz, 1-
CαH), 3.99 (2H, d, J =6.4 Hz, 2-CαH2), 3.97 (2H, d, J = 6.4 Hz, 3-CαH2), 3.95 (3H, s, 
CO2Me), 2.25 (2H, m, 2-CβH and 3-CβH), 1.43 (6H, d, J =6.0 Hz, 1-CβH3 and 1-
CγH3), 1.15 (12H, overlapping doublets, J = 6.0 Hz, 2-CγH3, 2-CδH3, 3-CγH3 and 
3CδH3); δC (125 MHz; CDCl3) 166.8, 165.1, 164.6, 147.6, 147.0, 145.0, 132.4, 
132.0, 129.1, 124.9, 123.4, 119.9, 119.0, 118.5, 118.3, 113.9, 112.3, 111.5, 110.2, 
75.1, 70.9, 52.0, 28.4, 28.3, 22.2, 19.4, 19.3; HRMS Found: 614.2834; C33H41N3O7 
[M+Na]
+
  requires 614.2837. 
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H2N-[ O-
i
Bu(3-HABA)]-[O-
i
Bu (3-HABA)]-[ O-
i
Pr(3-HABA)]-COOH, 1 
 
Prepared using procedure A from H2N-[ O-
i
Bu(3-HABA)]-[O-
i
Bu (3-HABA)]-[ O-
i
Pr(3-HABA)]-COOMe (43 mg, 0.07 mmol) to give the product as a pale yellow 
solid (18.4 mg, 45%); m.p. 211-213 °C (CH2Cl2–MeOH); νmax/cm
-1
 (solid state) 
3365, 3480, 2958, 2874, 2552, 1682; δH (500 MHz; d6-DMSO) 9.33 (1H, s, NH), 
9.10 (1H, s, NH), 8.25 (1H, d, J = 8.5 Hz, Ar-H), 8.19 (1H,  d, J = 8.1 Hz, Ar-H), 
7.61 (1H, dd, J = 8.1, 1.7 Hz, Ar-H), 7.58 (3H, m, Ar-H), 7.41 (1H, dd, J = 8.1 Hz, 
2.1, Ar-H), 7.38 (1H, d, J = 1.7 Hz, Ar-H), 6.86 (1H, d, J = 8.1 Hz, Ar-H), 4.74 (1H, 
spt, J = 6.1 Hz, 3-CαH), 3.97 (2H, d, J = 6.4 Hz, 1-CαH2), 3.83 (2H, d, J = 6.8 Hz, 2-
CαH2), 2.17 (1H, spt, J = 6.4 Hz, 1-CβH), 2.11 (1H, spt, J = 6.8 Hz, 2-CβH), 1.37 
(6H, d, J = 6.1 Hz, 3-CβH3 and 3-CγH3), 1.06 (6H, d, J = 6.4 Hz, 1-CγH3 and 1-
CδH3), 1.04 (6H, d, J = 6.8 Hz, 2-CγH3 and 1-CδH3); δC (125 MHz; d6-DMSO) 
166.8, 164.5, 164.4, 148.5, 148.4, 147.4, 144.8, 132.5, 131.3, 129.2, 126.6, 126.5, 
122.2, 121.3, 120.4, 120.0, 119.9, 113.9, 112.5, 110.5, 109.8, 74.5, 74.0, 71.4, 27.8, 
28.7, 21.6, 19.1, 19.0; HRMS Found: 600.2673; C32H39N3O7 [M+Na]
+
  requires 
600.2680. 
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H2N-[ O-
i
Pr(3-HABA)]-[O-
i
Bu (3-HABA)]-[ O-
i
Bu(3-HABA)]-COOH, 52 
 
Prepared using procedure A from H2N-[O-
i
Pr(3-HABA)]-[O-
i
Bu (3-HABA)]-[ O-
i
Bu(3-HABA)]-COOMe (24 mg, 0.04 mmol)  to give the product as a pale yellow 
solid (20 mg, 86%). m.p. 209-211 °C (CH2Cl2); νmax/cm
-1
 (solid state) 3379, 2959, 
2927, 2549, 1715; δH (500 MHz; d6-DMSO) 9.42 (1H, s, NH), 9.16 (1H, s, NH), 
8.15 (1H, d, J = 8.1 Hz, Ar-H), 8.08 (1H, d, J = 8.5 Hz, Ar-H), 7.60  (2H, m, Ar-H), 
7.57 (1H, dd, J = 8.5 Hz, 1.4, Ar-H), 7.55 (1H, d, J = 1.7 Hz, Ar-H), 7.44 (1H, d, J = 
1.4 Hz, Ar-H), 7.39 (1H, dd, J = 8.3, 1.9 Hz, Ar-H), 6.92 (1H, d, J = 7.7 Hz, Ar-H), 
4.64 (1H, spt, J = 6.1 Hz, 1-CαH), 3.93 (2H, d, J = 6.4 Hz, 2-CαH2), 3.90 (2H, d, J = 
6.4 Hz, 3-CαH2), 2.13 (1H, spt, J = 6.4 Hz, 2-CβH2), 2.11 (1H, spt, J = 6.4 Hz, 3-
CβH2), 1.31 (6H, d, J = 6.1 Hz, 1-CβH3 and 1-CγH3), 1.02 (6H, d, J = 6.4 Hz, 2-CγH3 
and 2-CδH3), 1.01 (6H, d, J = 6.4 Hz, 3-CγH3 and 3-CδH3); δC (125 MHz; d6-DMSO) 
166.8, 164.4, 164.2, 149.4, 149.0, 147.2, 143.9, 132.2, 131.5, 129.1, 127.0, 126.8, 
122.1, 121.8, 121.3, 121.1, 121.0, 120.0, 112.7, 112.2, 110.6, 110.5, 74.5, 74.4, 70.6, 
27.8, 27.7, 21.8, 19.1, 19.0; HRMS Found: 600.2675; C32H39N3O7 [M+Na]
+
  
requires 600.2680. 
5.4.2 Library Synthesis 
The compound library was prepared in parallel using the methods and building 
blocks described above, checking at pertinent times during the synthesis by crude 
NMR and LC-MS, to afford the below compounds. Compounds were either pure 
following final precipitation or purified by preparative HPLC.  Where the amount of 
material produced allowed 
13
C-NMR spectra were collected otherwise 
1
H-NMR and 
high resolution mass spectrometry were used to characterise the compound library. 
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H2N-[ O-Me(3-HABA)]-[O-
i
Pr (3-HABA)]-[ O-
i
Bu(3-HABA)]-COOH, 69 
 
δH (500 MHz; d6-DMSO) 9.35 (1H, s, Amide NH), 8.97 (1H, s, Amide NH), 8.28 
(1H, d, J = 8.5 Hz, Ar-H), 8.07 (1H, d, J = 8.5 Hz, Ar-H), 7.59 (4H, m, Ar-H), 7.35 
(2H, m, Ar-H), 6.70 (1H, d, J = 8.5 Hz, Ar-H), 4.78 (1H, spt, J = 6.0 Hz 2-CαH), 
3.90 (2H, d, J = 6.4 Hz, 3-CβH2), 3.85 (3H, s, 1-CαH3), 2.10 (1H, spt, J = 6.6 Hz, 3-
CαH), 1.38 (6H, d, J = 6.0 Hz, 2-CβH3 and 2-CδH3), 1.02 (6H, d, J = 6.8 Hz, 3-CδH3 
and 3CγH3); HRMS Found: 536.2399, C29H33N3O7 [M+H]
+
 requires 536.2391; 
H2N-[ O-
i
Bu(3-HABA)]-[O-
i
Bu (3-HABA)]-[ O-
i
Bu(3-HABA)]-COOH, 70 
 
δH (500 MHz; d6-DMSO) 9.31 (1H, s, Amide N-H), 9.00 (1H, s, Amide N-H), 8.15 
(1H, d, J = 8.1 Hz, Ar-H), 8.00 (1H, d, J = 8.1 Hz, Ar-H), 7.61 (4H, m, Ar-H), 7.35 
(2H, m, Ar-H), 6.71 (1H, d, J = 8.5 Hz, Ar-H), 4.05 (2H, d, J = 6.4 Hz, 1-CαH2), 
3.92 (4H, m, 2-CαH2 and 3-CαH2), 2.11 (3H, m, 1-CβH, 2-CβH and 3-CβH), 1.02 
(18H, m, 1-CγH3 and CδH3, 2-CγH3 and CδH3 and 3-CγH3 and CδH3); HRMS Found: 
614.2840, C33H41N3O7 [M+Na]
+
 requires 614.2836. 
- 159 - 
H2N-[ O-
i
Bu(3-HABA)]-[O-
i
Pr (3-HABA)]-[ O-
i
Bu(3-HABA)]-COOH, 71 
 
δH (500 MHz; d6-DMSO) 9.35 (1H, s, Amide N-H), 8.96 (1H, s, Amide N-H), 8.28 
(1H, d, J = 8.5 Hz, Ar-H), 8.07 (1H, d, J = 8.1 Hz, Ar-H), 7.58 (4H, m, Ar-H), 7.32 
(2H, m, Ar-H), 6.72 (1H, d, J = 8.1 Hz, Ar-H), 4.78 (1H, spt, J = 6.0 Hz, 2-CαH2), 
3.89 (2H, d, J = 6.8 Hz, 1-CαH2), 3.81 (2H, d, J = 6.8 Hz, 3-CαH), 2.09 (2H, m, 1-
CβH and 3-CβH), 1.38 (6H, d, J = 6.0 Hz, 2-CβH3 and 2-CγH3), 1.03 (6H, d, J = 6.8 
Hz, 1-CγH3 and 1-CδH3), 1.01 (6H, d, J = 6.8 Hz, 3-CγH3 and 3-CδH3); HRMS 
Found: 578.2863, C32H39N3O7 [M+H]
+
 requires 578.286;  
H2N-[ O-Bn(3-HABA)]-[O-Bn (3-HABA)]-[ O-Bn(3-HABA)]-COOH, 72 
 
δH (500 MHz; d6-DMSO) 9.54 (1H, m, Amide NH), 9.14 (1H, s, Amide NH), 8.11 
(2H, m, Ar-H), 7.63 (10H, m, Ar-H), 7.48 (2H, m, Ar-H), 7.34 (12H, m, Ar-H), 6.76 
(1H, d, J = 8.1 Hz, Ar-H), 5.29 (2H, m, Benzylic CH2), 5.25 (2H, s, Benzylic CH2), 
5.12 (2H, s, Benzylic CH2); δC (125 MHz; d6-DMSO) 166.8, 165.8, 164.5, 164.4, 
149.3, 149.0, 145.9, 136.6, 136.5, 13200, 131.6, 131.2, 130.0, 129.9, 128.4, 128.4, 
128.0, 127.9, 127.9, 127.8, 127.5, 127.4, 127.3, 127.2, 125.9, 122.5, 121.8, 121.3, 
- 160 - 
120.3, 115.4, 113.1, 112.9, 111.6, 111.3, 70.3, 70.2, 70.1; HRMS m/z (ESI) Found: 
716.2352, C42H35N3O7 [M+Na]
+
  requires 716.2367. 
H2N-[ O-
i
Pr(3-HABA)]-[O-
i
Pr (3-HABA)]-[ O-
i
Pr(3-HABA)]-COOH, 73 
 
δH (500 MHz; d6-DMSO) 9.28 (1H, s, Amide N-H), 8.94 (1H, s, Amide N-H), 8.3 
(1H, d, J = 8.5 Hz, Ar-H), 8.18 (1H, d, J = 8.5 Hz, Ar-H), 7.60-7.54 (4H, m, Ar-H), 
7.35-7.32 (2H, m, Ar-H), 6.72 (1H, d, J = 8.1 Hz, Ar-H), 4.79 (1H, spt, J = 6.0 Hz, 
CαH), 4.72 (1H, spt, J = 6.0 Hz, CαH), 4.60 (1H, spt, J = 6.Hz, CαH), 1.39 (6H, d, J 
= 6.0 Hz, CβH3 and CγH3), 1.35 (6H, d, J = 6.0 Hz, CβH3 and CγH3), 1.32 (6H, d, J 
= 6.0 Hz, CβH3 and CγH3); HRMS Found: 550.2558, C30H35N3O7 [M+H]
+
 requires 
550.2547. 
H2N-[ O-
i
Bu(3-HABA)]-[O-
i
Pr (3-HABA)]-[ O-
i
Pr(3-HABA)]-COOH, 74 
 
δH (500 MHz; d6-DMSO) 9.30 (1H, s, Amide N-H), 9.08 (1H, s, Amide N-H), 8.25 
(1H, d, J = 8.5 Hz, Ar-H), 8.17 (1H, d, J = 8.1 Hz, Ar-H), 7.59 (4H, m, Ar-H), 7.38 
(2H, m, Ar-H), 6.91 (1H, d, J = 7.7 Hz, Ar-H), 4.79 (1H, spt, J = 6 Hz, 2-CαH), 4.69 
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(1H, spt, J = 6 Hz, 3-CαH), 3.84 (2H, d, J = 6.8 Hz, 1-CβH2), 2.09 (1H, spt, J = 6.8 
Hz, 1-CαH), 1.39 (6H, d, J = 6.0 Hz, 2-CβH3 and 2-CδH3), 1.34 (6H, d, J = 6.0 Hz, 
3-CβH3 and 3-CδH3), 1.02 (6H, d, J = 6.8 Hz, 1-CδH3 and 1-CγH3); δC (125 MHz; d6-
DMSO)166.9, 164.3, 164.2, 147.6, 147.2, 132.4, 132.0, 129.5, 126.6, 122.1, 121.3, 
120.9, 120.6, 120.0, 113.9, 112.2, 110.4, 74.2, 71.4, 71.4, 27.7, 21.8, 21.7; HRMS 
Found: 564.2716, C31H37N3O7 [M+H]
+
 requires 564.2704.  
H2N-[ O-Bn(3-HABA)]-[O-
i
Pr (3-HABA)]-[ O-
i
Pr(3-HABA)]-COOH, 75 
 
 
δH (500 MHz; d6-DMSO) 9.31 (1H, s, Amide NH), 9.07 (1H, s, Amide NH), 8.23 
(1H, d, J = 8.1 Hz, Ar-H), 8.16 (1H, d, J = 8.1 Hz, Ar-H), 7.60-7.51 (7H, m, Ar-H), 
7.41-7.38 (3H, m, Ar-H), 7.34-7.31 (1H, m, Ar-H), 6.92 (1H, d, J = 8.1 Hz, Ar-H), 
5.23 (2H, s, 1-Cα), 4.78 (1H, spt, J = 6.1 Hz, 2-Cα), 4.71 (1H, spt, J = 6.1 Hz, 3-Cα), 
1.37 (6H, d, J = 6.1 Hz, 2-Cβ and 2-Cγ), 1.34 (6H, d, J = 6.1 Hz, 3-Cβ and 3-Cγ); δC 
(125 MHz; d6-DMSO) 166.9, 164.3, 164.2, 147.6, 147.3, 136.9, 132.4, 132.0, 129.5, 
128.4, 127.7, 127.3, 126.7, 122.1, 121.3, 121.2, 120.8, 119.9, 113.9, 112.3, 111.4, 
71.5, 71.4, 69.5, 21.8, 21.7; HRMS Found: 598.2562, C34H35N3O7 [M+H]
+
 requires 
598.2547. 
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H2N-[ O-2-hydroxyethyl(3-HABA)]-[O-
i
Pr (3-HABA)]-[ O-
i
Pr(3-HABA)]-
COOH, 76 
 
δH (500 MHz; d6-DMSO) 9.27 (1H, s, Amide NH), 8.95 (1H, s, Amide NH), 8.28 
(1H, d, J = 8.5 Hz, Ar-H), 8.16 (1H, d, J = 8.1 Hz, Ar-H), 7.56 (4H, m, Ar-H), 7.35 
(2H, m, Ar-H), 6.70 (1H, d, J = 8.1 Hz, Ar-H), 4.79 (1H, spt, J = 6 Hz, 2-Cα), 4.71 
(1H, spt, J = 6.0 Hz, 3-Cα), 4.02 (2H, t, J = 4.7 Hz, 1-Cα), 3.75 (2H, t, J = 4.7 Hz, 
1-Cβ), 1.39 (6H, d, J = 6.0 Hz, 2-Cβ and 2-Cγ), 1.35 (6H, d, J = 6.0 Hz, 3-Cβ and 
3-Cγ); HRMS Found: 552.2343, C29H33N3O8 [M+H]
+
 requires 552.2340;  
5.4.3 Synthesis of KCN-1 
4-(2-methylbut-3-yn-2-yloxy)benzaldehyde, 78 
 
Following a literature procedure,
176
 4-hydroxy benzaldehyde (664 mg, 5.4 mmol), 
potassium carbonate (1.5 g, 10.8 mmol), potassium iodide (1.5g, 9.2 mmol) and 
copper iodide (52 mg, 5 mol%) were dissolved in DMF (20 ml) and 3-chloro-3-
methyl-1-butyne (1.1 ml, 9.8 mmol)  was added. The reaction was heated to 65 °C 
for 2.5 hours, allowed to cool to r.t. diluted with ether (30 ml) and washed with 1 M 
aqueous sodium hydroxide (3 × 15 ml) and brine (2 × 15 ml), dried over MgSO4 and 
concentrated in vacuo to yield the title compound as an orange oil (1.01g, 99%). 
νmax/cm
-1
 (solid state) 3291, 2990, 1698, 1601, 1577; δH (500 MHz; CDCl3) 9.91 
(1H, s, CHO), 7.83 (2H, d, J = 8.7 Hz, Ar-H), 7.35 (2H, d, J = 8.7 Hz, Ar-H), 2.69 
(1H, s, Alkynyl CH), 1.73 (6H, s, 2 × Me); δC (125 MHz; CDCl3) 190.9, 161.1, 
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131.3, 131.2, 119.6, 84.8, 73.4, 72.4, 29.4; HRMS m/z (ESI) Found: 188.0842, 
C12H12O2 [M+H]
+
 requires 188.0837. 
2,2-dimethyl-2H-chromene-6-carbaldehyde, 79 
 
Following a literature procedure,
176
 4-(2-methylbut-3-yn-2-yloxy)benzaldehyde (1 g, 
5.3 mmol) was dissolved in toluene (5 ml) and heated to 190 °C under microwave 
irradiation for 25 minutes, allowed to cool, diluted with ethyl acetate and 
concentrated in vacuo to yield the title compound as a dark orange oil (1 g, quant.). 
νmax/cm
-1
 (solid state) 2976, 2648, 1690, 1600; δH (500 MHz; CDCl3) 9.83 (1H, s, 
CHO), 7.66 (1H, dd, J = 8.2 Hz, 1.4, Ar-H), 7.52 (1H, dd, J = 1.4 Hz, Ar-H), 6.87 
(1H, dd, J = 8.2 Hz, Ar-H), 6.37 (1H, d, J = 10.1 Hz, Alkene), 5.70 (1H, d, J = 9.6 
Hz, Alkene), 1.48 (6H, s, 2 × Me); δC (125 MHz; CDCl3) 190.9, 158.7, 131.9, 131.4, 
129.9, 127.8, 121.2, 116.8, 116.0, 77.9, 28.5; HRMS m/z (ESI) Found: 188.0830, 
C12H12O2 [M+H]
+
 Requires 188.0837. 
N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]aniline, 80 
 
Prepared using a modified literature procedure
177
, aniline (1 ml, 10.6 mmol) was 
added to a solution of 2,2-dimethyl-2H-chromene-6-carbaldehyde (1 g, 5.3 mmol) 
and p-toluenesulfonic acid (200 mg, 1.06 mmol) in methylene chloride (20 ml) and 
heated to reflux for 3 hours. Reaction mixture concentrated in vacuo and NMR used 
to confirm full conversion to imine, residue dissolved in toluene (30 ml) and cooled 
to 0 °C (ice bath), diisobutylaluminum hydride (1 M in hexanes, 10.6 ml, 10.6 
mmol) was added dropwise and the reaction stirred overnight and allowed to warm 
to r.t., cooled to 0 °C and quenched by the dropwise addition of saturated aqueous 
ammonium chloride solution with vigorous stirring. The resulting precipitate was 
removed by filtration and the filtrate diluted with ethyl acetate (30 ml), washed with 
water (10 ml),  1M aqueous HCl (3 × 10 ml) and brine (10 ml), dried over MgSO4 
and concentrated in vacuo to yield the title compound as a brown oil (907 mg, 64%). 
νmax/cm
-1
 (solid state) 3417, 2974, 2864, 1603, 1505; δH (500 MHz; CDCl3) 7.09 
(2H, t, J = 7.8 Hz, Aniline Ar-H), 7.00 (1H, dd, J = 8.2, 1.8 Hz, Chromene Ar-H), 
6.89 (1H, dd, J = 1.4 Hz, Chromene Ar-H), 6.67-6.61 (2H, m, Aniline and 
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Chromene Ar-H), 6.55 (2H, dd, J = 7.8 Hz, Aniline Ar-H), 6.20 (1H, d, J = 9.6 Hz, 
Alkene), 5.52 (1H, d, J = 9.6 Hz, Alkene), 4.1 (2H, s, Benzylic CH2), 3.88 (1H, s 
(br), NH), 1.34 (6H, s, 2 × Me); δC (125 MHz; CDCl3) 152.2, 148.2, 131.4, 131.0, 
129.2, 128.4, 125.6, 122.2, 121.3, 117.5, 116.4, 112.9, 76.2, 47.9, 28.0; HRMS m/z 
(ESI) m/z (ESI) Found: 266.1539, C18H19NO [M+H]
+
  requires 266.1539. 
N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-3,4-dimethoxy-N-phenylbenzene-1-
sulfonamide/KCN-1 
 
Prepared using a modified literature procedure,
177
 3,4-dimethoxybenzene sulfonyl 
chloride (890 mg, 3.77 mmol) was added to a solution of N-[(2,2-dimethyl-2H-
chromen-6-yl)methyl]aniline (500 mg, 1.88 mmol) and triethylamine (1.3 ml, 9.4 
mmol) in methylene chloride (50 ml) and the reaction heated to reflux overnight, 
allowed to cool to r.t. and diluted with methylene chloride, washed with water, 
saturated aqueous sodium bicarbonate,  1M aqueous HCl, and brine, dried over 
MgSO4 and concentrated in vacuo. The residue was purified by column 
chromatography eluting with 20-30% ethyl acetate in petrol to yield the title 
compound as a yellow solid (596 mg, 68%). νmax/cm
-1
 (solid state) 2974, 2934, 1586, 
1507; δH (500 MHz; CDCl3) 7.33 (1H, dd, J = 8.5, 2.1 Hz, Ar-H), 7.23-7.19 (3H, m, 
Ar-H), 7.01-6.99 (2H, m, Ar-H), 6.96 (1H, dd, J = 1.8 Hz, Ar-H), 6.93-6.86 (3H, m, 
Ar-H), 6.59 (1H, d, J = 8.2 Hz, Ar-H), 6.21 (1H, d, J = 10.1 Hz, Alkene), 5.56 (1H, 
d, J = 9.6 Hz, Alkene), 4.62 (2H, s, Benzylic CH2), 3.93 (3H, s, OMe), 3.74 (3H, s, 
OMe), 1.37 (6H, s, 2 × Me); HRMS m/z (ESI) Found: 466.168811, C26H27NO5S 
[M+H]
+
  requires 466.16827.  
5.4.4 Synthesis of Helix 2 Mimetics 
2-Bromo-N-(triphenylmethyl)-acetamide, 87 
 
A solution of tritylamine (500 mg, 1.93 mmol) and triethylamine (0.73 mL, 5.25 
mmol) in CH2Cl2 (5ml) was added drop-wise to a cooled solution (0 °C) of bromo-
acetyl bromide (0.8 mL, 1.75 mmol) and triethylamine (0.73 mL, 5.25 mmol) in 
DCM (10 mL) with rapid stirring under an inert atmosphere. The reaction was 
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stirred and allowed to warm to room temperature over 15 hours. The reaction 
mixture was concentrated in vacuo and immediately purified by column 
chromatography eluting with CH2Cl2. Fractions containing product were 
concentrated in vacuo to a black solid which upon trituration with MeOH gave the 
product as a colourless solid (608 mg, 91%). m.p. 201-203 °C (CH2Cl2); Rf 0.35 
(CH2Cl2); νmax/cm
-1
 (solid state) 3261, 3053, 3032, 1660; δH (500 MHz; CDCl3) 7.75 
(1H, s, NH), 7.33 (10H, m, Ar-H), 7.25 (5H, d, J = 6.9 Hz, Ar-H), 3.91 (2H, s, CH2); 
δC (125 MHz; CDCl3) 164.3 (Carbonyl), 144.1 (trityl), 128.6 (trityl), 128.2 (trityl), 
127.3 (trityl), 30.0 (CH2) quaternary carbon not observed; m/z  (ES) 404 (100%, 
MH
+
), 402 (100%, MH
+
), 243 (50%, Trt
+
); HRMS Found: 402.0475; C21H18NOBr 
[M+Na]
+
  requires 402.0464. 
 
S-trityl-mercapto-ethanol, 89 
 
Following a literature procedure,
179
 mercaptoethanol (0.23 ml, 3.27 mmol) was 
added to a solution of trityl chloride (1g, 3.59 mmol) in THF (5 mL) and heated to 
reflux for 4 hours, the reaction was allowed to cool, concentrated in vacuo and 
triturated with 1:2 EtOAc–Hexane to yield the desired compound as a colourless 
solid (466 mg, 44%). m.p. 108-110 °C (Hexane); νmax/cm
-1
 (film) 3336 (broad), 
3063, 2926, 1592; δH (500 MHz; CDCl3) 7.50 (6H, d, J = 7.8 Hz, trityl), 7.34 (6H, 
m, trityl), 7.27 (3H, m, trityl), 3.42 (2H, t, J = 6.2 Hz, CH2), 2.53 (2H, t, J= 6.2 Hz, 
CH2), 1.93 (1H, s, OH); δC (125 MHz; CDCl3) 144.8 (trityl), 129.7 (trityl), 128.1 
(trityl), 126.8 (trityl), 66.74 (CH2S), 35.26 (CH2O), quaternary carbon not observed; 
m/z (ES) [MH]
+
 343, [2M+Na]
+ 
663; HRMS Found: 343.1143; C21H20OS [M+Na]
+
  
requires 343.1127. 
Methyl 4-nitro-3-{2-[(triphenylmethyl)sulfanyl]ethoxy}benzoate, 90 
 
Diisopropyl azodicarboxylate (DIAD) (0.09 mL, 0.45 mmol) was added to a cooled 
solution (0 °C) of methyl 3-hydroxy-4-nitrobenzoate (88 mg, 0.45 mmol), S-trityl 
mercaptoethanol (200 mg, 0.63 mmol) and triphenylphosphine (116 mg, 0.45 mmol) 
in anhydrous THF (5 mL) under an inert atmosphere and reaction allowed to warm 
to room temperature with stirring. After 3 days the reaction was concentrated in 
vacuo, dissolved in CH2Cl2 (10 mL) and washed with H2O (2 × 10 mL), saturated 
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aqueous sodium bicarbonate (3 × 10 mL) and brine (10 mL), dried over MgSO4 and 
concentrated in vacuo to a yellow oil. The oil was purified by column 
chromatography eluting with 1:1 CH2Cl2–petrol and 7:3 CH2Cl2–petrol sequentially 
to give the product as a colourless oil which crystallized to colourless needles on 
standing (79 mg, 35%). m.p. 79-81 °C (7:3 CH2Cl2, Petrol); Rf  0.35 (1:1, CH2Cl2, 
Petrol); νmax/cm
-1
 (Solid State) 3054, 2478, 2254, 2159, 2028, 1974, 1727; δH (500 
MHz; CDCl3) 7.70 (1H, d, J = 8.2 Hz, Ar-H), 7.57 (1H, dd, J = 8.5, 1.6 Hz, Ar-H), 
7.38 (7H, d, J = 7.8 Hz, trityl and Ar-H), 7.22 (6H, t, J = 7.8 Hz, trityl), 7.13 (3H, t, 
J = 7.8 Hz, trityl), 3.87 (3H, s, CO2Me), 3.64 (2H, t, J = 6.8 Hz, CH2S), 2.63 (2H, t, 
J = 6.8 Hz, OCH2); δC (125 MHz; CDCl3) 165.1, 151.4, 144.5, 142.5, 134.7, 129.6, 
128.1, 126.9, 125.3, 121.6, 115.7, 68.3, 67.0, 52.8, 33.7; HRMS Found: 522.1339; 
C29H25NO5S [M+Na]
+
  requires 522.1346. 
Methyl 3-[2-(methoxymethoxy)ethoxy]-4-nitrobenzoate, 91 
 
1-Bromo-2-(methoxymethoxy)ethane (0.41 mL, 3.55 mmol) was added to a solution 
of methyl 3-hydroxy-4-nitrobenzoate (500 mg, 2.54 mmol) and potassium carbonate 
(1.7 g, 12.7 mmol) in DMF (10 mL) and heated to 50 °C for 24 hours, allowed to 
cool and partitioned between EtOAc (20 mL) and H2O (20 mL). The organic layer 
was separated and washed with H2O (20 mL) and brine (20 mL), dried over MgSO4, 
concentrated in vacuo to give a yellow solid and purified by column 
chromatography eluting with CH2Cl2 to give the desired product as a pale yellow 
solid (209 mg, 29%). m.p. 58-60 °C (CH2Cl2); Rf  0.3 (CH2Cl2); νmax/cm
-1
 (Solid 
state) 2966, 2942, 2891, 1726; δH (500 MHz; CDCl3) 7.83 (1H, d, J = 8.2 Hz, Ar-H), 
7.77 (1H, s, Ar-H), 7.69 (1H, d, J = 8.2 Hz, Ar-H), 4.70 (2H, s, CH2), 4.35 (2H, t, J 
= 4.6 Hz, CH2), 3.96 (3H, s, CO2Me), 3.94 (2H, t, J = 4.6 Hz, CH2), 3.38 (3H, s, 
OMe); δC (125 MHz; CDCl3) 165.1, 151.7, 142.6, 134.8, 125.3, 121.6, 115.7, 96.6, 
69.4, 65.3, 55.2, 52.8; HRMS Found: 308.0746; C12H15NO7 [M+Na]
+
  requires 
308.0741. 
Methyl 3-[(triphenylmethyl)carbamoyl]methoxy-4-nitrobenzoate, 92  
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2-Bromo-N-(triphenylmethyl)-acetamide (600 mg, 1.58 mmol) was added to a 
solution of methyl 3-h ydroxy-4-nitrobenzoate (258mg, 1.31 mmol) and potassium 
carbonate (900 mg, 6.58 mmol) in DMF (10 mL) and heated to 50 °C for 24 hours 
then allowed to cool and partitioned between EtOAc (20 mL) and H2O (20 mL). The 
organic layer was separated and washed with saturated aqueous solution of sodium 
bicarbonate (20ml), H2O (20 ml) and brine (20 ml), dried over MgSO4, concentrated 
in vacuo to an orange solid which was recrystallised from methanol to give a white 
solid (155.4 mg, 23%), m.p. 205 °C (MeOH), νmax/cm
-1
 (film) 3407, 3058, 2950, 
2512, 2159, 1976, 1728; δH (500 MHz; CDCl3) 8.14 (1H, s (broad), N-H), 8.02 (1H, 
d, J = 8.1 Hz, Ar-H), 7.80 (1H, dd, J = 8.5 Hz, 1.7, Ar-H), 7.74 (1H, d, J = 1.4 Hz, 
Ar-H), 7.34-7.26 (15H, m, trityl), 4.68 (2H, s (broad), CH2), 3.98 (3H, s (broad), 
OMe); δC (125 MHz; CDCl3) 164.9, 164.6, 150.2, 144.2, 135.8, 128.6, 128.0, 127.2, 
126.4, 122.8, 155.5, 91.9, 70.6, 68.3, 53.0; HRMS Found: 519.1533; C29H24N2O6 
[M+Na]
+
 requires 519.1527. 
Methyl 3-{2-[(triphenylmethyl)sulfanyl]ethoxy}-4-aminobenzoate, 93 
 
Prepared using procedure E from methyl 3-{2-[(triphenylmethyl)sulfanyl]ethoxy}-4-
nitrobenzoate (220 mg, 0.44 mmol)  and purified by alumina column 
chromatography eluting with 1% ethyl acetate–DCM followed by 1% MeOH–DCM 
to give a pale yellow oil (101 mg, 49%), νmax/cm
-1
 (film)  3486, 3374, 3057, 2948, 
1704, 1615; δH (300 MHz; CDCl3) 7.52 (1H, dd, J = 8.2, 1.6 Hz, Ar-H), 7.45 (6H, 
m, Trityl and Ar-H), 7.25 (10H, m, Trityl), 6.63 (1H, d, J = 8.2 Hz, Ar-H), 3.83 (5H, 
m, OMe and CH2), 2.65 (2H, t, J = 6.3 Hz, CH2); δC (75 MHz; CDCl3) 144.8, 144.6, 
141.4, 129.5, 128.0, 126.8, 124.4, 119.3, 113.2, 112.6, 66.99, 51.72, 31.54; HRMS 
Found: 492.1603; C29H27NO3S  [M+Na]
+
 requires 492.1604. 
Methyl 3-[2-(methoxymethoxy)ethoxy]-4-aminobenzoate, 94 
 
Prepared using procedure E from methyl 3-[2-(methoxymethoxy)ethoxy]-4-
nitrobenzoate (416 mg, 1.46 mmol) to give a pale yellow oil (369 mg, 99%), 
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νmax/cm
-1
 (film) 3480, 3365, 2949, 2887, 1704; δH (500 MHz; CDCl3) 7.56 (1H, d, J 
= 8.2 Hz, Ar-H), 7.48 (1H, s, Ar-H), 6.67 (1H, d, J = 7.8 Hz, Ar-H), 4.71 (2H, s, 
OCH2O), 4.38 (2H, s (broad), NH2), 4.22 (2H, t, J = 4.4 Hz, CH2), 3.92 (2H, t, J = 
4.4 Hz, CH2), 3.86 (3H, s, OMe), 3.39 (3H, s, OMe); δC (125 MHz; CDCl3) 167.2, 
145.0, 141.8, 124.5, 119.2, 113.3, 113.0, 96.5, 68.1, 66.1, 55.3, 51.6; HRMS Found: 
278.0999; C12H17NO5 [M+Na]
+
 requires 278.0999. 
Methyl 3-[(triphenylmethyl)carbamoyl]methoxy-4-aminobenzoate, 95 
 
Prepared using procedure E from methyl 3-[(triphenylmethyl)carbamoyl]methoxy-4-
nitrobenzoate (220 mg, 0.44 mmol) to give a beige solid (153 mg, 65%), m.p. 132-
134 °C, νmax/cm
-1
 (film) 3338, 3056, 2949, 2581, 1966, 1671; δH (500 MHz; d6-
DMSO) 8.76 (1H, s, NH), 7.42 (1H, dd, J = 8.2, 1.8 Hz, Ar-H), 7.36 (1H, d, J = 1.4 
Hz, Ar-H), 7.28-7.17 (15H, m, trityl), 6.68 (1H, d, J = 8.2 Hz, Ar-H), 5.72 (2H, s 
(broad), NH2), 4.75 (2H, s, CH2), 3.79 (3H, s, OMe); δC (125 MHz; d6-DMSO) 
167.1, 166.2, 144.4, 143.8, 128.4, 127.7, 127.5, 126.5, 124.3, 112.9, 112.4, 69.2, 
61.8, 51.3, 48.5; HRMS Found: 489.1790,  C29H26N2O4 [M+Na]
+
 requires 489.1785. 
4-Nitro-3-{2-[(triphenylmethyl)sulfanyl]ethoxy}benzoic acid, 96 
 
Prepared using procedure C from methyl 4-Nitro-3-{2 
[(triphenylmethyl)sulfanyl]ethoxy} benzoate (220 mg, 0.44 mmol) to give a 
colourless solid (195 mg, 91%), m.p. 194-196 °C  νmax/cm
-1
 (film) 3057, 2654, 1693; 
δH (500 MHz; CDCl3) 7.94 (1H, d, J = 8.2 Hz, Ar-H), 7.65 (1H, dd, J = 8.2 Hz, 1.4, 
Ar-H), 7.56 (1H, s, Ar-H), 7.37-7.24 (15H, m, trityl), 3.99 (2H, t, J = 6.2 Hz, CH2), 
2.54 (2H, t, J = 6.2 Hz, CH2); δC (125 MHz; CDCl3) 165.6, 150.1, 144.1, 142.1, 
129.0, 128.0, 126.8, 124.9, 121.6, 115.4, 67.56, 66.19, 30.64; HRMS Found: 
508.119; C28H23NO5S [M+Na]
+
 requires 508.1189. 
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3-[2-(Methoxymethoxy)ethoxy]-4-nitrobenzoic acid, 97 
 
Prepared using procedure C from methyl 3-[2-(methoxymethoxy)ethoxy]-4-
nitrobenzoate (400 mg, 1.4 mmol) to give a colourless solid, (262.6 mg, 69%), m.p. 
131-133 °C; νmax/cm
-1
 (film) 3063, 2938, 2542, 2159, 2025, 1691; δH (500 MHz; 
CDCl3) 7.90-7.87 (2H, m, Ar-H), 7.81 (1H, dd, J = 8.2, 1.4 Hz, Ar-H), 4.76 (2H, s, 
OCH2O), 4.41 (2H, t, J = 4.4 Hz, CH2), 4.00 (2H, t, J = 4.4 Hz, CH2), 3.44 (3H, s, 
OMe); δC (125 MHz; CDCl3) 169.4, 151.7, 143.3, 133.8, 125.4, 122.4, 116.3, 96.6, 
69.5, 65.4, 55.3; HRMS Found: 294.0571, C11H13NO7 [M+Na]
+
 requires 294.0584;  
 
3-[(Triphenylmethyl)carbamoyl]methoxy-4-nitrobenzoic acid, 98 
 
Prepared using procedure C from methyl 3-[(triphenylmethyl)carbamoyl]methoxy-
4-nitrobenzoate (220mg, 0.44 mmol) to give an off white solid (157mg, 74%); m.p. 
222-224 °C; νmax/cm
-1
 (film) 3398, 3059, 2828, 2581, 1961, 1699; δH (500 MHz; d6-
Acetone) 8.21 (1H, s (broad), NH), 8.07 (1H, d, J = 8.2 Hz, Ar-H), 7.93 (1H, d, J = 
1.4 Hz, Ar-H), 7.84 (1H, dd, J = 8.5, 1.6 Hz, Ar-H), 7.32-7.25 (15H, m, trityl), 4.98 
(2H, s, CH2); δC (125 MHz; CDCl3) 166.1, 165.7, 151.4, 145.7, 143.1, 136.5, 129.6, 
128.5, 127.7, 126.4, 123.3, 117.0, 70.92, 69.22, 49.6; HRMS Found: 505.1362; 
C28H22N2O6 [M+Na]
+
 requires 505.137. 
Methy 3-Hydroxy-4-aminobenzoate, 99 
 
4-amino-3-hydroxybenzoic acid (1 g, 6 mmol) was heated to reflux in methanol (20 
ml) and sulphuric acid (2 ml) for 16 hours, allowed to cool to r.t. and sodium 
bicarbonate added until gas evolution ceased. The resulting solid was removed by 
filtration and the filtrate concentrated in vacuo, suspended in water (20 ml) and 
extracted with ethyl acetate (3 × 30 ml). The combined organics were washed with 
brine (20 ml), dried over MgSO4 and concentrated in vacuo to yield the title 
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compound as a beige solid (854 mg, 85%). νmax/cm
-1
 (solid state) 3398, 3315, 2948, 
2583, 1705, 1604; δH (500 MHz; d6-DMSO) 9.40 (1H, s, OH), 7.26 (2H, m, Ar-H), 
6.60 (1H, d, J = 8.7 Hz, Ar-H), 5.36 (2H, s, NH), 3.74 (3H, s, OMe); δC (125 MHz; 
d6-DMSO) 166.4, 142.7, 142.3, 122.5, 116.5, 116.2, 114.5, 112.4, 51.1; HRMS m/z 
(ESI) Found: 190.0493, C8H8NO3 [M+Na]
+
  requires 190.0475. 
 
O2N-[O-MOM-Hydroxyethyl(3-HABA)]-[(3-HABA)]-COOMe, 100 
 
PyBOP (1664 mg, 3.2 mmol) and diisopropylethylamine (1.2 ml, 6.67 mmol) were 
added sequentially to a solution of 3-[2-(Methoxymethoxy)ethoxy]-4-nitrobenzoic 
acid (725 mg, 2.67 mmol) in dichloromethane (30 ml) and the reaction stirred for 30 
minutes. After which time methy 3-hydroxy-4-aminobenzoate (446 mg, 2.67 mmol) 
was added and the reaction stirred at r.t. overnight. The reaction mixture was 
concentrated in vacuo and re-dissolved in dimethylformamide (20 ml). Caesium 
carbonate (3.8 g, 13.55 mmol) was added and the reaction stirred at r.t. for 
overnight. The reaction mixture was then poured into ethyl acetate (40 ml) and 
washed copiously with water and brine, dried over MgSO4 and concentrated in 
vacuo. The residue was purified by column chromatography eluting with 5:95 
ether/dichloromethane to give the title compound as a yellow solid (491 mg,  44%).. 
νmax/cm
-1
 (solid state) 2952, 2869, 1716, 1674, 1524; 
1
H NMR (500 MHz, d6-
DMSO) δ 10.39 (s, 1H, OH), 9.84 (s, 1H, Amide NH), 8.02 (d, J = 8.3 Hz, 1H, Ar-
H), 7.92 (d, J = 8.3 Hz, 1H, Ar-H), 7.89 (s, 1H, Ar-H), 7.66 (dd, J = 8.3, 1.4 Hz, 
1H), 7.55 (d, J = 1.9 Hz, 1H, Ar-H), 7.50 (dd, J = 8.3, 1.9 Hz, 1H, Ar-H), 4.64 (s, 
2H, O-CH2-O), 4.51 – 4.39 (t, 2H, CH2), 3.92 – 3.80 (m, 5H, OMe and CH2), 3.28 
(s, 3H, OMe); HRMS found 421.1245, C19H20N2O9 [M+H]
+
 requires 421.1241 
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O2N-[O-MOM-hydroxyethyl(3-HABA)]-[O-(N-Trt)carbamoylmethoxy-(3-
HABA)]-COOMe, 101 
 
 
2-Bromo-N-(triphenylmethyl)-acetamide (217 mg, 0.57 mmol) was added to a 
suspension of methyl 3-hydroxy-4-{3-[2-(methoxymethoxy)ethoxy]-4-
nitrobenzamido}benzoate (200 mg, 0.48 mmol) and potassium carbonate (331 mg, 
2.4 mmol) in dimethylformamide (20 ml) and the reaction heated to 50 °C 
overnight. The reaction mixture was then poured into water (20 ml) and the resulting 
precipitate collected by filtration. The precipitate was purified by column 
chromatography eluting with 5:95 ether/dichloromethane to give the title compound 
as a pale yellow solid (138 mg, 40%). νmax/cm
-1
 (solid state) 3381, 2964, 2821, 1969; 
1
H NMR (500 MHz, CDCl3) δ 9.49 (s, 1H, Amide N-H), 8.53 (d, J = 8.5 Hz, 1H, 
Ar-H), 7.86 (d, J = 8.5 Hz, 1H, Ar-H), 7.70 (d, J = 8.8 Hz, 1H, Ar-H), 7.63 (s, 1H, 
Ar-H), 7.44 (d, J = 8.4 Hz, 1H, Ar-H), 7.27 (m, J = 11.9, 6.7 Hz, 10H, Trityl), 7.20 
(d, J = 7.1 Hz, 1H, Ar-H), 7.14 – 7.08 (m, 5H, Trityl), 4.68 (s, 4H, O-CH2-O and O-
CH2-CONR), 4.21 – 4.13 (t, J = 4.2 Hz 2H, CH2), 3.92 (s, 3H, OMe), 3.76 – 3.71 (t, 
J = 4.2 Hz, 2H, CH2), 3.40 (s, 3H, OMe); 
13
C NMR (125 MHz, CDCl3) δ 167.50, 
166.14, 163.51, 152.20, 147.51, 143.83, 141.61, 139.23, 133.67, 128.70, 128.62, 
128.50, 128.16, 128.03, 127.48, 126.24, 125.72, 120.71, 119.05, 117.13, 114.03, 
96.57, 71.16, 71.07, 69.40, 65.25, 55.27, 52.28; HRMS found 720.2555, 
C40H37N3O10 requires [M+H]
+
 720.2551 
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H2N-[O-MOM-hydroxyethyl(3-HABA)]-[O-(N-Trt)carbamoylmethoxy-(3-
HABA)]-COOMe 
 
Using standard procedure E on 0.19 mmol scale to give the title compound as a 
colourless oil (74 mg, 56%). νmax/cm
-1
 (solid state) 3343, 2950, 1673; 
1
H NMR (500 
MHz, CDCl3) δ 8.57 (s, 1H, Amide N-H), 8.49 (d, J = 8.5 Hz, 1H, Ar-H), 7.73 (dd, J 
= 8.5, 1.1 Hz, 1H, Ar-H ), 7.57 (s, 1H, Ar-H), 7.36 (d, J = 1.1, 1H, Ar-H), 7.25 (s, 
1H, Ar-H), 7.15 (dd, J = 7.4, 2.8 Hz, 10H, Trityl), 7.05 (dd, J = 6.7, 2.7 Hz, 5H, 
Trityl), 6.45 (d, J = 8.1 Hz, 1H, Ar-H), 4.62 (s, 2H, O-CH2-O), 4.61 (s, 2H, O-CH2-
CON), 4.20 (s, 2H, NH2), 4.14 – 4.07 (t, J = 4.4 Hz, 2H, CH2), 3.83 (s, 3H, OMe), 
3.79 – 3.74 (t, J = 4.4 Hz, 2H, CH2), 3.32 (s, 3H, OMe); 
13
C NMR (125 MHz, 
CDCl3) δ 166.36, 166.26, 165.19, 145.87, 145.79, 144.08, 141.14, 133.17, 128.46, 
128.13, 127.31, 125.28, 125.00, 123.46, 120.81, 119.83, 113.51, 113.44, 111.73, 
104.21, 96.64, 70.64, 69.46, 68.28, 66.14, 63.78, 55.33, 52.20. 
H2N-[O-hydroxyethyl(3-HABA)]-[O-carbamoylmethoxy-(3-HABA)]-COOH, 
102 
 
H2N-[O-MOM-hydroxyethyl(3-HABA)]-[O-(N-Trt)carbamoylmethoxy-(3-
HABA)]-COOMe (35 mg, 0.05 mmol) was dissolved in 1:1 
tetrahydrofuran/methanol (5 ml) and treated with 1M sodium hydroxide solution (3 
ml) for 2 hours. The reaction mixture was then acidified to pH 1 with concentrated 
HCl and stirred overnight. The reaction mixture was concentrated in vacuo and 
purified by mass directed preparative HPLC. νmax/cm
-1
 (solid state) 3408, 1663; 
1
H 
NMR (500 MHz, d6-DMSO) δ 9.67 (s, 1H, Amide N-H), 8.13 (d, J = 8.4 Hz, 1H, 
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Ar-H), 7.62 (dd, J = 8.4, 1.8 Hz, 1H, Ar-H), 7.51 (d, J = 1.8 Hz, 1H, Ar-H), 7.45 
(dd, J = 8.3, 1.9 Hz, 1H, Ar-H), 7.41 (d, J = 1.9 Hz, 1H, Ar-H), 6.67 (d, J = 8.2 Hz, 
1H, Ar-H), 4.62 (s, 2H, CH2), 4.01 (t, J = 4.8 Hz, 2H, CH2), 3.75 (t, J = 4.7 Hz, 2H, 
CH2); HRMS found 390.1301 C18H19N3O7 requires [M+H]
+
 390.1295 
Methyl 4-amino-3-(prop-2’-en-1’-yloxy)benzoate  
 
Prepared using standard procedure D on a 2.1 mmol scale (397 mg, 91%). νmax/cm
-1
 
(solid state) 3367, 2991, 1692; 
1
H NMR (500 MHz, CDCl3) δ 7.55 (dd, J = 8.2, 1.8 
Hz, 1H, 6-CH), 7.46 (d, J = 1.7 Hz, 1H, 2-CH), 6.67 (d, J = 8.2 Hz, 1H, 5-CH), 6.08 
(ddt, J = 17.2, 10.6, 5.4 Hz, 1H, 2’-CH), 5.42 (dq, J = 17.3, 1.6 Hz, 1H, 3’-CHtrans)), 
5.30 (dq, J = 10.5, 1.4 Hz, 1H, 3’-CHcis)), 4.61 (dt, J = 5.4, 1.4 Hz, 2H, 1-CH2), 3.86 
(s, 3H, OMe); 
13
C NMR (125 MHz, CDCl3) δ 167.27, 145.01, 141.38, 133.04, 
124.28, 119.46, 117.88, 113.33, 112.68, 69.30, 51.68; HRMS found 208.0969, 
C11H13NO3 [M+H]
+
 requires 208.0968 
4-nitro-3-(prop-2’-en-1’-yloxy)benzoic acid  
 
Prepared using standard procedure C on a 2.52 mmol scale (535 mg, 95%). νmax/cm
-1
 
(solid state) 2824, 2598, 2538, 1683;  
1
H NMR (500 MHz, d6-DMSO) δ 13.60 (s, 
1H, OH), 7.96 (d, J = 8.3 Hz, 1H, 5-CH), 7.75 (d, J = 1.5 Hz, 1H, 2-CH), 7.63 (dd, J 
= 8.3, 1.6 Hz, 1H, 6-CH), 6.02 (ddt, J = 17.2, 10.5, 4.9 Hz, 1H, 2’-CH), 5.41 (dq, J = 
17.3, 1.7 Hz, 1H, 3’C-Htrans), 5.29 (dq, J = 10.6, 1.5 Hz, 1H, 3’C-Hcis), 4.83 (dt, J = 
4.9, 1.6 Hz, 2H, 1’-CH2); 
13
C NMR (125 MHz, d6-DMSO) δ 165.71, 150.32, 142.18, 
135.57, 132.32, 124.98, 121.47, 117.88, 115.73, 69.59; HRMS m/z (ESI) Found: 
222.041033, C10H9NO5  [M-H]
-
 Requires 222.040796. 
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5.4.5 Late Stage Functionalization 
The allyl bearing trimer was prepared in parallel using the methods and building 
blocks described above, checking at pertinent times during the synthesis by crude 
NMR and LC-MS, to afford the below compounds. Compounds were either pure 
following final precipitation or purified by preparative HPLC.   
O2N-[O-Allyl(3-HABA)]-[O-iBu (3-HABA)]-[ O-iPr (3-HABA)]-COOMe, 103 
 
νmax/cm
-1
 (solid state) 3421, 2975, 1704, 1680; 
1
H NMR (500 MHz, CDCl3) δ 8.85 
(s, 1H, Amide N-H), 8.76 (s, 1H, Amide N-H), 8.63 (d, J = 8.4 Hz, 1H, Ar-H), 8.60 
(d, J = 8.5 Hz, 1H, Ar-H), 7.93 (d, J = 8.3 Hz, 1H, Ar-H), 7.71 (dd, J = 8.5, 1.7 Hz, 
1H, Ar-H), 7.69 (d, J = 1.5 Hz, 1H, Ar-H), 7.59 (m, 2H, Ar-H), 7.42 (m, 2H), 6.06 
(ddt, J = 17.2, 10.2, 5.0 Hz, 1H, 1-CβH), 5.52 (ddd, J = 17.1, 2.7, 1.5 Hz, 1H, 1-
CγHtrans), 5.38 (ddd, J = 10.7, 2.5, 1.3 Hz, 1H1-CγHcis), 4.83 – 4.67 (m, 3H, 1-CαH2 
and 3-CαH), 3.98 (d, J = 6.5 Hz, 2H, 2- CαH2), 3.90 (s, 3H, OMe), 2.22 (dp, J = 13.3, 
6.7 Hz, 1H, 2-CβH), 1.46 (d, J = 6.0 Hz, 6H, 3-CβH3 and 3-CγH3), 1.11 (d, J = 6.7 
Hz, 6H, 2-CγH3 and 2-CδH3); 
13
C NMR (125 MHz, CDCl3) δ 166.74, 164.22, 
162.98, 152.15, 147.84, 145.79, 141.96, 139.64, 132.93, 131.13, 130.68, 130.64, 
126.02, 125.11, 123.31, 119.01, 118.93, 118.59, 117.71, 114.49, 113.14, 110.62, 
75.26, 71.88, 70.31, 52.09, 28.25, 22.23, 19.31; HRMS found 628.2276, 
C32H35N3O9 [M+Na]
+
 requires 628.2265 
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O2N-[O-iBu(3-HABA)]-[O-Allyl (3-HABA)]-[ O-iPr (3-HABA)]-COOMe, 104 
 
νmax/cm
-1
 (solid state) 3428, 2961, 1792, 1714; 
1
H NMR (500 MHz, CDCl3) δ 8.81 
(s, 1H, Amide N-H), 8.73 (s, 1H, Amide N-H), 8.61 (d, J = 8.4 Hz, 1H, Ar-H), 8.57 
(d, J = 8.5 Hz, 1H, Ar-H), 7.88 (d, J = 8.3 Hz, 1H, Ar-H), 7.68 (dd, J = 8.5, 1.7 Hz, 
1H, Ar-H), 7.63 (d, J = 1.6 Hz, 1H, Ar-H), 7.59 (d, J = 1.8 Hz, 1H, Ar-H), 7.57 (d, J 
= 1.7 Hz, 1H, Ar-H), 7.41 (dd, J = 8.5, 1.8 Hz, 1H, Ar-H), 7.38 (dd, J = 8.3, 1.7 Hz, 
1H, Ar-H), 6.11 (ddt, J = 17.2, 10.6, 5.4 Hz, 1H, 2-CβH), 5.47 (ddd, J = 17.3, 2.8, 
1.5 Hz, 1H, 2-CγHtrans), 5.39 (ddd, J = 10.5, 2.3, 1.1 Hz, 1H, 2-CγHcis), 4.86 – 4.68 
(m, 3H, 2-CαH2 and 3-CαH), 3.94 (d, J = 6.5 Hz, 2H, 1-CαH2), 3.88 (s, 3H, OMe), 
2.16 (dt, J = 13.3, 6.6 Hz, 1H, 1-CβH), 1.45 (d, J = 6.1 Hz, 6H, 3-CβH3 and 3-CγH3), 
1.06 (d, J = 6.7 Hz, 6H, 1-CγH3 and 1-CδH3); 
13
C NMR (125 MHz, CDCl3) δ 166.69, 
164.09, 163.23, 152.75, 147.39, 145.78, 141.70, 139.55, 132.88, 132.03, 130.82, 
130.54, 125.81, 125.10, 123.24, 119.22, 119.19, 119.05, 118.58, 117.47, 113.95, 
113.12, 111.06, 76.07, 71.87, 69.82, 52.06, 28.20, 22.22, 19.00; HRMS found 
606.2456, C32H35N3O9 [M+H]
+
 requires 606.2446 
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O2N-[ O-iBu(3-HABA)]-[O-iBu (3-HABA)]-[ O-Allyl(3-HABA)]-COOMe, 105 
 
νmax/cm
-1
 (solid state) 3435, 2956, 1714, 1679; 
1
H NMR (500 MHz, CDCl3) δ 8.83 
(s, 1H, Amide N-H), 8.78 (s, 1H, Amide N-H), 8.66 (d, J = 8.4 Hz, 1H, Ar-H), 8.64 
(d, J = 8.5 Hz, 1H, Ar-H), 7.94 (d, J = 8.3 Hz, 1H, Ar-H), 7.77 (dd, J = 8.5, 1.6 Hz, 
1H, Ar-H), 7.66 (d, J = 1.4 Hz, 1H, Ar-H), 7.64 – 7.57 (m, 2H, Ar-H), 7.46 (dd, J = 
8.4, 1.6 Hz, 1H, Ar-H), 7.42 (dd, J = 8.3, 1.5 Hz, 1H, Ar-H), 6.16 (ddt, J = 17.2, 
10.6, 5.4 Hz, 1H, 3-CβH), 5.52 (dd, J = 17.2, 1.2 Hz, 1H, 3-CγHtrans), 5.43 (dd, J = 
10.5, 1.1 Hz, 1H, 3-CγHcis), 4.75 (d, J = 5.4 Hz, 2H, 3-CαH2 ), 4.04 – 3.95 (m, 4H, 1-
CαH2 and 2-CαH2), 3.92 (s, 3H, OMe), 2.32 – 2.10 (m, 2H, 1-CβH and 2-CβH), 1.14 
(d, J = 6.7 Hz, 6H, 1-CγH3 and 1-CδH3), 1.10 (d, J = 6.7 Hz, 6H, 2-CγH3 and 2-
CδH3); 
13
C NMR (125 MHz, CDCl3) δ 166.63, 164.33, 163.08, 152.82, 147.78, 
146.53, 141.72, 139.61, 132.27, 132.25, 130.77, 130.44, 125.92, 125.12, 123.71, 
119.07, 118.89, 118.76, 118.62, 117.39, 113.74, 112.05, 110.54, 76.08, 75.20, 69.76, 
52.12, 28.28, 28.22, 19.36, 19.03; HRMS found 620.2609, C33H37N3O9 [M+H]
+
 
requires 620.2602 
Standard Proceedure G – Removal of Allyl Groups 
Allyl functionalised trimers were treated with palladium tetrakistriphenylphosphine 
(10 mol%) and sodium toluenesulfinate (1.2 eq) in THF (1ml/mg) overnight, 
concentrated in vacuo and purified by column chromatography eluting with Et2O in 
DCM. 
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O2N-[(3-HABA)]-[O-iBu (3-HABA)]-[ O-iPr (3-HABA)]-COOMe, 106 
 
Prepared using standard procedure G on  0.58 mmol scale (267 mg, 81%).
 1
H NMR 
(500 MHz, CDCl3) δ 10.61 (s, 1H, OH), 8.87 (s, 1H, Amide NH), 8.77 (s, 1H, 
Amide NH), 8.64 (m, 2H, Ar-H), 8.28 (d, J = 8.7 Hz, 1H, Ar-H), 7.74 (dd, J = 8.5, 
1.7 Hz, 1H, Ar-H), 7.68 (d, J = 1.9 Hz, 1H, Ar-H), 7.63 (d, J = 1.8 Hz, 1H, Ar-H), 
7.61 (d, J = 1.7 Hz, 1H, Ar-H), 7.47 (dd, J = 8.8, 1.9 Hz, 1H, Ar-H), 7.44 (dd, J = 
8.5, 1.8 Hz, 1H, Ar-H), 4.78 (hept, J = 6.2 Hz, 1H, 3-CαH), 4.00 (d, J = 6.6 Hz, 2H, 
2-CαH2), 3.92 (s, 3H, OMe), 2.24 (dp, J = 13.4, 6.6 Hz, 1H, 2-CβH), 1.46 (d, J = 6.1 
Hz, 6H3-CβH3 and 3-CγH3), 1.12 (d, J = 6.7 Hz, 6H, 2-CγH3 and 2-CδH3); HRMS 
Found: 566.212;  C29H31N3O9 [M+H]
+
 requires 566.2133 
O2N-[O-iBu(3-HABA)]-[(3-HABA)]-[O-iPr(3-HABA)]-COOMe 
 
Prepared using standard procedure G on a 0.4 mmol scale (168 mg, 75%). 
1
H NMR 
(500 MHz, d6-DMSO) δ 10.34 (s, 1H, OH), 9.86 (s, 1H, Amide NH), 9.22 (s, 1H, 
Amide NH), 8.25 (d, J = 8.4 Hz, 1H, Ar-H), 8.00 (d, J = 8.3 Hz, 1H, Ar-H), 7.88 (d, 
J = 8.3 Hz, 1H, Ar-H), 7.83 (d, J = 1.5 Hz, 1H, Ar-H), 7.66 – 7.60 (m, 2H, Ar-H), 
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7.58 (d, J = 1.7 Hz, 1H, Ar-H), 7.49 (d, J = 2.0 Hz, 1H, Ar-H), 7.44 (dd, J = 8.3, 2.0 
Hz, 1H, Ar-H), 4.82 – 4.69 (m, 1H, 3-CαH), 4.05 (d, J = 6.4 Hz, 2H, 1-CαH2), 3.33 
(s, 3H, OMe) 2.06 (sept, 6.6 Hz, 1H, 1-CβH), 1.36 (d, J = 6.0 Hz, 6H, 3-CβH3 and 3-
CγH3), 0.99 (d, J = 6.7 Hz, 6H, 1-CγH3 and 1-CδH3); HRMS Found 566.2126; 
C29H31N3O9 [M+H]
+
 requires 566.2133. 
 
O2N-[O-iBu(3-HABA)] O-iBu(3-HABA)]-[(3-HABA)]-COOMe 
 
Prepared using standard procedure G on a 1 mmol scale (442 mg, 74%).
 1
H NMR 
(500 MHz, d6-DMSO) δ 10.37 (s, 1H, OH), 9.81 (s, 1H, Amide NH), 9.54 (s, 1H, 
Amide NH), 8.02 (d, J = 8.3 Hz, 1H, Ar-H), 7.96 (app.t, J = 8.0 Hz, 2H, Ar-H), 7.80 
(d, J = 1.5 Hz, 1H, Ar-H), 7.66 (d, J = 1.8 Hz, 1H, Ar-H), 7.64 – 7.59 (m, 2H, Ar-
H), 7.53 (d, J = 2.0 Hz, 1H, Ar-H), 7.48 (dd, J = 8.3, 1.9 Hz, 1H, Ar-H), 4.03 (d, J = 
6.5 Hz, 2H, 1-CαH2), 3.93 (d, J = 6.4 Hz, 2H, 2-CαH2), 3.83 (s, 3H, OMe), 2.17 – 
1.97 (m, 2H, 1-CβH and 2-CβH), 1.01 (d, J = 6.8 Hz, 6H, 1-CγH3 and 1-CδH3), 0.99 
(d, J = 6.8 Hz, 6H, 2-CγH3 and 2-CδH3); HRMS Found 580.2288; C30H33N3O9 
[M+H]
+
 requires 580.2289. 
Standard Procedure H – Side chain introduction by Mitsunobu reaction 
De-allylated nitro ester trimers were dissolved in THF (1 ml/10 ml substrate) and 
PPh3 (2 eq.), alcohol (2 eq.) and DIAD (2 eq.) added sequentially. The reaction was 
stirred overnight at r.t., concentrated in vacuo. Amine products were isolated by 
SCX column and used without further purification. 
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H2N-[(3-HABA)]-[O--
i
Bu(3-HABA)]-[ O-
i
Pr(3-HABA)]-COOH, 110 
 
 
Prepared by standard procedures E and C and purification by mass directed HPLC 
(14.4 mg, 62%). 
1
H NMR (500 MHz, d6-DMSO) δ 9.30 (s, 1H, Amide NH), 8.86 (s, 
1H, Amide NH), 8.28 (d, J = 8.2 Hz, 1H, Ar-H), 8.16 (d, J = 8.3 Hz, 1H, Ar-H), 
7.61 – 7.53 (m, 4H), 7.27 (d, J = 2.1 Hz, 1H, Ar-H), 7.19 (dd, J = 8.3, 2.1 Hz, 1H, 
Ar-H), 6.64 (d, J = 8.2 Hz, 1H, Ar-H), 4.76 – 4.67 (m, 1H, 3-CαH), 3.97 (d, J = 6.6 
Hz, 2H, 2-CαH2), 1.90 – 1.79 (m, 1H, 2-CβH), 1.35 (d, J = 6.0 Hz, 6H, 3-CβH3 and 3-
CγH3), 1.03 (d, J = 6.7 Hz, 6H, 2-CγH3 and 2-CδH3); HRMS found 522.2244 
C28H31N3O7 [M+H]
+
 requires 522.2234 
H2N-[2-(pyrrolidin-1-yl)ethoxy(3-HABA)]-[O--
i
Bu(3-HABA)]-[O—iPr(3-
HABA)]-COOH, 111 
 
Prepared by standard procedure H followed by standard procedures E and C and 
purification by mass directed HPLC (7.8 mg, 36%).
 1
H NMR (500 MHz, d6-DMSO) 
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δ 9.16 (s, 1H, Amide NH), 9.00 (s, 1H, Amide NH), 8.50 (s, 1H, Ar-H), 8.20 (d, J = 
8.4 Hz, 1H, Ar-H), 7.89 (d, J = 7.8 Hz, 1H, Ar-H), 7.56 (m,  3H, Ar-H), 7.46 (s, 1H, 
Ar-H), 7.37 (d, J = 7.2 Hz, 1H, Ar-H), 6.70 (d, J = 8.6 Hz, 1H, Ar-H), 4.61 (dt, J = 
12.1, 6.1 Hz, 1H, 3-CαH), 4.10 (t, J = 6.0 Hz, 2H, 1-CβH
2
), 3.95 (d, J = 6.5 Hz, 2H, 
2-CβH2), 2.83 (t, J = 6.0 Hz, 1H, 1-CαH2), 2.58 – 2.51 (m, 4H, pyrrolidine 2 × CH2) 
2.14 (dt, J = 13.1, 6.5 Hz, 1H, 2-CβH), 1.73 – 1.65 (m, 4H, pyrrolidine 2 × CH2) 
1.31 (d, J = 6.0 Hz, 6H, 3-CβH3 and 3-CγH3), 1.25 – 1.09 (m, 5H), 1.08 – 0.97 (d, J 
=  6.7 Hz, 6H, 2-CγH3 and 2-CδH3). HRMS Found 619.3136 C34H42N4O7 [M+H]
+
 
requires 619.3126 
 H2N-[O-
i
Bu(3-HABA)]-[(3-HABA)]-[O-
i
Pr(3-HABA)]-COOH, 112 
 
Prepared by standard procedures E and C and purification by mass directed HPLC 
(11.8 mg, 51%). 
1
H NMR (500 MHz, d6-DMSO) δ 9.26 (s, 1H, Amide NH), 9.15 (s, 
1H, Amide NH), 8.22 (d, J = 8.3 Hz, 1H, Ar-H), 7.99 (d, J = 8.4 Hz, 1H), 7.63 – 
7.52 (m, 4H) 7.47 (d, J = 2.0 Hz, 1H), 7.42 (dd, J = 8.1, 1.7 Hz, 1H), 6.70 (d, J = 8.0 
Hz, 1H), 4.77 – 4.69 (m, 1H, 3-CαH), 3.81 (d, J = 6.5 Hz, 2H, 1-CαH2), 2.13 – 2.02 
(m, 1H, 1-CβH), 1.36 (d, J = 6.0 Hz, 6H, 3-CβH3 and 3-CγH3), 1.02 (d, J = 6.7 Hz, 
6H, 1-CγH3 and 1-CδH3); HRMS found 522.2241 C28H31N3O7 [M+H]
+
 requires 
522.2234 
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H2N-[ O--
i
Bu(3-HABA)]-[ 3-(dimethylamino)propoxy (3-HABA)]-[O-
i
Pr(3-
HABA)]-COOH, 113 
 
Prepared by standard procedure H followed by standard procedures E and C and 
purification by mass directed HPLC (11 mg, 49%). 
1
H NMR (500 MHz, d6-DMSO) 
δ 9.28 (s, 1H, Amide N-H), 9.04 (s, 1H, Amide N-H), 8.22 (d, J = 8.3 Hz, 1H, Ar-
H), 8.11 (d, J = 8.5 Hz, 1H, Ar-H), 7.64 – 7.55 (m, 5H, Ar-H), 7.37 – 7.33 (m, 1H, 
Ar-H) 6.70 (d, J = 8.0 Hz, 1H, Ar-H), 4.74 – 4.66 (m, 1H, 3-CαH), 4.20 (t, J = 6.2 
Hz, 2H, 2-CαH2), 3.80 (t, J = 5.4 Hz, 2H, 2-CγH2), 2.41 (m, 2H, 2-CβH2), 2.14 (s, 
6H, 2 × NMe), 1.97 (m, 1H, 1-CβH) 1.35 (dd, J = 6.0, 1.8 Hz, 6H, 3-CβH3 and 3-
CγH3), 1.02 (dd, J = 6.7, 3.1 Hz, 6H, 1-CγH3 and 1-CδH3); HRMS Found 607.3138, 
C33H42N4O7 [M+H]
+ 
requires 607.3126. 
H2N-[ O--
i
Bu(3-HABA)]-[ 2-(pyrrolidin-1-yl)ethoxy (3-HABA)] -[O-
i
Pr(3-
HABA)]-COOH, 114 
 
Prepared by standard procedure H followed by standard procedures E and C and 
purification by mass directed HPLC (6.2 mg, 29%). 
1
H NMR (500 MHz, d6-DMSO) 
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δ 9.28 (s, 1H, Amide NH), 9.26 (s, 1H, Amide NH), 8.39 – 8.25 (m, 2H, Ar-H), 8.08 
(d, J = 9.6 Hz, 1H, Ar-H), 7.72 – 7.50 (m, 5H, Ar-H), 7.33 (m, 1H, Ar-H), 4.74 – 
4.63 (m, 1H, 3-CαH), 4.29 (m, 2H, 2-CβH2), 3.80 (d, J =6.5 Hz, 2H, 1-CαH2), 2.84 
(m, 2H, 2-CαH2), 2.09 (m, 1H, 1-CβH), 1.60 – 1.50 (m, 4H, pyrrolidine 2 × CH2), 
1.35 (d, J = 6.0 Hz, 6H, 3-CβH3 and 3-CγH3), 1.03 (d, J = 6.7 Hz, 6H, 1-CγH3 and 1-
CδH3); HRMS Found 619.3142, C34H42N4O7 [M+H]
+ 
requires 619.3126j 
H2N-[O-
i
Bu(3-HABA)]-[O-
i
Bu(3-HABA)]-[(3-HABA)]-COOH, 115 
 
Prepared by standard procedures E and C and purification by mass directed HPLC 
(5.5 mg, 20%). 
1
H NMR (500 MHz, d6-DMSO) δ 9.47 (s, 1H, Amide NH), 8.99 (s, 
1H, Amide NH), 8.24 (d, J = 8.3 Hz, 1H, Ar-H), 7.92 (d, J = 8.3 Hz, 1H, Ar-H), 
7.64 – 7.58 (m, 2H, Ar-H), 7.50 (d, J = 1.9 Hz, 1H, Ar-H), 7.45 (dd, J = 8.3, 1.9 Hz, 
1H, Ar-H), 7.35 (dd, J = 8.2, 1.9 Hz, 1H, Ar-H), 7.31 (d, J = 1.9 Hz, 1H, Ar-H), 
6.70 (d, J = 8.2 Hz, 1H, Ar-H), 3.96 (d, J = 6.3 Hz, 2H, 1-CαH2), 3.79 (d, J = 6.5 Hz, 
2H, 2-CαH2), 2.18 – 2.01 (m, 2H, 1-CβH and 2-CβH), 1.05 (d, J = 6.7 Hz, 6H, 1-CγH3 
and 1-CδH3), 1.02 (d, J = 6.7 Hz, 6H, 2-CγH3 and 2-CδH3); HRMS found 536.23994 
C29H33N3O7 [M+H]
+
 requires 536.2391 
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H2N-[O-
i
Bu (3-HABA)]- [O--
i
Bu(3-HABA)]- [3-(dimethylamino)propoxy (3-
HABA)]-COOH, 116 
 
Prepared by standard procedure H followed by standard procedures E and C and 
purification by mass directed HPLC (15 mg, 70%). 
1
H NMR (500 MHz, d6-DMSO) 
δ 9.50 (s, 1H, Amide N-H), 9.00 (s, 1H, Amide N-H), 8.25 (d, J = 8.3 Hz, 1H, Ar-
H), 8.00 (t, J = 9.2 Hz, 1H, Ar-H), 7.64 – 7.59 (m, 3H, Ar-H), 7.58 (d, J = 1.6 Hz, 
1H, Ar-H), 7.35 (dd, J = 8.2, 1.9 Hz, 1H, Ar-H), 7.29 (d, J = 1.8 Hz, 1H, Ar-H), 
6.69 (d, J = 8.2 Hz, 1H, Ar-H), 4.19 (t, J = 5.9 Hz, 2H, 3-CαH2), 3.10 – 2.99 (m, 3H, 
3-CγH2), 2.64 – 2.57 (s, 6H, 2 × NMe), 2.19 – 2.01 (m, 4H, 1-CβH, 2-CβH and 3-
CβH2), 1.05 (t, J = 5.5 Hz, 6H, 1-CγH3 and 1-CδH3), 1.01 (d, J = 4.8 Hz, 6H, 2-CγH3 
and 2-CδH3); HRMS Found 621.3293 C34H44N2O7 [M+H]
+
 requires 621.3288. 
H2N-[O-
i
Bu (3-HABA)] -[O-
i
Bu(3-HABA)] -[2-(pyrrolidin-1-yl) ethoxy(3-
HABA)]-COOH, 109 
 
Prepared by standard procedure H followed by standard procedures E and C and 
purification by mass directed HPLC (16 mg, 72%). 
1
H NMR (500 MHz, d6-DMSO) 
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δ 9.83 (s, 1H, Amide-NH), 8.99 (s, 1H, Amide-NH), 8.25 (d, J = 8.4 Hz, 1H, Ar-H), 
8.04 (d, J = 8.3 Hz, 1H, Ar-H), 7.77 (s, 1H, Ar-H), 7.69 (dd, J = 8.4, 1.7 Hz, 1H, Ar-
H), 7.64 (dd, J = 8.3, 1.4 Hz, 1H, Ar-H), 7.61 (d, J = 1.5 Hz, 2H, Ar-H), 7.35 (dd, J 
= 8.3, 1.6 Hz, 1H, Ar-H), 7.30 (d, J = 1.7 Hz, 1H, Ar-H), 6.71 (d, J = 8.2 Hz, 1H, 
Ar-H), 4.45 (t, J = 4.4 Hz , 2H, 3-CαH2), 4.01 (d, J = 6.3 Hz, 2H, 1-CαH2), 3.79 (d, J 
= 6.5 Hz, 2H, 2-CαH2), 3.59 (m, 2H, 3-CβH2), 2.15 (dt, J = 13.5, 6.6 Hz, 1H, 1-CβH), 
2.08 (dt, J = 13.2, 6.7 Hz, 1H, 2-CβH),1.93-1.86 (m, 4H, pyrrolidine 2 × CH2),  1.27 
– 1.22 (m, 4H, pyrrolidine 2 × CH2), 1.05 (d, J = 6.7 Hz, 6H, 1-CγH3 and 1-CδH3), 
1.02 (d, J = 6.7 Hz, 6H, 2-CγH3 and 2-CδH3); HRMS Found 633.3294 C35H44N2O7 
[M+H]
+
 requires 633.3282 
H2N-[O-
i
Bu (3-HABA)]- [O--
i
Bu(3-HABA)]- [pyridin-4-ylmethoxy (3-HABA)]-
COOH, 117 
 
Prepared by standard procedure H followed by standard procedures E and C and 
purification by mass directed HPLC (8.7 mg, 40%). 
1
H NMR (500 MHz, d6-DMSO) 
δ 9.57 (s, 1H, Amide NH), 8.99 (s, 1H, Amide NH), 8.22 (d, J = 8.4 Hz, 1H, Ar-H), 
8.04 (d, J = 8.3 Hz, 1H, Ar-H), 8.01 (d, J = 7.9 Hz, 1H, Ar-H), 7.71 (d, J = 1.7 Hz, 
1H, Ar-H), 7.66 – 7.52 (m, 4H, Ar-H), 7.51 (d, J = 1.9 Hz, 1H, Ar-H), 7.44 (dt, J = 
7.6, 3.8 Hz, 1H, Ar-H), 7.35 (dd, J = 8.2, 1.9 Hz, 1H, Ar-H), 7.31 (t, J = 2.0 Hz, 1H, 
Ar-H), 6.71 (d, J = 8.2 Hz, 1H, Ar-H), 5.41 (s, 2H, 3-CαH2), 3.90 (d, J = 6.2 Hz, 2H, 
, 1-CαH2), 3.79 (d, J = 6.5 Hz, 2H, , 2-CαH2), 2.19 – 2.03 (m, 2H, 1-CβH and 2-CβH), 
1.04 (d, J = 6.7 Hz, 6H, 1-CγH3 and 1-CδH3), 1.02 (d, J = 6.7 Hz, 6H, 2-CγH3 and 2-
CδH3); HRMS Found 627.2820 C35H38N4O7 [M+H]
+
 requires 627.2813 
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H2N-[ O--
i
Bu(3-HABA)]-[O-TFD (3-HABA)]-[O-
i
Pr(3-HABA)]-COOH, 128 
 
Prepared following standard procedure G followed by standard procedure E. The 
resulting material was dissolved in THF and cooled to 0 °C and sodium hydride (1 
eq.) added. The reaction mixture was stirred for 30 minutes at 0 °C before 3-[4-
(iodomethyl)phenyl]-3-(trifluoromethyl)-3H-diazirine (1.1 eq.) was added. The 
reaction mixture was stirred overnight and allowed to warm to r.t. The reaction 
mixture was then diluted with methanol and treated with 1M NaOH (aq.). Finally 
the reaction mixture was concentrated in vacuo and purified by mass directed HPLC 
(2.05 mg, 16%). 
1
H NMR (500 MHz, CDCl3) δ 8.82 (s, 1H, Amide NH), 8.64 (d, J = 
8.3 Hz, 1H, Ar-H), 8.57 (m, 2H, Amide NH and Ar-H), 7.71 (d, J = 8.5 Hz, 1H, Ar-
H), 7.63 (s, 1H, Ar-H), 7.55 (s, 1H, Ar-H), 7.44 (d, J = 8.2 Hz, 2H, Ar-H), 7.37 (d, J 
= 9.1 Hz, 1H, Ar-H), 7.33 (s, 1H, Ar-H), 7.08 (d, J = 7.7 Hz, 1H, Ar-H), 6.60 (d, J = 
8.1 Hz, 1H, Ar-H), 5.21 (s, 2H, 2-CαH2), 4.73 – 4.64 (m, 1H, 3-CαH), 3.75 (d, J = 
6.4 Hz, 2H, 1-CαH2), 2.11 – 2.04 (m, 1H, 1-CβH), 1.39 (d, J = 6.0 Hz, 6H, 3-CβH3 
and 3-CγH3), 0.97 (t, J = 9.0 Hz, 6H, 2-CγH3 and 2-CδH3); HRMS Found: 720.2639; 
C37H36F3N5O7 [M+H]
+ 
requires 720.2639. 
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H2N-[ O--
i
Bu(3-HABA)]-[O-
i
Bu(3-HABA)]-[O-TFD(3-HABA)]-COOH, 129 
 
Prepared following standard procedure G followed by standard procedure E. The 
resulting material was dissolved in THF and cooled to 0 °C and sodium hydride (1 
eq.) added. The reaction mixture was stirred for 30 minutes at 0 °C before 3-[4-
(iodomethyl)phenyl]-3-(trifluoromethyl)-3H-diazirine (1.1 eq.) was added. The 
reaction mixture was stirred overnight and allowed to warm to r.t. The reaction 
mixture was then diluted with methanol and treated with 1M NaOH (aq.). Finally 
the reaction mixture was concentrated in vacuo and purified by mass directed HPLC 
(4.6 mg, 44%). 
1
H NMR (500 MHz, CDCl3) δ 8.79 (s, 1H, Amide NH), 8.76 (s, 1H, 
Amide NH), 8.72 (d, J = 8.5 Hz, 1H, Ar-H), 8.68 (d, J = 8.4 Hz, 1H, Ar-H), 7.88 (d, 
J = 8.6 Hz, 1H, Ar-H), 7.72 (s, 1H, Ar-H), 7.58 (s, 1H, Ar-H), 7.53 (d, J = 8.2 Hz, 
2H, Ar-H), 7.44 (s, 1H, Ar-H), 7.40 – 7.33 (m, 2H, Ar-H), 7.30 (d, J = 3.8 Hz, 2H, 
Ar-H), 6.78 (d, J = 8.1 Hz, 1H, Ar-H), 5.31 (s, 2H, 3-CαH2), 3.96 (d, J = 6.4 Hz, 2H, 
1-CαH2), 3.90 (d, J = 6.5 Hz, 2H, 2-CαH2), 2.31 – 2.04 (m, 2H, 1-CβH and 2-CβH), 
1.14 (d, J = 6.7 Hz, 6H, 1-CγH3 and 1-CδH3), 1.10 (d, J = 6.7 Hz, 6H, 2-CγH3 and 2-
CδH3); HRMS Found: 734.2780; C38H38F3N5O7 [M+H]
+ 
requires 734.2796. 
5.4.6 Protein Digestion and LC-MS/MS 
p300 protein was dialysed into 50 mM ammonium bicarbonate buffer overnight and 
concentrated to ~ 1mg/ml. 1 ml of protein solution was heated to 40 °C with shaking 
for 10 minutes. The solution was then treated with DTT (final concentration 10 mM) 
and heated to 80 °C with shaking for 15 minutes. The solution was then allowed to 
cool, and treated with iodoacetamide (final concentration 20 mM) in the dark for 30 
minutes. Trypsin was then added (1:50 trypsin:protein) and the reaction agitated at 
37 °C overnight. The reaction was then quenched with TFA and MeCN and 
analysed by LC-MS/MS on a Bruker Maxis II instrument. Data was analysed using 
BioTools (Bruker Daltronics). 
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5.4.7 Photo-Crosslinking Experiments 
A solution containing the photo-crosslinking compound (150 μM) and p300 (100 
μM) in assay buffer was prepared and analysed by LC-MS on a Bruker HCT Ultra. 
Separate solutions containing only compound or only protein were treated 
identically. The solutions were then irradiated with UV light (365 nm) for 1 hour 
whilst cooled in an ice bath. The LC-MS analysis was then repeated. The protein 
signals were examined for any increase of adduct formation.  
5.4.8 Synthesis of glycine linked monomer 
Prop-2’-en-1’-yl 3-hydroxy-4-nitrobenzoate, 132 
 
Para-toluene sulfonic acid (2 g, 11 mmol) was added to a solution of 3-hydroxy-4-
nitrobenzoic acid (10 g, 55 mmol) in allyl alcohol (30 ml) and the reaction heated to 
80 °C overnight then allowed to cool to r.t. The reaction mixture was diluted with 
ethyl acetate (50 ml) and washed with water (30 ml), saturated aqueous sodium 
bicarbonate (2 × 30 ml) and brine (30 ml), dried over MgSO4 and concentrated in 
vacuo to a yellow amorphous solid (8.9 g, 73%) νmax/cm
-1
 (solid state) 3316, 1722;  
1
H NMR (500 MHz, CDCl3) δ 10.53 (s, 1H, phenol OH), 8.20 (d, J = 8.8 Hz, 1H, 6-
CH), 7.87 (s, 1H, 2-CH), 7.66 (d, J = 8.8 Hz, 1H, 5-CH), 6.06 (ddd, J = 16.7, 11.2, 
5.6 Hz, 1H, 2’C-H ), 5.46 (d, J = 17.2 Hz, 1H, 3’C-Htrans), 5.36 (d, J = 10.4 Hz, 1H, 
3’C-Hcis), 4.88 (d, J = 5.6 Hz, 2H, 1’-CH2); 
13
C NMR (125 MHz, CDCl3) δ 164.01, 
154.67, 138.05, 135.83, 131.43, 125.29, 121.71, 120.65, 119.22, 66.55; HRMS 
Found 222.0411 C10H9NO5 [M-H]
-
 requires 222.0407 
Prop-2’-en-1’-yl 3-(2’’-methylpropoxy)-4-nitrobenzoate, 133 
 
1-bromo-2-methylpropane (3.6 ml, 33.6 mmol) was added to a suspension of Prop-
2’-en-1’-yl 3-hydroxy-4-nitrobenzoate (5 g, 22.4 mmol) and potassium carbonate 
(15.4 g, 112 mmol) in dimethylformamide (50 ml) and the reaction heated to 50 °C 
with stirring overnight. The reaction mixture was then diluted with ethyl acetate 
- 188 - 
(100 ml), washed copiously with water and brine, dried over MgSO4 and 
concentrated in vacuo to give the title compound as a red oil (3.55 g, 60%). νmax/cm
-
1
 (solid state) 2961, 2875, 1718; 
1
H NMR (500 MHz, CDCl3) δ 7.80 (d, J = 8.4 Hz, 
1H, 5-CH), 7.73 (s, 1H, 2C-H), 7.67 (dd, J = 8.4, 1.3 Hz, 1H, 6-CH), 6.04 (ddd, J = 
16.3, 11.0, 5.8 Hz, 1H, 2’-CH), 5.43 (dd, J = 17.2, 1.2 Hz, 1H, 3’-CHtrans), 5.33 (dd, 
J = 10.3, 0.8 Hz, 1H, 3’-CHcis), 4.86 (d, J = 5.8 Hz, 2H, 1’-CH2), 3.93 (d, J = 6.4 Hz, 
2H, 1’’-CH2), 2.15 (spt, J = 6.6 Hz, 1H, 2’’-CH), 1.06 (d, J = 6.9 Hz, 6H, 3’’-CH3 
and 4’’CH3); 
13
C NMR (125 MHz, CDCl3) δ 164.45, 152.05, 142.51, 134.75, 
131.64, 125.15, 121.06, 118.98, 115.42, 75.95, 66.39, 28.19, 18.98; HRMS Found: 
302.0998, C14H17NO5 [M+Na]
+
 requires 302.0998. 
Prop-2’-en-1’-yl 4-amino-3-(2’’-methylpropoxy)benzoate, 134  
 
Tin (II) chloride dihydrate (4 g, 17.9 mmol) was added to a solution of prop-2’-en-
1’-yl 3-(2’’-methylpropoxy)-4-nitrobenzoate (1 g, 3.58 mmol) in ethyl acetate (70 
ml) and the reaction heated to 50 °C overnight. The reaction was allowed to cool and 
poured into 1M NaOH solution (50 ml). The organic layer was separated and 
washed with 1M NaOH (3 × 30 ml), dried over MgSO4 and concentrated in vacuo to 
a pale yellow oil (880 mg, 98%). νmax/cm
-1
 (solid state) 3588, 2914, 1742, 1635; 
1
H 
NMR (500 MHz, CDCl3) δ 7.60 (dd, J = 8.2, 1.6 Hz, 1H, 6-CH), 7.48 (d, J = 1.4 Hz, 
1H, 2C-H), 6.69 (d, J = 8.2 Hz, 1H, 5-CH), 6.07 (ddd, J = 17.2, 10.4, 1.4 Hz, 1H, 2’-
CH), 5.42 (dd, J = 17.2, 1.4 Hz, 1H, 3’-CHtrans), 5.29 (dd, J = 10.4, 1.4 Hz, 1H, 3’-
CHcis), 4.81 (d, J = 5.6 Hz, 2H, 1’-CH2), 3.85 (d, J = 6.5 Hz, 2H, 1’’-CH2), 2.25 – 
1.98 (sept, 6.6 Hz, 1H, , 2’’-CH), 1.08 (d, J = 6.6 Hz, 6H, 3’’-CH3 and 4’’CH3); 
13
C 
NMR (125 MHz, CDCl3) δ 166.54, 145.60, 141.36, 132.82, 123.99, 119.40, 117.70, 
113.08, 112.15, 74.72, 65.07, 28.30, 19.34; HRMS Found: 250.1438, C14H19NO3 
[M+H]
+
 requires 250.1437 
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Prop-2’-en-1’-yl4-(2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}acetamido)-3-
(2’’-methylpropoxy)benzoate, 135 
 
Dichlorotriphenylphosphorane (5.8 g, 17.6 mmol) was added to a solution of Fmoc-
glycine (2 g, 7.06 mmol) and prop-2’-en-1’-yl 4-amino-3-(2’’-
methylpropoxy)benzoate (880 mg, 3.53 mmol) in chloroform (50 ml) and the 
reaction heated to reflux overnight. The reaction was allowed to cool to r.t. and 
concentrated in vacuo. The residue was purified by column chromatography eluting 
with dichloromethane to give the title compound as a colourless amorphous solid 
(1.3g, 71%). νmax/cm
-1
 (solid state) 3398, 2958, 2873, 1697; 
1
H NMR (500 MHz, 
CDCl3) δ 8.59 (s, 1H, Amide NH), 8.48 (d, J = 8.4 Hz, 1H, Ar-H), 7.80 (d, J = 6.3 
Hz, 1H, Ar-H), 7.74 (d, J = 8.4 Hz, 1H, Ar-H), 7.62 (s, 1H, Ar-H), 7.56 (d, J = 1.2 
Hz, 1H, Ar-H), 7.43 (s, 1H, Ar-H), 7.33 (s, 1H, Ar-H), 6.08 (ddd, J = 17.2, 10.4, 5.6 
Hz, 1H, 2’-CH), 5.44 (d, J = 17.2 Hz, 1H, 3’-CHtrans), 5.33 (d, J = 10.4 Hz, 1H, 3’-
CHcis), 4.85 (d, J = 5.6 Hz, 2H, 1’-CH2), 4.48 (d, J = 7.0 Hz, 2H, gly-CH2), 4.26 (t, J 
= 6.9 Hz, 1H, Fmoc-CH), 4.10 (s, 1H br s, 1H, carbamate NH), 3.85 (d, J = 6.4 Hz, 
2H, Fmoc-CH2), 2.12 (sept, J = 6.7 Hz, 1H, 2’’-CH), 1.04 (d, J = 6.7 Hz, 6H, 3’’-
CH3 and 4’’CH3); 
13
C NMR (125 MHz, CDCl3) δ 167.19, 165.92, 146.97, 143.62, 
141.33, 132.32, 131.40, 127.84, 127.12, 125.49, 124.99, 123.21, 120.07, 118.67, 
118.28, 111.66, 75.15, 67.58, 65.63, 47.08, 45.90, 28.20, 19.25; HRMS found: 
529.234309, C31H32N2O6  [M+H]
+
 Requires 529.233313. 
4-(2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}acetamido)-3-(2-
methylpropoxy)benzoic acid, 136 
 
- 190 - 
Palladium tetrakis(triphenylphosphine) (110 mg, 0.095 mmol, 5 mol%) was added 
to a solution of Prop-2’-en-1’-yl4-(2-{[(9H-fluoren-9-
ylmethoxy)carbonyl]amino}acetamido)-3-(2’’-methylpropoxy)benzoate (1 g, 1.89 
mmol) and sodium p-toluenesulfinate (505 mg, 2.83 mmol) in tetrahydrofuran (50 
ml) and the reaction stirred at r.t. for 24 hours. The reaction mixture was filtered 
through Celite and concentrated in vacuo. The residue was purified by column 
chromatography eluting with 5-10% methanol in dichloromethane to give the title 
compound as a yellow solid (741 mg, 80%). νmax/cm
-1
 (solid state) 3395, 3302, 2963, 
1697; 
1
H NMR (500 MHz, d6-DMSO) δ 8.98 (s, 1H, Amide N-H) 8.24 (d, J = 8.0 
Hz, 1H, Ar-H), 7.95 (br. s, 1H, carbamate-NH), 7.90 (d, J = 7.4 Hz, 2H, Ar-H), 7.72 
(d, J = 7.4 Hz, 2H, Ar-H), 7.57 (d, J = 7.4 Hz, 1H, Ar-H), 7.52 (s, 1H, Ar-H), 7.42 
(t, J = 7.2 Hz, 2H, Ar-H), 7.33 (t, J = 7.3 Hz, 2H, Ar-H), 4.34 (d, J = 6.6 Hz, 2H, 
Fmoc-CH2), 4.25 (t, J = 6.6 Hz, 1H, Fmoc-CH), 3.86 (d, J = 6.0 Hz, 2H, Gly-CH2), 
3.83 (d, J = 6.6 Hz, 2H, 1”-CH2), 2.07 – 1.94 (m, 1H, 2’’-CH), 0.95 (d, J = 6.7 Hz, 
6H, 3’’-CH3 and 4’’CH3);
13
C NMR (125 MHz, d6-DMSO) δ 168.27, 147.24, 143.68, 
140.72, 130.81, 127.65, 127.05, 125.14, 122.29, 120.11, 118.80, 112.00, 74.62, 
66.01, 46.57, 27.59, 18.94; HRMS found 489.2032 C28H28N2O6 requires [M+H]
+
 
489.2020 
5.4.9 Preparation of Peptide-Oligobenzamide Hybrids 
Prepared following an adapted literature method.
152
 Fmoc-monomer acid chlorides 
were prepared as previously described and loaded onto a CEM liberty peptide 
synthesiser. Gly-loaded Wang resin was swelled in NMP for 30 minutes prior to 
loading onto the synthesiser. The previously described methods were used to 
synthesise the oligobenzamide portion of the molecule, ending with the Fmoc-Gly-
monomer. The peptide portion was then extended using standard Fmoc peptide 
synthesis as described above.  
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H2N-QLTSYCEVNAPIQSRNLLQG--[O-
i
Bu(3-HABA)]-[O-
i
Bu(3-HABA)]-[O-
i
Pr(3-HABA)]-G-NH2, 137 
 
LC-MS m/z (ES) 1455.3 [M+2H]
2+
, 970.4 [M+3H]
3+
 HRMS Found: 1454.2223 
C131H199N33O40S requires [M+2H]
2+
 1454.2209 
 
 
  
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.90
-20
50
100
150
180
GMB2014 #5 GMB712 DAD_Signal_A
mAU
min
1 - 2.619
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Ac-QLTSYSEVNAPIQSRNLLQG--[O-
i
Bu(3-HABA)]-[O-
i
Bu(3-HABA)]-[ O-
i
Pr(3-HABA)]-G-NH2, 138 
 
LC-MS m/z (ES) 1468.2 [M+2H]
2+ 
HRMS Found: 1467.7340, C133H201N33O42 
requires [M+2H]
2+
 1467.7393 
 
  
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.91
-20
0
25
50
75
100
140
GB2015 #2 838 prep 15 DAD_Signal_C
mAU
min
1 - 2.363
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Appendix I – Alternative Peptide PEG Linking Strategies 
Initially, a one pot conjugation procedure was developed to allow the modular 
assembly of peptidic regions with linkers of various lengths thus negating the 
requirement to perform the peptide synthesis in triplicate. A route combining copper 
catalysed azide alkyne cycloaddition and thiol-ene reactions was envisioned. This 
was trialled with a model system as shown below. This reaction sequence 
progressed successfully in one pot as followed by LC-MS. By treating the 
commercially available NHS-PEG-Maleimide compound with a short azido-
alkylamine followed by a thiol, the click handle and the first component can be 
introduced regioselectively. Finally, addition of an alkyne along with a copper 
catalyst affords the PEG linked compound. 
 
This one pot procedure was then progressed onto using a peptide containing and C-
terminal propargyl glycine and another with an N-terminal thiol as shown below and 
monitored by LC-MS. The final click reaction progressed with small molecule 
alkynes but not the alkynyl peptide. The peptide appeared to be unstable to the 
reaction conditions.  
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A shorter alkynyl peptide was prepared and  used to optimise the click reaction as 
shown in the table below. Using these optimised conditions, the full length peptide 
could cleanly undergo click reactions. However, when the complete one pot 
procedure was attempted using the optimised conditions, no product was observed.  
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Conditions Outcome 
1 eq. Cu, 1 eq. Ascorbate, DMSO No Reaction 
1.1 eq. Cu, 1 eq. Ascorbate, DMSO Conversion to product and degradation 
1.1 eq. Cu, 10 eq. Ascorbate, DMSO Conversion to product and degradation 
1 eq. Cu, 1 eq. TBTA, 10 eq. Ascorbate, 
DMSO 
Conversion to product and degradation 
1.1 eq. Cu, 10 eq. TCEP, DMSO No Reaction 
1 eq. Cu, 10 eq. Ascorbate, 1:1 
THF/Water 
Conversion to product 
1 eq. Cu, 10 eq. Ascorbate, 10 eq. TBTA, 
1:1 THF/Water 
Conversion to product and stable o/n 
 
 
 
At this stage it was decided to prepare the PEG-Peptide conjugates via linear peptide 
synthesis incorporating the PEG chain as with any other monomer.  
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Appendix II – Alternative Synthetic Routes to Designed Compounds 
Alternative Route via cyclic sulfamidate: 
 
No sulfamidate ring opening was observed with the sulfonamide anion under forcing 
conditions. 
 
Alternative Route via aminolysis: 
 
 
 
All attempts to improve the conversion in the final step lead to a complex mixture of 
undesired compounds. 
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Alternative Route via Mitsunobu ring closing: 
 
 
Conditions to cleanly reduce the azide could not be identified.   
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Appendix III – Crystallographic Data 
The diffraction data were collected and solved by Dr Chris Pask at the School of 
Chemistry X-ray facility.  
Measurements were carried out at 120K on an Agilent SuperNova diffractometer 
equipped with an Atlas CCD detector and connected to an Oxford Cryostream low 
temperature device using mirror monochromated Cu Kα radiation (λ= 1.54184 Å) 
from a Microfocus Nova X-ray source. The structure was solved by direct methods 
using SHELXS
203
 and refined by a full matrix least squares technique based on F2 
using SHELXL97.
203
 
The compound crystallised as colourless needles by slow evaporation of 1:1 CHCl3 
and Et2O. The compound crystallised in an orthorhombic cell and was solved in the 
P212121 space group, with one molecule in the asymmetric unit.  
All non-hydrogen atoms were located in the Fourier Map and refined 
anisotropically. All hydrogen atoms were placed in calculated positions and refined 
isotropically using a “riding model”. 
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Empirical formula C13H24N2O 
Formula weight 224.34 
Temperature/K 120.0(2) 
Crystal system orthorhombic 
Space group P212121 
a/Å 5.06544(18) 
b/Å 11.4671(4) 
c/Å 22.0794(8) 
α/° 90.00 
β/° 90.00 
γ/° 90.00 
Volume/Å
3
 1282.51(8) 
Z 4 
ρcalcg/cm
3
 1.162 
μ/mm-1 0.572 
F(000) 496.0 
Crystal size/mm
3
 0.16 × 0.07 × 0.04 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 8 to 148.36 
Index ranges -6 ≤ h ≤ 6, -14 ≤ k ≤ 13, -27 ≤ l ≤ 26 
Reflections collected 13058 
Independent reflections 2564 [Rint = 0.0468, Rsigma = 0.0292] 
Data/restraints/parameters 2564/0/150 
Goodness-of-fit on F
2
 1.046 
Final R indexes [I>=2σ (I)] R1 = 0.0344, wR2 = 0.0849 
Final R indexes [all data] R1 = 0.0375, wR2 = 0.0871 
Largest diff. peak/hole / e Å
-3
 0.15/-0.23 
Flack parameter -0.2(3) 
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Appendix IV 
Reducing agent screen on the reaction of 40 to 42 – ratios determined by crude 
NMR with reference to authentic separated samples.  
Reducing Agent dr / cis:trans 
NaBH4 60:40 
NaBH(OAc)3 80:20 
Pd/C, Ammonium Formate, Reflux 92:8 
Borane•THF 58:42 
Ammonium Formate, Reflux 22:78 
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